Objection Deadline: February 24, 2020 @ 12:00 p.m. (ET)

#### UNITED STATES BANKRUPTCY COURT FOR THE SOUTHERN DISTRICT OF NEW YORK

In re:	Chapter 11
PURDUE PHARMA L.P., et al., 1	Case No. 19-23649 (RDD)
Debtors.	(Jointly Administered)

#### FOURTH MONTHLY FEE STATEMENT OF ALIXPARTNERS, LLP, FINANCIAL ADVISOR TO THE CHAPTER 11 DEBTORS FOR ALLOWANCE OF COMPENSATION FOR SERVICES RENDERED AND FOR REIMBURSEMENT OF EXPENSES FOR THE PERIOD DECEMBER 1, 2019 THROUGH DECEMBER 31, 2019

Name of Applicant: ALIXPARTNERS, LLP			
Applicant's Role in Case:	Financial Advisor to the Chapte	er 11 Debtors	
Date Order of Employment Signed:	November 21, 2019 [Docket No. 528], <i>Nunc Pro Tunc</i> to September 15, 2019		
Time manied acrossed by this statement.	Beginning of Period	End of Period	
Time period covered by this statement:	December 1, 2019	December 31, 2019	
Summary of Total	Fees and Expenses Requested:		
<b>Total fees requested in this statement:</b>	\$936,499.80 (80% of \$1,170,624	.75)	
<b>Total expenses requested in this statement:</b>	\$59,835.26		
Total fees and expenses requested in this statement: \$996,335.06			
This is a(n): X Monthly Application Interim Application Final Application			

The Debtors in these cases, along with the last four digits of each Debtor's registration number in the applicable jurisdiction, are as follows: Purdue Pharma L.P. (7484), Purdue Pharma Inc. (7486), Purdue Transdermal Technologies L.P. (1868), Purdue Pharma Manufacturing L.P. (3821), Purdue Pharmaceuticals L.P. (0034), Imbrium Therapeutics L.P. (8810), Adlon Therapeutics L.P. (6745), Greenfield BioVentures L.P. (6150), Seven Seas Hill Corp. (4591), Ophir Green Corp. (4594), Purdue Pharma of Puerto Rico (3925), Avrio Health L.P. (4140), Purdue Pharmaceutical Products L.P. (3902), Purdue Neuroscience Company (4712), Nayatt Cove Lifescience Inc. (7805), Button Land L.P. (7502), Rhodes Associates L.P. (N/A), Paul Land Inc. (7425), Quidnick Land L.P. (7584), Rhodes Pharmaceuticals L.P. (6166), Rhodes Technologies (7143), UDF LP (0495), SVC Pharma LP (5717) and SVC Pharma Inc. (4014). The Debtors' corporate headquarters is located at One Stamford Forum, 201 Tresser Boulevard, Stamford, CT 06901.

#### **ALIXPARTNERS, LLP**

# SUMMARY OF HOURS AND FEES BY PROFESSIONAL FOR THE PERIOD DECEMBER 1, 2019 THROUGH DECEMBER 31, 2019

PROFESSIONAL	TITLE	RATE (1)	HOURS	FEES
Lisa Donahue	Managing Director	\$1,165	17.4	\$ 20,271.00
Richard Collura	Managing Director	\$1,080	92.7	100,116.00
Barry Folse	Managing Director	\$1,080	8.5	9,180.00
Jesse DelConte	Director	\$945	150.2	141,939.00
Mark F Rule	Director	\$895	31.1	27,834.50
Kevin M McCafferty	Director	\$895	141.3	126,463.50
Michael Hartley	Director	\$830	120.6	100,098.00
Isaac Fisboin	Director	\$775	8.8	6,820.00
Gabe J Koch	Director	\$830	137.6	114,208.00
Ryan D Sublett	Senior Vice President	\$725	92.1	66,772.50
Jon D Hecht	Senior Vice President	\$665	76.0	50,540.00
Isabel Arana de Uriate	Senior Vice President	\$615	144.1	88,621.50
Sam J Canniff	Senior Vice President	\$615	82.2	50,553.00
David Samikkannu	Senior Vice President	\$615	52.4	32,226.00
Fernando O Silva	Senior Vice President	\$615	19.9	12,238.50
Kaitlyn A Sundt	Senior Vice President	\$490	0.3	147.00
Laurie C Verry	Senior Vice President	\$490	4.0	1,960.00
Andrew D DePalma	Vice President	\$480	164.7	79,056.00
Nate A Simon	Vice President	\$480	132.4	63,552.00
Hart Ku	Vice President	\$440	150.0	66,000.00
Sam K Lemack	Vice President	\$440	160.2	70,488.00
Tammy Brewer	Vice President	\$430	4.2	1,806.00
Kiera M Davids	Vice President	\$400	14.1	5,640.00
<b>Total Professional Hour</b>	rs and Fees		1,804.8	\$ 1,236,530.50
Less 50% Travel Fees				(65,905.75)
Subtotal				\$ 1,170,624.75
Less 20% Holdback				(234,124.95)
<b>Invoice Total</b>				\$ 936,499.80
(1) Travel time rates are re	educed by 50%			
Tim. Of time faces are it		Average	Billing Rate	\$ 648.62

#### **ALIXPARTNERS, LLP**

# SUMMARY OF HOURS AND FEES BY MATTER CATEGORY FOR THE PERIOD DECEMBER 1, 2019 THROUGH DECEMBER 31, 2019

CODE	MATTER CATEGORY	FEES			
101	Chapter 11 Process/Case Management	107.7	\$ 84,408.50		
102	Budget Process Management	2.9	2,146.50		
103	Cash Management	Cash Management 212.8			
104	Communication with Interested Parties	27.7	19,427.00		
105	U.S. Trustee / Court Reporting Requirements	70.9	39,993.00		
106	Business Analysis & Operations	845.3	585,542.00		
107	POR Development 3.1		2,573.00		
108	Executory Contracts 2.3		2,041.50		
110	Special Projects				
112	Retention and Engagement Administration	4.0	1,960.00		
113	Fee Statements and Fee Applications	19.9	8,821.50		
114	Court Hearings	10.1	9,104.00		
115	Forensic Analysis	307.4	237,912.00		
150	Travel Time <sup>(1)</sup>		65,905.75		
		1,804.8	\$ 1,170,624.75		
		Average Billing Rate	\$ 648.62		

 $<sup>^{(1)}</sup>$  Travel time rates are reduced by 50%

#### **ALIXPARTNERS, LLP**

#### SUMMARY OF EXPENSES FOR THE PERIOD DECEMBER 1, 2019 THROUGH DECEMBER 31, 2019

EXPENSE CATEGORY	E	XPENSE
Airfare	\$	15,931.63
Ground Transportation		10,692.77
Lodging		27,592.25
Meals		5,411.04
Other		207.57
Total	\$	59,835.26

AlixPartners, LLP ("AlixPartners"), as Financial Advisor to the Debtors and its affiliated Debtors, (collectively, the "Debtors"), hereby submits this Fourth Monthly Fee Statement (the "Fee Statement") seeking compensation for professional services rendered and reimbursement of out-of-pocket expenses for the period December 1, 2019 through December 31, 2019 (the "Compensation Period"), pursuant to the Order Establishing Procedures For Interim Compensation and Reimbursement of Expenses for Retained Professionals (Docket No. 528) (the "Interim Compensation Order") and the Order Authorizing Debtors to Retain and Employ AlixPartners, LLP as its Financial Advisor Nunc Pro Tunc to the September 16, 2019 [Docket No. 528] (the "Retention Order").

Detailed time descriptions of the services performed by each professional, organized by discrete project and by day is attached hereto as **Exhibit A**. Exhibit A (a) identifies the individuals that rendered services in each subject matter; (b) describes each activity or service that each individual performed; and (c) states the number of hours (in tenths of an hour) spent by each individual providing the services during the Compensation Period.

A detailed analysis of the out-of-pocket expenses showing the amount incurred by each professional in each expense category by day is attached hereto as **Exhibit B**.

19-23649-shl Doc 821 Filed 02/10/20 Entered 02/10/20 19:42:17 Main Document

Pg 6 of 154

WHEREFORE, AlixPartners respectfully requests that it be granted an allowance of

compensation for professional services rendered during the Compensation Period in the amount

of \$1,170,624.75, without prejudice to a final allowance of compensation, plus reimbursement of

actual and necessary out-of-pocket expenses incurred in the amount of \$59,835.26, and that the

Court grant AlixPartners such other and further relief as is just and proper. Pursuant to the

Interim Compensation Order, AlixPartners seeks payment of professional fees in the amount of

\$936,499.80 (80% of \$1,170,624.75) and expenses in the amount of \$59,835.26, for a total

amount of \$996,335.06.

Dated: February 10, 2020

ALIXPARTNERS, LLP 909 Third Avenue, 28th Floor

New York, NY 10022

/s/ Lisa Donahue

By: Lisa Donahue

Managing Director

#### Exhibit A

#### **Alix Partners, LLP**

**Detailed Description of AlixPartners' Fees and Hours by Matter Category** 

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2120733-2

Re: Chapter 11 Process/Case Management

Date	Consultant	Description of Services	Hours
12/01/19	JD	Review correspondence from management and Davis Polk re: OSR next steps	0.60
12/01/19	JD	Review draft Willis Towers Watson and Lowne declaration re: wage motion support.	1.30
12/02/19	DS	Meeting with D. Samikkannu, I Arana, and J. DelConte (all AlixPartners) re: various ongoing work streams and plan for December	0.50
12/02/19	RDS	Coordinate North Carolina interview schedule - email correspondence with AlixPartners team and D. McGuire, J. Carlisle, A. Oliveira (all Purdue)	0.50
12/02/19	JD	Call with L. Donahue, and J. DelConte (both AlixPartners) re: go forward work streams.	0.50
12/02/19	JD	Meeting with D. Samikkannu, I Arana, and J. DelConte (all AlixPartners) re: various ongoing work streams and plan for December	0.50
12/02/19	IA	Review of CEO pay timeline and details in response to requests from Davis Polk.	0.70
12/02/19	IA	Correspondence with client and follow up with firms on billing for Canadian proceedings.	0.60
12/02/19	IA	Meeting with D. Samikkannu, I Arana, and J. DelConte (all AlixPartners) re: various ongoing work streams and plan for December	0.50
12/02/19	GJK	Project management - key activities for week ahead	0.50
12/03/19	IA	Advisors call with PJT, DPW and the company to review open items and key weekly activities.	1.00
12/03/19	LJD	Prepare for and participate in weekly call with AlixPartners, Davis Polk and PJT Partners re: work stream coordination.	0.60

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2120733-2

Re: Chapter 11 Process/Case Management

Date	Consultant	Description of Services	Hours
12/03/19	BF	Weekly call with AlixPartners, Davis Polk and PJT Partners re: work stream coordination.	0.50
12/03/19	GJK	Weekly call with AlixPartners, Davis Polk and PJT Partners re: work stream coordination.	0.50
12/03/19	GJK	Finalize and send out weekly activity list	0.20
12/03/19	RDS	Weekly call with AlixPartners, Davis Polk and PJT Partners re: work stream coordination.	0.50
12/03/19	RDS	Correspondence with C. Chomiack (Purdue/Avrio) and J. DelConte (AlixPartners) re Avrio business plan review meetings	0.50
12/03/19	RDS	Case management - North Carolina meeting preparation and communication with J. DelConte, and H. Ku (both AlixPartners) re status of business planning workstream	0.60
12/03/19	JD	Prepare for and participate in weekly call with AlixPartners, Davis Polk and PJT Partners re: work stream coordination.	0.60
12/03/19	JD	Call with J. DelConte, A. DePalma (both AlixPartners), and DPW eDiscovery team re: protective order and Bates stamping process.	0.60
12/03/19	JD	Call with J. DelConte, A. DePalma (both AlixPartners), DPW Litigation and Skadden re: DOJ request list.	0.70
12/03/19	JD	Review supplemental L. Donahue declaration. Correspondence re: same.	0.60
12/03/19	JD	Conversation with Associate General Counsel re: latest work plan and go forward strategy.	0.80
12/03/19	DS	Weekly call with AlixPartners, Davis Polk and PJT Partners re: work stream coordination.(partial participation)	0.40
12/03/19	ADD	Call with J. DelConte, A. DePalma (both AlixPartners), DPW Litigation and Skadden re: DOJ request list.	0.70

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2120733-2

Re: Chapter 11 Process/Case Management

Date	Consultant	Description of Services	Hours
12/03/19	ADD	Call with J. DelConte, A. DePalma (both AlixPartners), and DPW eDiscovery team re: protective order and Bates stamping process.	0.60
12/04/19	JD	Finalize supplemental L. Donahue declaration.	0.40
12/04/19	JD	Review final 2020 budget presentation for tomorrow's board meeting.	1.30
12/04/19	JD	Review materials pulled together to be responsive to a diligence question re: intercompany matrices.	0.40
12/04/19	IA	Prepare summary of employees who may have been involved with the commercialization of opioids in the past.	0.90
12/04/19	IA	Correspondence with HR in response to questions regarding upcoming wages hearing.	0.90
12/04/19	IA	Review of prior analyses and materials related to headcount in preparation for wages hearing.	1.70
12/04/19	IA	Follow up on Management's request for a summary of employees who may have been involved in prior commercialization of opioids.	0.60
12/05/19	IA	Review source files for CEO 2018 and 2019 compensation.	0.80
12/05/19	IA	Prepare summary of CEO 2018 and 2019 compensation based on time earned.	1.40
12/05/19	IA	Correspondence with Davis Polk and internal AP team on CEO compensation diligence.	1.20
12/05/19	IA	Reconcile agreed LTRP payments by employee to latest employee roster from HR.	1.10
12/05/19	IA	Review and update calculations of yearly LTRP grants for latest Purdue active employee roster and made adjustments for agreement with UCC.	2.20

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2120733-2

Re: Chapter 11 Process/Case Management

Date	Consultant	Description of Services	Hours
12/05/19	IA	Review and update calculations of yearly LTRP grants for latest Rhodes active employee roster and made adjustments for agreement with UCC.	1.40
12/05/19	BF	Call with M Hartley and B. Folse (both AlixPartners) to review status of critical vendor motion and other case developments.	0.40
12/05/19	MH	Call with B. Folse and M. Hartley (both AlixPartners) to review status of critical vendor motion and other case developments.	0.40
12/05/19	JD	Correspondence with Davis Polk re: scheduling out employee claims for unpaid bonuses	0.50
12/05/19	JD	Correspondence with Davis Polk re: CEO compensation negotiation	0.80
12/06/19	JD	Correspondence with Davis Polk, PJT Partners and management re: de-designating certain materials for an AHC presentation	0.70
12/06/19	DS	Correspondence with A. DePalma (AlixPartners) re: confidentiality designations and protocol of certain items to be posted	0.40
12/06/19	BF	Call in to Sackler family defenses meeting.	1.00
12/06/19	IA	Follow up on upcoming payment of hourly bonuses for Rhodes and correspondence with company to verify amounts.	1.80
12/06/19	IA	Correspondence with management on timeline of CEO compensation in response to requests from Davis Polk.	0.70
12/06/19	IA	Review of CEO historical wages and benefits payments and drafting of summaries in response to diligence requests.	1.30
12/09/19	RDS	Weekly key activities tracker	0.20

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2120733-2

Re: Chapter 11 Process/Case Management

Date	Consultant	Description of Services	Hours
12/09/19	JD	Discussion with Associate General Counsel re: case progress and upcoming deadlines and work stream progress	0.90
12/10/19	JD	Review potential rate increases	0.20
12/10/19	JD	Weekly professional's update call with AlixPartners, Davis Polk and PJT Partners	0.70
12/10/19	JD	Call with B. Folse, G. Koch, J. DelConte, and M. Hartley (all AlixPartners) to discuss current status and staffing needs for the international diligence team.	0.30
12/10/19	GJK	Weekly professional's update call with AlixPartners, Davis Polk and PJT Partners	0.70
12/10/19	GJK	Call with B. Folse, G. Koch, J. DelConte, M. Hartley (all AlixPartners) to discuss current status and staffing needs for the international diligence team.	0.30
12/10/19	RDS	Weekly professional's update call with AlixPartners, Davis Polk and PJT Partners	0.70
12/10/19	IA	Advisor call with PJT and Davis Polk to discuss upcoming deliverable and open items.	0.70
12/10/19	BF	Call with B. Folse, G. Koch, J. DelConte, M. Hartley (all AlixPartners) to discuss current status and staffing needs for the international diligence team.	0.30
12/10/19	LJD	Prepare for and attend weekly professional's update call with AlixPartners, Davis Polk and PJT Partners	0.90
12/11/19	JD	Review details re: retention plan	0.80
12/11/19	JD	Conversation and correspondence with management and Davis Polk re: professional fee payment process	0.50
12/12/19	JD	Correspondence with management and Davis Polk re: PBGC information sharing process	0.30

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2120733-2

Re: Chapter 11 Process/Case Management

Date	Consultant	Description of Services	Hours
12/12/19	JD	Conversation with Associate General Counsel re: open work stream process	0.70
12/12/19	JD	Review progress and status of ongoing work streams. Prepare agenda for update call.	0.90
12/12/19	JD	Participate in a call with management, Davis Polk, PJT and AlixPartners re: status update and ongoing work streams.	0.50
12/12/19	BF	Participate in a call with management, Davis Polk, PJT and AlixPartners re: status update and ongoing work streams.	0.50
12/12/19	NAS	Prepare to speak to IAC diligence status on 12/13 AlixPartners engagement team update call.	0.40
12/13/19	NAS	Prepare to speak to IAC diligence status on 12/13 AlixPartners engagement team update call.	0.30
12/13/19	NAS	Prepare for and attend AlixPartners weekly team update call.	0.90
12/13/19	NAS	Email correspondence with G. Koch (AlixPartners) regarding key takeaways from internal AlixPartners engagement team call (G. Koch couldn't attend call).	0.20
12/13/19	SJC	Prepare for and attend AlixPartners weekly team update call.	1.00
12/13/19	IA	Prepare for and attend AlixPartners weekly team update call.	1.00
12/13/19	IA	Follow up on diligence requests from non consenting states regarding CEO compensation.	1.60
12/13/19	BF	Partial attendance AlixPartners weekly team update call.	0.50
12/13/19	LJD	Prepare for and attend AlixPartners weekly team update call.	0.90

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2120733-2

Re: Chapter 11 Process/Case Management

Date	Consultant	Description of Services	Hours
12/13/19	MH	Prepare for and attend AlixPartners weekly team update call.	1.00
12/13/19	FOS	Attend AlixPartners weekly team update call.	0.80
12/13/19	SKL	Prepare for and attend AlixPartners weekly team update call.	0.90
12/13/19	НК	Prepare for and attend AlixPartners weekly team update call.	0.90
12/13/19	JD	Call with Associate General Counsel re: diligence process.	0.40
12/13/19	JD	Review SOFA/SOAL details re: CEO comp. Review detailed information for pre SOFA/SOAL periods to determine how much detail can be provided to nonconsenting states.	0.90
12/13/19	JD	Review existing engagement barriers	0.30
12/13/19	JD	Correspondence with Davis Polk re: engagement barriers. Review documentation re: same.	0.70
12/13/19	JD	Attend AlixPartners weekly team update call.	0.80
12/13/19	JD	Call with Davis Polk, J. DelConte, and A. DePalma (both AlixPartners) re: business plan diligence materials.	0.30
12/13/19	JD	Correspondence with management and Davis Polk re: diligence designations and go forward planning.	0.70
12/13/19	JDH	Prepare for and attend AlixPartners weekly team update call.	1.00
12/13/19	RC	Attend AlixPartners weekly team update call.	0.80
12/13/19	ADD	Call with Davis Polk, J. DelConte, and A. DePalma (both AlixPartners) re: business plan diligence materials.	0.30
12/13/19	KM	Attend AlixPartners weekly team update call.	0.80
12/13/19	ADD	Prepare for and attend AlixPartners weekly team update call.	0.90

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2120733-2

Re: Chapter 11 Process/Case Management

Date	Consultant	Description of Services	Hours
12/16/19	JD	Correspondence with internal AlixPartners team and Davis Polk re: Akin Gump planned statement in court on Thursday re: AlixPartners client disclosure.	0.90
12/16/19	JD	Review cash management motion for cash balances as of the petition date. Correspondence with management and Davis Polk re: same.	0.30
12/16/19	JD	Review AlixPartners information barriers. Correspondence with Davis Polk and E. Kardos (AlixPartners) re: same.	0.80
12/16/19	JD	Review non-consenting states public health filing.	0.40
12/16/19	JD	Review additional barrier details.	0.20
12/16/19	JD	Correspondence with Teneo re: responding to media inquiries.	0.30
12/16/19	JD	Correspondence with management re: confidentiality designations.	0.50
12/17/19	JD	Review draft declaration re: client disclosure	0.40
12/17/19	JD	Correspondence with management re: vendor forms. Review draft vendor forms.	0.50
12/17/19	JD	Review updated analysis of CEO compensation. Provide comments re: same. Correspondence with Davis Polk re: same.	1.30
12/17/19	JD	Review correspondence re: client disclosure.	0.50
12/17/19	JD	Conversation with management re: de-designation process and go forward diligence process.	0.80
12/17/19	JD	Attend weekly advisor call with Davis Polk, PJT, Prime Clerk and AlixPartners.	0.50
12/17/19	JD	Conversation with L. Donahue (AlixPartners) re: AlixPartners client disclosure process.	0.30
12/17/19	SKL	Prepare for and attend weekly advisor call with Davis Polk, PJT, Prime Clerk and AlixPartners.	0.70

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2120733-2

Re: Chapter 11 Process/Case Management

Date	Consultant	Description of Services	Hours
12/17/19	LJD	Attend weekly advisor call with Davis Polk, PJT, Prime Clerk and AlixPartners.	0.50
12/17/19	LJD	Conversation with J. DelConte (AlixPartners) re: AlixPartners client disclosure process.	0.30
12/17/19	IA	Follow up on diligence requests from Davis Polk regarding CEO compensation.	1.80
12/17/19	IA	Correspondence with management regarding weekly sales by product reports and edits to final output to posted to the data room.	1.10
12/17/19	IA	Follow up on IT transition diligence requests from Province and coordination for call with management.	0.40
12/17/19	IA	Prepare for and attend weekly advisor call with Davis Polk, PJT, Prime Clerk and AlixPartners.	0.80
12/17/19	GJK	Partial attendance at weekly advisor call with Davis Polk, PJT, Prime Clerk and AlixPartners.	0.40
12/18/19	GJK	Review initial draft of Mundipharma business plan model with N. Simon and G. Koch (both AlixPartners).	0.60
12/18/19	GJK	Project management/coordination of Mundi diligence, including planning for next Tax meeting and Advisors meeting	1.50
12/18/19	NAS	Review initial draft of Mundipharma business plan model with N. Simon and G. Koch (both AlixPartners).	0.60
12/18/19	IA	Review of filed retention applications on docket to inform payment of retained professionals' fees in Purdue cash forecast model.	1.40
12/18/19	JD	Conversations with Davis Polk re: settlement payments.	0.40
12/18/19	JD	Correspondence with L. Donahue and Davis Polk re: meeting planning.	0.40

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2120733-2

Re: Chapter 11 Process/Case Management

Date	Consultant	Description of Services	Hours
12/18/19	JD	Correspondence with E. Kardos (AlixPartners) and Davis Polk re: filing declaration on AlixPartners client disclosure.	0.50
12/18/19	JD	Review AlixPartners rate change letter and declaration and correspondence with management re: same.	0.60
12/19/19	JD	Review correspondence from Davis Polk and the AHC re: ACH investment banker.	0.30
12/19/19	NAS	Follow-up meeting with Norton Rose tax specialists Debevoise & Plimpton tax specialists, financial, legal, and tax advisors to UCC and Ad-Hoc Committee, N Simon and G. Koch (both AlixPartners) to discuss tax implications of sale of Mundipharma entities.	2.00
12/19/19	NAS	Discussion with G. Koch, N. Simon (both AlixPartners), B. Bromberg (FTI), P. Topper (Jefferies), and J. Turner (PJT) to align on current Mundipharma diligence priorities.	0.50
12/19/19	NAS	Call with G. Koch and N. Simon (both AlixPartners) to discuss key takeaways from tax and financial advisor meetings and align on next steps.	0.20
12/19/19	GJK	Follow-up meeting with Norton Rose tax specialists; Debevoise & Plimpton tax specialists; financial, legal, and tax advisors to UCC and Ad-Hoc Committee; and G. Koch and N. Simon (both AlixPartners) to discuss tax implications of sale of Mundipharma entities.	2.00
12/19/19	GJK	Discussion with N. Simon, G. Koch (both AlixPartners), B. Bromberg (FTI), P. Topper (Jefferies), and J. Turner (PJT) to align on current Mundipharma diligence priorities.	0.50
12/19/19	GJK	Call with N. Simon and G. Koch (both AlixPartners) to discuss key takeaways from tax and financial advisor meetings and align on next steps.	0.20

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2120733-2

Re: Chapter 11 Process/Case Management

Date	Consultant	Description of Services	Hours
12/19/19	GJK	Meeting with M. Hartley and G. Koch (both AlixPartners) to discuss current Mundipharma diligence status and next steps	0.50
12/19/19	MH	Call with company counsel to review trade agreement options with polynox supplier.	0.50
12/20/19	MH	Prepare for and attend weekly AlixPartners team call.	0.70
12/20/19	BF	Prepare for and attend weekly AlixPartners team call.	0.60
12/20/19	LJD	Prepare for and attend weekly AlixPartners team call.	0.80
12/20/19	HK	Prepare for and attend weekly AlixPartners team call.	0.70
12/20/19	NAS	Discussion with G. Koch and N. Simon (both AlixPartners) regarding key takeaways from R&D/Medical Affairs overview and key discussion topics for internal AlixPartners workstream updates.	0.20
12/20/19	NAS	Prepare for and attend weekly AlixPartners team call.	0.60
12/20/19	SJC	Attend weekly AlixPartners team call.	0.50
12/20/19	JD	Attend weekly AlixPartners team call.	0.50
12/20/19	JD	Call with Davis Polk, J. DelConte and A. DePalma (both AlixPartners) re: protective order and diligence designations.	0.60
12/20/19	JD	Prepare updated agenda for AlixPartners update call.	0.70
12/20/19	JD	Correspondence with Davis Polk and management re: scrubbing confidential data out of the various presentations posted in the data room.	0.70
12/20/19	JD	Correspondence with Davis Polk re: Dr. Landau compensation from Purdue Canada.	0.30
12/20/19	JD	Call with Davis Polk, J. DelConte and A. DePalma (both AlixPartners) re: protective order and diligence designations.	0.60

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2120733-2

Re: Chapter 11 Process/Case Management

Date	Consultant	Description of Services	Hours
12/20/19	JDH	Attend weekly AlixPartners team call.	0.50
12/20/19	GJK	Discussion with N. Simon and G. Koch (both AlixPartners) regarding key takeaways from R&D/Medical Affairs overview and key discussion topics for internal AlixPartners workstream updates.	0.20
12/20/19	KM	Prepare for and attend weekly AlixPartners team call.	0.80
12/20/19	ADD	Prepare for and attend weekly AlixPartners team call.	0.60
12/23/19	JD	Conversation with Davis Polk re: Dr. Landau compensation from Purdue Canada.	0.30
12/23/19	JD	Correspondence with management re: professional fee payments prior to year end.	0.70
12/23/19	JD	Correspondence with management and Davis Polk re: insurance renewals.	0.50
12/30/19	JD	Catch up call with Associate General Counsel	0.50
12/30/19	JD	Correspondence with Davis Polk and management re: protective order confidentiality designations. Review data room files for designation purposes.	1.40
12/31/19	JD	Call with DPW, Purdue AGC, J. DelConte, and A. DePalma (both AlixPartners) re: diligence process	0.30
12/31/19	JD	Review meeting timing re: IAC London meetings	0.30
12/31/19	ADD	Call with DPW, Purdue AGC, J. DelConte, and A. DePalma (both AlixPartners) re: diligence process	0.30
12/31/19	RDS	Prepare budgeting outline for RALP management offsite	1.10
		Total _	107.70

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice #

2120733-2

Re:

Chapter 11 Process/Case Management

Client/Matter #

012589.00101

#### Fee Recap:

Consultant	Hours	Rate	Amount
Sam K Lemack	1.60	440.00	704.00
Hart Ku	1.60	440.00	704.00
Andrew D DePalma	3.40	480.00	1,632.00
Nate A Simon	5.90	480.00	2,832.00
Fernando O Silva	0.80	615.00	492.00
David Samikkannu	1.30	615.00	799.50
Isabel Arana de Uriarte	27.60	615.00	16,974.00
Sam J Canniff	1.50	615.00	922.50
Jon D Hecht	1.50	665.00	997.50
Ryan D Sublett	4.10	725.00	2,972.50
Michael Hartley	2.60	830.00	2,158.00
Gabe J Koch	8.10	830.00	6,723.00
Kevin M McCafferty	1.60	895.00	1,432.00
Jesse DelConte	37.50	945.00	35,437.50
Barry Folse	3.80	1,080.00	4,104.00
Richard Collura	0.80	1,080.00	864.00
Lisa Donahue	4.00	1,165.00	4,660.00
Total Hours & Fees	107.70	_	84,408.50

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2120733-2

Re: **Budget Process Management** 

Date	Consultant	Description of Services	Hours
12/02/19	RDS	Review 5-year G&A plan from J. Lowne (Purdue)	1.40
12/05/19	RDS	Correspondence with D. McGuire (Purdue) re supply chain organization structure	0.20
12/05/19	RDS	Follow up with Rhodes Tech personnel on discussion follow ups	0.40
12/23/19	JD	Call with management re: updated professional fee forecast	0.20
12/31/19	RDS	Review latest Rhodes third-party volume budget	0.70
		Total =	2.90

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice #

2120733-2

Re:

**Budget Process Management** 

Client/Matter #

012589.00102

#### Fee Recap:

Consultant	Hours	Rate	Amount
Ryan D Sublett	2.70	725.00	1,957.50
Jesse DelConte	0.20	945.00	189.00
Total Hours & Fees	2.90		2,146.50

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2120733-2

Date	Consultant	Description of Services	Hours
12/02/19	DS	Draft email to TXP financial analyst re: cash data needed for weekly report	0.20
12/02/19	DS	Follow up with C. Robertson (Davis Polk) re: 8-weeks prepetition cash report approval, outlining key items	0.50
12/02/19	IA	Review of actual weekly operating expenses and editing of assumptions in cash forecast model to reflect latest run rate assumptions.	2.10
12/02/19	IA	Correspondence with client and review of updated Purdue commercial rebates forecast for December.	1.30
12/02/19	IA	Correspondence with management on R&D upcoming payments.	0.30
12/02/19	IA	Update Purdue cash forecast model to reflect latest assumptions on R&D payments.	0.80
12/02/19	IA	Review and update of summary on UCC negotiations on wages and benefits.	2.50
12/02/19	SKL	Prepare updated bridge analysis re: FTI inquiry on cash actuals.	1.10
12/02/19	SKL	Continue to finalize the 11.22 Cash Actuals report.	2.60
12/02/19	SKL	Finalize review of IAC transactions and transaction mapping re: Cash Actuals.	1.70
12/03/19	SKL	Finalize updates to the bridge analysis re: Cash Actuals.	0.50
12/03/19	SKL	Finalize cash report for week ending 11.22.	2.70
12/03/19	SKL	Begin putting to together the weekly cash actuals report for week ending 11/29	2.70
12/03/19	SKL	Reconcile latest paysource and East West cash transactions and categorize for the weekly cash actuals report.	2.30

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2120733-2

Date	Consultant	Description of Services	Hours
12/03/19	SKL	Prepare the updated IAC summary and categorize the IAC and Intercompany transactions according to the latest feedback provided by the company.	2.10
12/03/19	IA	Update rebate forecast for Purdue to include latest payments and latest estimate of Q3 amounts.	2.80
12/03/19	IA	Prepare file showing agreed LTRP payments for Below VP for Rhodes	1.90
12/03/19	DS	In response to Controller's (PPLP) request for backup supporting 12/31/2019 cash balance, draft detailed outline of points to consider	0.80
12/03/19	DS	Review and update retained professionals and restructuring professionals fee models and send to J. DelConte (AlixPartners)	1.40
12/03/19	DS	Put together Rhodes Rebates per cash report summary report (outlining discrepancies with GAAP report) and send to Controller (Rhodes) as basis for call	1.90
12/04/19	DS	Draft outline to J. DelConte (AlixPartners) re: cash summary, significant assumptions, and projected end of year balance	0.80
12/04/19	DS	Draft email to CFO (PPLP) outlining back support and assumptions to compare forecasted 12/31/2019 cash balance with draft number in Board of Directors package	1.10
12/04/19	DS	Put together analysis supporting AlixPartners' illustrative cash forecast support including: (1) support details for Rhodes net operating cash flow, (2) Rhodes' rebate payments, and (3) restructuring professionals and retained professional legal fees	2.20
12/04/19	IA	Prepare summary of end of year cash flow for discussion with management team.	1.70

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2120733-2

Date	Consultant	Description of Services	Hours
12/04/19	IA	Update Purdue cash flow forecast model for latest actuals and updated professional fees forecast.	3.20
12/04/19	SKL	Finalize updates to the 11/29 cash actuals report re: Purdue/Rhodes summaries.	2.30
12/04/19	SKL	Finalize pre-petition cash actual roll forward and begin finalizing updates to the June cash actuals per FTI request.	1.60
12/04/19	SKL	Begin review and categorization of the weekly A/P SAP report for the cash forecast.	1.20
12/04/19	SKL	Begin review and categorization of the weekly A/R SAP report for the cash forecast.	1.20
12/04/19	SKL	Continue to work through the 11/29 cash actuals report to finalize for distribution.	2.50
12/05/19	SKL	Finalize weekly cash actuals report and circulate to the AlixPartners team to review.	2.30
12/05/19	SKL	Finalize pre-petition cash actuals report per FTI diligence request.	2.60
12/05/19	SKL	Meeting with D. Samikkannu, I. Arana, S. Lemack (all AlixPartners), and PPLP controller re: estimated end of year cash position	1.10
12/05/19	IA	Meeting with D. Samikkannu, I. Arana, S. Lemack (all AlixPartners), and PPLP controller re: estimated end of year cash position	1.10
12/05/19	DS	Provide analysis and commentary on Rhodes' cash flows post-petition to FTI	1.70
12/05/19	DS	Draft email to management seeking approval for prepetition cash reporting requested by FTI	0.30
12/05/19	DS	Review CFO's comments about pre-petition cash reporting and incorporate into report	0.90

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2120733-2

Date	Consultant	Description of Services	Hours
12/05/19	DS	Meeting with D. Samikkannu, I. Arana, S. LeMack (all AlixPartners), and PPLP controller re: estimated end of year cash position	1.10
12/05/19	DS	Provide analysis and commentary re: IAC activity for the pre- and post-petition periods to FTI	1.60
12/05/19	DS	Provide information on Debtors' cash management system to FTI, specifically regarding zero-balance accounts	0.80
12/05/19	JD	Review final pre-petition cash actuals presentation	0.40
12/06/19	JD	Analysis of accrued and unpaid professional fees	0.60
12/06/19	DS	Review further revised 11/29 cash report received from S. LeMack (AlixPartners)	0.50
12/06/19	DS	Draft summary to send to J. DelConte (AlixPartners) resignificant items in 11/29 cash report	0.70
12/06/19	DS	Review and provide comments to S. LeMack (AlixPartners) re: 11/29 weekly cash actuals report	1.60
12/06/19	DS	Review updated cash forecast for Rhodes	1.10
12/06/19	DS	Update assumptions re: professional fees in forecast package	0.40
12/06/19	DS	Update cash forecast summary page for cash forecast package	0.50
12/06/19	DS	Update IAC transaction supporting schedule for cash forecast package	0.90
12/06/19	DS	Update rebates supporting schedule for cash forecast package	1.00
12/06/19	IA	Review actuals for week ended 11/29	1.30
12/06/19	SKL	Finalize last updates to the pre-petition cash actuals report.	2.30

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2120733-2

Date	Consultant	Description of Services	Hours
12/06/19	SKL	Finalize updates to the current week's cash actuals report.	1.90
12/06/19	SKL	Update the cash actuals deck with the latest comments re: weekly IAC transactions.	1.30
12/06/19	SKL	Roll the pre-petition cash actuals activity forward into the latest cash actuals report.	1.00
12/06/19	SKL	Continue to review the IAC activity for the 11/29 cash actuals report to confirm the IAC summary was in sync with the latest East West information.	1.30
12/09/19	SKL	Begin preparing the analysis of account balances remonthly operating report cash activity.	2.20
12/09/19	SKL	Continue to reconcile the cash activity re: investment accounts for the monthly operating report.	2.40
12/09/19	SKL	Begin preparing the reporting of cash activity re: monthly operating report.	2.60
12/09/19	SKL	Continue to finalize the analysis of cash disbursements and credits for the monthly operating report.	2.50
12/09/19	DS	Put together analysis and materials in response to Treasurer's (PPLP) questions on cash forecast	1.20
12/09/19	DS	Correspondence with J. DelConte (AlixPartners) re: approval of 11/29 week ended cash report	0.30
12/09/19	DS	Draft summary outline to management outlining key points of cash report and seeking feedback and comments	0.80
12/09/19	DS	Draft summary outline to C. Robertson (Davis Polk) outlining key points of cash report and seeking feedback and comments prior to posting to data room	0.40
12/09/19	DS	Follow up correspondence with counsel (PPLP) re: approval needed to post cash report to data room	0.20

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2120733-2

Date	Consultant	Description of Services	Hours
12/09/19	JD	Correspondence with management re: expense reimbursements	0.60
12/09/19	JD	Review and provide comments on last two weeks cash actuals reports	0.70
12/10/19	SKL	Continue to finalize the cash reports for the monthly operating report.	2.30
12/10/19	SKL	Begin reviewing the EastWest cash activity and categorizing transactions for the weekly cash actuals report.	2.30
12/10/19	SKL	Prepare updated 13 week cash actual summary to track cash activity across Purdue and Rhodes entities.	1.90
12/10/19	IA	Update Purdue Medicaid and Commercial rebate payment assumptions in 13 week cash flow forecast.	1.60
12/10/19	IA	Update Purdue customer collections forecast to reflect actual sales and anticipated fee for services credit deductions.	1.70
12/10/19	IA	Review updated report on voluntary terminations received from HR.	0.70
12/10/19	IA	Update Purdue OCP payment forecast based on approved caps by Tier.	1.30
12/10/19	IA	Draft detailed schedule of payments to restructuring professionals, to be included in cash forecast overview presentation.	1.80
12/10/19	IA	Update Purdue and Rhodes cash forecast overview presentation to reflect latest edits and assumption changes.	3.10
12/11/19	SKL	Continue to finalize the weekly cash actuals and update the report to include the disbursement/credit summary for the monthly operating report.	2.40

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2120733-2

Date	Consultant	Description of Services	Hours
12/11/19	SKL	Continue to reconcile and categorize all Paysource cash transactions for the weekly cash actuals report.	2.40
12/11/19	SKL	Reconcile the latest investment account activity and prepare for the cash actuals reporting.	2.10
12/11/19	SKL	Update the Purdue and Rhodes cash summaries re: weekly cash actuals.	2.70
12/12/19	SKL	Prepare updated agenda for tomorrow's call re: case management update.	0.60
12/12/19	SKL	Review the updated IAC cash activity and notes provided by K. Darragh (Purdue) and update the cash actuals report accordingly.	2.30
12/12/19	SKL	Update the past month's cash actuals reports with the latest investment activity re: Trustee Charges provided by J. Liceaga (Purdue) and rolled forward to the current week.	2.30
12/12/19	SKL	Finalize the weekly cash actuals with the latest feedback provided by the company and distribute to J. Lowne (Purdue) for final review.	2.10
12/13/19	SKL	Review the October monthly operating report and ensure that the updated investment activity re: Trustee Charges flowed through into the November monthly operating report.	2.40
12/13/19	SKL	Finalize updates to the monthly Purdue Separations report.	1.70
12/13/19	SKL	Finalize review and closing out of weekly cash-actuals report.	1.20
12/13/19	JD	Review final draft 13 week cash flow forecast and provide final comments. Review against budget cash flow outlook.	1.60
12/13/19	JD	Review final cash actuals report for the week.	0.50

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2120733-2

Date	Consultant	Description of Services	Hours
12/16/19	SKL	Review and reconcile the latest East West cash transactions as I began preparing the weekly cash report.	2.40
12/16/19	SKL	Review and reconcile weekly Intercompany and IAC transactions for this past week's cash report.	2.10
12/16/19	SKL	Begin reviewing the weekly Paysource information re: weekly cash report.	1.20
12/16/19	IA	Update professional fees forecast schedule to reflect filed applications and approved retentions.	1.80
12/16/19	IA	Update rebate schedule in forecast to reflect transition of medicare and commercial rebates third party payment vendor.	0.60
12/16/19	IA	Follow up on backup information for Medicare coverage gap payment by Purdue.	0.90
12/16/19	IA	Correspondence with Davis Polk on cash balances at the time of filing.	0.40
12/16/19	IA	Review of legal expense actuals post filing and upcoming payments.	1.90
12/16/19	IA	Follow up on review and approvals to post cash forecast for Purdue and Rhodes.	0.80
12/16/19	IA	Review of actuals for two weeks ended 12/6 and 12/13	1.90
12/16/19	IA	Follow up on upcoming Q3 end of year payments for Purdue cash forecast.	2.70
12/17/19	IA	Prepare responses to cash forecast and actuals diligence requests received from FTI.	1.60
12/17/19	IA	Correspondence with management on variances to cash forecast for prior weeks, including large Rhodes receipts and large non-recurring operating payments.	1.30
12/17/19	SKL	Begin categorization of all East West cash transactions recash reporting.	2.60

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2120733-2

Date	Consultant	Description of Services	Hours
12/17/19	SKL	Update bank summary information re: Rhodes and Purdue cash reporting.	2.30
12/17/19	SKL	Review latest investment activity and update the cash summaries accordingly.	1.30
12/18/19	SKL	Finalize the cash summaries and IAC summaries re: weekly cash reporting.	2.60
12/18/19	SKL	Review and reconcile the past month's weekly rebates and began to update the customer programs report accordingly.	2.40
12/18/19	SKL	Continue to updated the customer program's report re: Purdue weekly rebate information.	2.60
12/18/19	SKL	Continue to finalize the Purdue rebate categorization re: customer programs reporting.	2.10
12/19/19	SKL	Begin preparing the two-week weekly cash actuals to cash forecast reconciliation.	2.10
12/19/19	SKL	Finalize the weekly Rhodes cash actuals to cash forecast reconciliation.	2.00
12/19/19	IA	Review of questions on cash actuals received from FTI and drafting of responses.	1.50
12/19/19	IA	Review IAC and intercompany transactions for weeks ended 12/6 and 12/13	0.80
12/19/19	IA	Review filed application fees for retained professionals on docket	1.70
12/19/19	JD	Review draft cash actuals presentation to post for committee advisors. Provide comments re: same.	0.50
12/20/19	JD	Review and provide comments re: forecast to actual analysis.	0.80
12/20/19	IA	Review actuals tracking for the weeks ended 12/6 and 12/13.	1.40

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2120733-2

Date	Consultant	Description of Services	Hours
12/20/19	IA	Update Purdue and Rhodes forecast to actuals analysis for weeks ended 12/6 and 12/13	1.80
12/20/19	IA	Update cash report overview presentation for the weeks ended 12/6 and 12/13	1.70
12/20/19	SKL	Finalize the weekly cash report with the latest feedback and information provided by K. Darragh (Purdue) and J. Licega (Purdue).	2.20
12/20/19	SKL	Prepare the weekly cash reporting deck and prepare for distribution to the Purdue team for final sign-off.	2.30
12/20/19	SKL	Update the weekly cash report with additional slides re: cash actuals to cash forecast reconciliation.	1.20
12/20/19	SKL	Finalize the Rhodes rebate section of the customer programs report and began to review the Purdue piece.	2.50
12/23/19	SKL	Begin reviewing and reconciling this past week's East West cash transactions report.	2.70
12/23/19	SKL	Begin categorizing the East West cash transactions re: weekly cash actuals.	2.20
12/23/19	SKL	Review and reconcile the weekly Paysource transactions re: weekly cash reporting.	2.40
12/23/19	SKL	Continue to categorize and map the weekly Paysource transactions re: weekly cash reporting.	1.80
12/23/19	IA	Review cash actuals for the week ended 12/20.	1.40
12/23/19	IA	Correspondence with company and Davis Polk on professional fees forecast detail requested by committees.	0.30
12/23/19	IA	Draft professional fees detailed schedule as requested by committees.	0.40
12/24/19	SKL	Continue to finalize the weekly cash actuals report.	2.40
12/24/19	SKL	Review the latest IAC cash transactions and prepare the weekly cash summaries re: weekly cash actuals.	2.10

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2120733-2

Date	Consultant	Description of Services	Hours
12/24/19	JD	Correspondence with management re: professional fee payments	0.50
12/26/19	SKL	Review and reconcile the latest PPLP information provided re: monthly customer programs reporting.	2.10
12/27/19	JD	Correspondence with Davis Polk re: cash forecast diligence materials.	0.40
12/30/19	SKL	Review latest responses re: weekly cash inquiries and prepare updates to the weekly cash report accordingly.	0.90
		Total	212.80

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice #

2120733-2

Re:

Cash Management 012589.00103

Fee Recap:

Client/Matter #

Consultant	Hours	Rate	Amount
Sam K Lemack	127.20	440.00	55,968.00
David Samikkannu	24.90	615.00	15,313.50
Isabel Arana de Uriarte	54.10	615.00	33,271.50
Jesse DelConte	6.60	945.00	6,237.00
Total Hours & Fees	212.80		110,790.00

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice #

2120733-2

Re:

Communication with Interested Parties

Client/Matter #

012589.00104

Date	Consultant	Description of Services	Hours
12/03/19	IA	Correspondence with management on DOJ requests related to current employee roster.	0.40
12/03/19	IA	Reconcile current employee roster with files provided through diligence process to committees	1.80
12/03/19	IA	Draft summary of current employee roster to be provided to DOJ.	0.90
12/05/19	NAS	Summary of C. Landau (Purdue) compensation data per request from State of Massachusetts via M. Huebner (Davis Polk).	1.40
12/09/19	JD	Review materials pull together to answer open questions re: CEO comp and correspondence with Davis Polk re: same.	0.80
12/10/19	JD	Call with Davis Polk re: open diligence questions and process.	0.50
12/10/19	JD	Correspondence and discussions with Davis Polk, PJT Partners and FTI re: confidentiality designation and FTI report to be shared with the AHC members and review request list of materials to be shared from FTI.	1.30
12/11/19	JD	Call with management, PJT Partners and Davis Polk re: information sharing with the AHC members.	0.80
12/11/19	JD	Call with J. DelConte, A. DePalma (both AlixPartners), Purdue and UCC/AHC Advisors re. Business Plan Questions	1.10
12/11/19	ADD	Call with J. DelConte, A. DePalma (both AlixPartners), Purdue and UCC/AHC Advisors re. Business Plan Questions	1.10
12/12/19	JD	Call with Davis Polk and management re: PBGC information request response.	0.70

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2120733-2

Re: Communication with Interested Parties

Date	Consultant	Description of Services	Hours
12/12/19	JD	Review open diligence questions. Correspondence with UCC advisors re: same.	0.60
12/12/19	JD	Participate in an update call with PJT Partners, Davis Polk, management, Dechert, Skadden Arps and various shareholders and their representatives re: update call.	2.10
12/12/19	NAS	Build category breakdown of payments to C. Landau (Purdue) over 90 days and 270 days prior to filing as requested by interested parties.	0.70
12/13/19	NAS	Request insider payment data covering January 2018 through September 2018 from Purdue in order to respond to C. Landau (Purdue) compensation questions posed by counsel to UCC (Pillsbury).	0.60
12/13/19	NAS	Build detailed summary of compensation received by C. Landau (Purdue) in year prior to bankruptcy filing as requested by counsel to UCC (Pillsbury).	0.80
12/15/19	NAS	Consolidate and build summary of C. Landau (Purdue) compensation data covering January 2018 through September 2018 received to date as requested by counsel to UCC (Pillsbury).	1.20
12/16/19	NAS	Build summary of pre-SOFA period payments to insiders as requested by advisors to UCC.	0.40
12/17/19	NAS	Build summaries of compensation for C. Landau (Purdue) by year paid and year earned for conversations with advisors to UCC.	2.30
12/17/19	IA	Meeting with K. Tirabassi, K. Knechtel (both FTI), J. DelConte, I. Arana, and S. Lemack (all AlixPartners) to discuss outstanding questions re: Cash Forecast and Cash Actuals reports	0.70
12/17/19	SKL	Meeting with K. Tirabassi, K. Knechtel (both FTI), I. Arana, S. Lemack, and J. DelConte (all AlixPartners) to	0.70

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2120733-2

Re: Communication with Interested Parties

Date	Consultant	Description of Services	Hours
		discuss outstanding questions re: Cash Forecast and Cash Actuals reports	_
12/17/19	MH	Prepare response to committee questions on certain 503(b)(9) payments.	0.70
12/17/19	JD	Meeting with K. Tirabassi, K. Knechtel (both FTI), J. DelConte, I. Arana, and S. Lemack (all AlixPartners) to discuss outstanding questions re: Cash Forecast and Cash Actuals reports	0.70
12/18/19	JD	Conference call with management, Province and I. Arana (AlixPartners) re: IT integration plan	0.70
12/18/19	MH	Prepare 503(b)(9) report for committee with specific invoice support.	0.50
12/18/19	MH	Prepare package of information to support a trade agreement with a large REMS consortium provider.	0.60
12/18/19	IA	Conference call with management, Province and I. Arana (AlixPartners) re: IT integration plan	0.70
12/19/19	IA	Review of diligence items shared directly with committees to be posted to the data room.	0.80
12/20/19	MH	Research contracts for large REMS vendor to submit to the UCC professionals.	0.60
12/23/19	NAS	Revise detailed summary of C. Landau's (Purdue) compensation from 2018 through filing as requested by advisors to UCC.	0.90
12/30/19	JD	Prepare for and participate in a call with Province, Jefferies, FTI and PJT Partners re: BD opportunity and Purdue Canada transaction overviews.	0.60
		Total _	27.70

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice #

2120733-2

Re:

Communication with Interested Parties

Client/Matter #

012589.00104

#### Fee Recap:

Consultant	Hours	Rate	Amount
Sam K Lemack	0.70	440.00	308.00
Andrew D DePalma	1.10	480.00	528.00
Nate A Simon	8.30	480.00	3,984.00
Isabel Arana de Uriarte	5.30	615.00	3,259.50
Michael Hartley	2.40	830.00	1,992.00
Jesse DelConte	9.90	945.00	9,355.50
Total Hours & Fees	27.70		19,427.00

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice #

2120733-2

Re:

U. S. Trustee / Court Reporting Requirements

012589.00105 Client/Matter #

Date	Consultant	Description of Services	Hours
12/03/19	HK	Update vendor payments tracker with revised Accounts Payable data for internal discussion.	0.70
12/03/19	HK	Review of pre-petition invoices to confirm payments paid under Motion.	1.30
12/04/19	SKL	Review the SOFA/Schedule filings and provide update re: patents per request.	0.70
12/04/19	HK	Review of pre-petition invoices to confirm payments paid under Motion.	2.70
12/04/19	HK	Review draft trade agreements under the Vendor Motion.	1.60
12/05/19	HK	Update critical vendor payments tracker with revised Accounts Payable data.	1.50
12/06/19	HK	Review of pre-petition invoices to confirm payments paid under Motion.	1.40
12/09/19	HK	Update status tracking documents for vendor trade agreements	0.70
12/09/19	MH	Prepare new Monthly Operating Report template for November.	0.80
12/09/19	MH	Distribute work plan for November Monthly Operating Report.	0.30
12/09/19	MH	Update retained professionals release list to reflect new retention orders.	0.70
12/09/19	MH	Build new professional payment tracking system.	2.20
12/10/19	HK	Update tracking documents for Critical Vendor payments under motion	0.90
12/10/19	JD	Discussion with management re: additional accounting reserves and review latest MOR re: incorporating updated numbers into the upcoming filing.	0.90

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2120733-2

Re: U. S. Trustee / Court Reporting Requirements

Date	Consultant	Description of Services	Hours
12/11/19	HK	Update tracking documents for Critical Vendor payments under motion	1.30
12/11/19	HK	Update tracking documents for Critical Vendor payments under motion	0.20
12/11/19	HK	Update status tracking documents for vendor trade agreements	0.50
12/11/19	IF	Review cash transfers of Value Report for redactions	4.20
12/11/19	IF	Review cash transfers of Value Report for redactions.	4.20
12/11/19	NAS	Review insider T&E and housing payment data provided by Purdue/TXP Services for purposes of November 2019 Monthly Operating Report.	0.50
12/11/19	NAS	Request payroll, benefit, and one-off insider payment sources from Purdue/TXP for purposes of November 2019 Monthly Operating Report.	0.40
12/12/19	NAS	Request updated insider payment data for purposes of November 2019 Monthly Operating Report and consolidate data received to date.	1.00
12/12/19	НК	Update status tracking documents for vendor trade agreements	1.40
12/13/19	НК	Update tracking documents for Critical Vendor payments under motion	1.20
12/16/19	НК	Update tracking documents for Critical Vendor payments under motion	1.40
12/16/19	НК	Update status tracking documents for vendor trade agreements	1.60
12/16/19	NAS	Consolidate data sources and build model for insider payments section of November 2019 Monthly Operating Report.	1.80

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2120733-2

Re: U. S. Trustee / Court Reporting Requirements

Date	Consultant	Description of Services	Hours
12/16/19	NAS	Check all figures listed in initial draft of insider payments section for November 2019 Monthly Operating Report.	0.70
12/16/19	NAS	Further analysis of annual fair market value computation for vehicles used by C. Landau and M. Kesselman (both Purdue) as listed in company payroll reports.	0.50
12/17/19	NAS	Proof insider payments section of November 2019 Monthly Operating Report and revise where necessary.	1.70
12/17/19	NAS	Discussion with M. Hartley and N. Simon (both AlixPartners) regarding remaining open items for insider payments section of November 2019 Monthly Operating Report.	0.30
12/17/19	HK	Update status tracking documents for vendor trade agreements	1.40
12/17/19	НК	Meeting with J. Lowne, E. Ruiz, S. Daniel, J. Carlisle, L. Harding (all Purdue), D. Fogel (Rhodes), H. Ku, and M. Hartley (both AlixPartners) on critical vendor management issues.	0.40
12/17/19	MH	Review submitted data for inclusion in the November Monthly Operating Report.	2.20
12/17/19	МН	Discussion with N. Simon and M. Hartley (both AlixPartners) regarding remaining open items for insider payments section of November 2019 Monthly Operating Report.	0.30
12/18/19	MH	Prepare initial draft of the November Monthly Operating Report.	2.80
12/18/19	НК	Update tracking documents for Critical Vendor payments under motion	1.80
12/18/19	HK	Update status tracking documents for vendor trade agreements	1.30

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2120733-2

Re: U. S. Trustee / Court Reporting Requirements

Date	Consultant	Description of Services	Hours
12/19/19	НК	Update status tracking documents for vendor trade agreements	0.50
12/19/19	НК	Update tracking documents for Critical Vendor payments under motion	1.60
12/19/19	MH	Finalize edits to the November Monthly Operating Report.	2.40
12/19/19	JD	Review and provide comments re: draft November MOR.	0.70
12/20/19	MH	Create and submit final November Monthly Operating Report for filing.	0.80
12/20/19	НК	Update status tracking documents for vendor trade agreements	0.50
12/20/19	NAS	Review of final November 2019 Monthly Operating Report for accuracy.	0.60
12/23/19	НК	Update status tracking documents for vendor trade agreements	1.10
12/23/19	НК	Update tracking documents for Critical Vendor payments under motion	1.30
12/24/19	НК	Update status tracking documents for vendor trade agreements	1.80
12/26/19	НК	Update status tracking documents for vendor trade agreements	0.80
12/26/19	НК	Review IAC diligence materials for COGS reduction initiatives	1.40
12/26/19	НК	Update tracking documents for Critical Vendor payments under motion	1.80
12/27/19	НК	Update tracking documents for Critical Vendor payments under motion	0.40
12/27/19	НК	Update status tracking documents for vendor trade agreements	1.40

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2120733-2

Re: U. S. Trustee / Court Reporting Requirements

Date	Consultant	Description of Services	Hours
12/30/19	HK	Update status tracking documents for vendor trade agreements	1.80
12/30/19	HK	Update tracking documents for Critical Vendor payments under motion	1.80
12/31/19	HK	Update status tracking documents for vendor trade agreements	0.70
		Total	70.90

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice #

2120733-2

Re:

U. S. Trustee / Court Reporting Requirements

Client/Matter #

012589.00105

#### Fee Recap:

Consultant	Hours	Rate	Amount
Hart Ku	40.20	440.00	17,688.00
Sam K Lemack	0.70	440.00	308.00
Nate A Simon	7.50	480.00	3,600.00
Isaac Fisboin	8.40	775.00	6,510.00
Michael Hartley	12.50	830.00	10,375.00
Jesse DelConte	1.60	945.00	1,512.00
Total Hours & Fees	70.90		39,993.00

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice #

2120733-2

Re:

**Business Analysis & Operations** 

Client/Matter #

012589.00106

Date	Consultant	Description of Services	Hours
12/01/19	GJK	Strawman Outline for Due Diligence Deck for IAC	1.00
12/01/19	GJK	Notes on Canada budget from Nov 2019 Board Meeting	1.00
12/01/19	GJK	Notes on Europe Budget from Nov 2019 Board Meeting	1.50
12/01/19	GJK	Notes on LAM Budget from Nov 2019 Board Meeting	1.50
12/01/19	GJK	Notes on overall budget from Nov 2019 Board Meeting	1.00
12/01/19	JD	Review high-level preliminary G&A 5 year plan	0.40
12/01/19	JD	Review initial draft Purdue Canada CMO proposal presentation from PJT	0.50
12/02/19	JD	Review long term business plan details re: G&A forecast and discuss same with management.	0.70
12/02/19	GJK	IAC project coordination, including follow up activities (info request lists, diligence workstreams)	1.00
12/02/19	GJK	Meeting with G. Koch, N. Simon, and M. Hartley (all AlixPartners) to prepare accounts payable release list.	0.50
12/02/19	GJK	Mundi financial comparison with Evercore financials	2.10
12/02/19	DS	Draft outline to Controller (PPLP) re: significant items in monthly flash report and seeking feedback	0.70
12/02/19	DS	Review cash discounts data sent by Controller (Rhodes), incorporate into analysis, and include in draft Customer Programs report	1.40
12/02/19	DS	Review Coverage Gap data sent by Controller (Rhodes) and incorporate into draft Customer Programs report	0.80
12/02/19	JD	Review updated draft October flash report to post for various creditor advisors. Provide comments re: same.	1.20
12/02/19	JD	Correspondence with Davis Polk and Willis Towers Watson re: outstanding wage questions prior to the hearing on Wednesday.	0.70

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2120733-2

Re: **Business Analysis & Operations** 

Date	Consultant	Description of Services	Hours
12/02/19	JD	Review analysis of various compensation packages and outstanding compensation programs for the company. Provide updated figures to Davis Polk for the hearing.	0.90
12/02/19	JD	Review latest draft Board deck re: 2020 budget. Provide comments re: same.	2.00
12/02/19	JD	Review analysis of and correspondence re: attrition estimates.	0.50
12/02/19	DS	Correspondence with Controller (Rhodes) re: follow-up items for October Customer Programs monthly report	0.40
12/02/19	DS	Review draft October monthly flash report and send to J. DelConte (AlixPartners) for approval before sending to management for review	0.90
12/02/19	DS	Review Q3 commercial rebates data sent by Controller (Rhodes) and reconcile with items identified in AlixPartners' cash reporting process	1.70
12/02/19	DS	Draft email with calculation of discounts/big 3 discounts to be reviewed by Controller (Rhodes)	0.30
12/02/19	KM	Review and research background information re. API marketplace competitors and market share	1.20
12/02/19	KM	Review and research background information re. API marketplace deals and transactions.	0.90
12/02/19	KM	Call with D.Fogel, R. Shamblen, J. Freidrichsen (all Rhodes) K. McCafferty, and R. Sublett (both AlixPartners) re: API market competition, growth opportunities, and partnership opportunities	1.60
12/02/19	KM	Call with R. Sublett, and K. McCafferty (both AlixPartners) re API market workstreams	0.20
12/02/19	KM	Review API market analysis for discussion with D.Fogel, R. Shamblen, J. Freidrichsen (all Rhodes)	0.90

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2120733-2

Re: **Business Analysis & Operations** 

Date	Consultant	Description of Services	Hours
12/02/19	RDS	API market research	1.70
12/02/19	RDS	Prepare for API call with J. Fredrickson (Purdue) - review market dynamics and previous production volumes	1.20
12/02/19	RDS	Call with D.Fogel, R. Shamblen, J. Freidrichsen (all Rhodes) K. McCafferty, and R. Sublett (both AlixPartners) re: API market competition, growth opportunities, and partnership opportunities	1.60
12/02/19	RDS	Call with R. Sublett, and K. McCafferty (both AlixPartners) re API market workstreams	0.20
		Prepare API market analysis for key Rhodes APIs	
12/02/19	KM	Prepare personnel restructuring analysis and review	1.60
12/02/19	KM	presentation	1.90
12/02/19	GJK	Meeting with G. Koch, M. Hartley, and N. Simon (all AlixPartners) to review November 2019 Mundipharma budget materials presented to Board of Directors and discuss key take aways.	1.50
12/02/19	GJK	Meeting with G. Koch, M. Hartley, and N. Simon (all AlixPartners) to discuss outline for Mundipharma diligence report.	1.00
12/02/19	NAS	Track executed trade agreements submitted by critical vendors to ensure payment is made for pre-petition amounts owed.	0.50
12/02/19	NAS	Meeting with G. Koch, M. Hartley, and N. Simon (all AlixPartners) to review November 2019 Mundipharma budget materials presented to Board of Directors and discuss key takeaways.	1.50
12/02/19	NAS	Review current draft of IAC diligence summary and proposed report structure in advance of meeting with G. Koch and M. Hartley (both AlixPartners).	1.30

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2120733-2

Re: **Business Analysis & Operations** 

Date	Consultant	Description of Services	Hours
12/02/19	NAS	Compile questions related to IAC diligence that have been submitted to Norton Rose/Mundipharma and note which have been addressed within IAC diligence tracking document.	1.60
12/02/19	NAS	Meeting with G. Koch, N. Simon, and M. Hartley (all AlixPartners) to prepare accounts payable release list.	0.50
12/02/19	NAS	Meeting with G. Koch, M. Hartley, and N. Simon (all AlixPartners) to discuss outline for Mundipharma diligence report.	1.00
12/02/19	HK	Meeting with J. Lowne, E. Ruiz, S. Daniel (all Purdue), H. Ku, and M. Hartley (both AlixPartners) to discuss vendor payment management efforts.	0.50
12/02/19	MH	Meeting with CFO to review critical vendor status and develop plan to finish the project.	0.40
12/02/19	MH	Meeting with J. Lowne, E. Ruiz, S. Daniel (all Purdue), H. Ku, and M. Hartley (both AlixPartners) to discuss vendor payment management efforts.	0.50
12/02/19	MH	Meeting with G. Koch, M. Hartley, and N. Simon (all AlixPartners) to discuss outline for Mundipharma diligence report.	1.00
12/02/19	МН	Meeting with G. Koch, M. Hartley, and N. Simon (all AlixPartners) to review November 2019 Mundipharma budget materials presented to Board of Directors and discuss key takeaways.	1.50
12/02/19	MH	Meeting with G. Koch, N. Simon, and M. Hartley (all AlixPartners) to prepare accounts payable release list.	0.50
12/02/19	MH	Update release lists with new trade agreement activity.	0.70
12/02/19	LJD	Review and comment on PJT presentation regarding insourcing options	0.90

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2120733-2

Re: **Business Analysis & Operations** 

Date	Consultant	Description of Services	Hours
12/02/19	LJD	Call with B. Folse, L. Donahue, and J. DelConte (all AlixPartners) re: go forward work streams.	0.50
12/02/19	MH	Develop analysis process to evaluate paid critical vendor invoices for petition status.	0.40
12/02/19	ADD	Update interested parties list.	1.40
12/02/19	ADD	Download and compile vendor spend and outstanding invoice data.	1.10
12/03/19	ADD	Compile and prepare files for upload to the data room.	2.90
12/03/19	ADD	Submit approval requests to upload files submitted in response to diligence requests to data room.	1.30
12/03/19	ADD	Draft response to diligence request in preparation for discussion with counsel.	1.30
12/03/19	ADD	Review board materials and compile financial presentations for upload to data room	1.60
12/03/19	МН	Follow-up call with R. Chesley, G. Rodgers (both DLA Piper), G. Koch, M. Hartley, N. Simon (all AlixPartners), and advisors to UCC and Ad-Hoc Committee to address questions on Mundipharma compliance investigation memo.	1.00
12/03/19	МН	Call with Philippe Mazas (Mundipharma), G. Koch, M. Hartley, N. Simon (all AlixPartners), and advisors to UCC and Ad-Hoc Committee to provide an overview of Mundipharma IT systems and capabilities. (partial attendance)	0.50
12/03/19	MH	Attend meetings with E. Ruiz (Purdue), various company vendor specialists, H. Ku, and M. Hartley (both AlixPartners) on vendor trade agreement statuses.	1.00
12/03/19	MH	Prepare analysis of possible additional 503(b)(9) qualifying invoices for research.	1.90

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2120733-2

Re: **Business Analysis & Operations** 

Date	Consultant	Description of Services	Hours
12/03/19	MH	Create new deletion script to stop additional payments to settled critical vendors.	0.80
12/03/19	MH	Research legal vendor not releasing from accounts payable.	0.60
12/03/19	MH	Prepare accounts payable release list.	0.70
12/03/19	МН	IAC diligence team coordination meeting with G. Koch, M. Hartley, and N. Simon (all AlixPartners) to ensure alignment on priorities and to determine allocation of workstreams.	1.20
12/03/19	MH	Develop new project plan outline for IAC analysis.	1.20
12/03/19	MH	Discussion with M. Hartley and H. Ku (both AlixPartners) on vendor trade agreement statuses.	0.30
12/03/19	HK	Attend meetings with E. Ruiz (Purdue), various company vendor specialists, H. Ku, and M. Hartley (both AlixPartners) on vendor trade agreement statuses.	1.00
12/03/19	НК	Discussion with M. Hartley and H. Ku (both AlixPartners) on vendor trade agreement statuses.	0.30
12/03/19	HK	Review and update IAC diligence status.	0.80
12/03/19	НК	Review diligence documents to analyze cost savings opportunities identified in board budget presentations.	3.20
12/03/19	IA	Prepare file showing agreed LTRP payments by employee for VPs and above as request by HR.	1.60
12/03/19	HK	Update plan on due diligence research coordination.	1.00
12/03/19	НК	Review budget documents of independent affiliated companies.	3.50
12/03/19	NAS	Research into global opioid prescription trends to assess projections made by Mundipharma management to Board of Directors.	0.60

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2120733-2

Re: **Business Analysis & Operations** 

Date	Consultant	Description of Services	Hours
12/03/19	NAS	Analyze Mundipharma legal entity descriptions and product flow maps provided by Norton Rose to understand both functional and legal structure of Mundipharma network of companies.	1.70
12/03/19	NAS	Revise IAC diligence tracker to incorporate latest requests, documents received, interviews held, and questions outstanding.	1.40
12/03/19	NAS	Review materials related to Mundipharma China compliance in advance of call with DLA Piper.	0.40
12/03/19	NAS	Follow-up call with R. Chesley, G. Rodgers (both DLA Piper), G. Koch, M. Hartley, N. Simon (all AlixPartners), and advisors to UCC and Ad-Hoc Committee to address questions on Mundipharma compliance investigation memo.	1.00
12/03/19	NAS	Call with P. Mazas (Mundipharma), G. Koch, M. Hartley, N. Simon (all AlixPartners), and advisors to UCC and Ad- Hoc Committee to provide an overview of Mundipharma IT systems and capabilities.	1.20
12/03/19	NAS	Follow-up discussion with G. Koch and N. Simon (both AlixPartners) regarding key takeaways from compliance call with DLA Piper and Mundipharma IT Services overview.	0.50
12/03/19	NAS	IAC diligence team coordination meeting with G. Koch, M. Hartley, and N. Simon (all AlixPartners) to ensure alignment on priorities and to determine allocation of workstreams.	1.20
12/03/19	RDS	Meeting with J. Northington (Purdue), R. Sublett, and K. McCafferty (both AlixPartners) re quality organization - spans and layers of control under various scenario analysis	2.10
12/03/19	RDS	Slide creation for quality org structure	0.40

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2120733-2

Re: **Business Analysis & Operations** 

Date	Consultant	Description of Services	Hours
12/03/19	RDS	Conversation with J. Carlisle (Purdue) re board meeting update and NC cost scenarios	0.20
12/03/19	RDS	Quality organization value mapping	0.60
12/03/19	RDS	Correspondence with Rhodes Tech management to chase deliverables	0.30
12/03/19	RDS	Presentation slides - low scenario strategic layout	1.50
12/03/19	RDS	Meeting with D. Igo (Purdue), R. Sublett, and K. McCafferty (both AlixPartners) re group dynamics in the tech transfer function	1.40
12/03/19	KM	Discussion with D. McGuire (Purdue) re: Wilson site visit logistics	0.30
12/03/19	KM	Analysis re: Quality function headcount for Wilson, RT and RP in preparation for discussion with J. Northington (Purdue)	1.40
12/03/19	DS	Call with Controller (Rhodes) re: commercial rebates classification for purposes of October Customer Programs report	0.40
12/03/19	DS	Draft outline to CFO (Purdue) describing contents of October monthly flash report and key items to note	1.20
12/03/19	KM	Meeting with D. Igo (Purdue) K. McCafferty, and R. Sublett (both AlixPartners) re group dynamics in the tech transfer function	1.40
12/03/19	KM	Meeting with J. Northington (Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re quality organization - spans and layers of control under various scenario analysis	2.10
12/03/19	DS	Correspondence with Controller (PPLP) re: monthly flash report process going forward	0.30

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2120733-2

Re: **Business Analysis & Operations** 

Date	Consultant	Description of Services	Hours
12/03/19	DS	Correspondence with Analyst (PPLP) re: GPO fees disbursements in October	0.30
12/03/19	DS	Draft email to general counsel outlining key items and seeking approval to post monthly flash report	0.40
12/03/19	DS	Correspondence with C. Robertson (Davis Polk) re: approval for monthly flash report	0.30
12/03/19	DS	Revise October monthly flash report based on comments received from C. Robertson	0.50
12/03/19	DS	Review commercial rebates supporting detail provided by financial analyst (Rhodes)	1.70
12/03/19	DS	Provide follow up questions to Controller and financial analyst (Rhodes) re: commercial rebates supporting detail	0.70
12/03/19	JD	Review analysis of updated employee roster in response to DOJ request.	0.50
12/03/19	JD	Review supplemental Donahue declaration	0.20
12/03/19	JD	Correspondence with management re: outstanding and accrued professional fees.	0.70
12/03/19	JD	Review documentation created in response to DOJ diligence request list. Provide comments re: same.	0.60
12/03/19	JD	Review and provide comments re: latest cash flow forecast and year end cash estimates.	1.30
12/03/19	JD	Coordination and planning of work streams re: business planning.	0.40
12/03/19	GJK	IAC diligence info request updates - what information has been provided	0.50
12/03/19	GJK	Project coordination, including follow ups with other advisors (Provence, FTI, Jefferies)	1.20
12/03/19	GJK	Follow-up call with R. Chesley, G. Rodgers (both DLA Piper), G. Koch, M. Hartley, N. Simon (all AlixPartners),	1.00

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel Rhodes Technologies Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2120733-2

Re: Business Analysis & Operations

Date	Consultant	Description of Services	Hours
		and advisors to UCC and Ad-Hoc Committee to address questions on Mundipharma compliance investigation memo.	
12/03/19	GJK	Call with P. Mazas (Mundipharma), G. Koch, M. Hartley, N. Simon (all AlixPartners), and advisors to UCC and Ad- Hoc Committee to provide an overview of Mundipharma IT systems and capabilities.	1.20
12/03/19	GJK	Follow-up discussion with G. Koch and N. Simon (both AlixPartners) regarding key takeaways from compliance call with DLA Piper and Mundipharma IT Services overview.	0.50
12/03/19	GJK	IAC diligence team coordination meeting with G. Koch, M. Hartley, and N. Simon (all AlixPartners) to ensure alignment on priorities and to determine allocation of workstreams. (partial attendance)	0.50
12/03/19	GJK	Financial analysis - high level P&L analysis based on available Mundi information	2.80
12/03/19	GJK	Financial analysis - DCF impact of revised projections	2.60
12/03/19	JD	Review outstanding diligence request lists from PJT Partners re: UCC and ACH business plan diligence. Review certain items up for approval to be responsive to said requests.	2.20
12/04/19	GJK	Review and comparison of Canada budget books	1.90
12/04/19	GJK	Updates to DCF projections	2.50
12/04/19	GJK	Adjustments to DCF based on risks related to LAM performance and Celltrion assets	2.40
12/04/19	GJK	Work session with G. Koch, N. Simon, and H. Ku (all AlixPartners) to review revisions to diligence tracker, draft of proposed diligence report outline, and summary of	1.50

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2120733-2

Re: **Business Analysis & Operations** 

Date	Consultant	Description of Services	Hours
		OpEx reduction projections presented by Mundipharma management to Board of Directors in November 2019.	
12/04/19	GJK	Review of cost reduction activities developed by H Ku (AlixPartners)	0.50
12/04/19	GJK	Review of org structure and strawman updates by N. Simon (AlixPartners)	0.50
12/04/19	GJK	Mundi strawman development	2.20
12/04/19	JD	Review CEO compensation arrangements. Discussion re: next steps in negotiations.	0.70
12/04/19	DS	Correspondence with financial analyst (Rhodes) re: Medicaid and Industrial Funding Fee payments	0.30
12/04/19	DS	Update October Customer Program report with Medicaid and Industrial Funding fee payment data	0.70
12/04/19	DS	Send draft October Customer Programs report to management and general counsel for review, outlining key items and supporting data	0.50
12/04/19	DS	Update October Customer Program report for Medicaid by state data obtained from financial analyst (PPLP), i.e. detail behind Cumberland fundings	2.10
12/04/19	DS	Update October Customer Program report for Medicaid by state data obtained from financial analyst (PPLP), i.e. detail behind iContracts fundings	1.70
12/04/19	DS	Follow up with general counsel re: approval process for monthly flash report	0.40
12/04/19	DS	Draft email to C. Robertson (Davis Polk) seeking final approval for draft monthly flash report	0.20
12/04/19	DS	Further refine iContracts by state allocation based on additional detail provided by Controller (Rhodes)	1.30

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2120733-2

Re: **Business Analysis & Operations** 

Date	Consultant	Description of Services	Hours
12/04/19	KM	Meeting with B. Addicks (Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re supply chain and packaging development functions	1.10
12/04/19	KM	Meeting with J. Northington (Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re quality headcount scenarios for Avrio, development pipeline and various reporting structures	0.60
12/04/19	KM	Meeting with D. McGuire, J. Carlisle (both Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re. staffing for various, production volume scenarios (partial attendance)	1.10
12/04/19	KM	Review Wilson manufacturing productivity monthly and YTD dashboard and reports	0.60
12/04/19	KM	Prepare Wilson Quality organization spans of control analysis for discussion with J. Northington (Purdue)	0.90
12/04/19	RDS	Layout quality organization heads and identify individuals for various scenarios	0.50
12/04/19	RDS	Prepare follow ups for B. Addicks (Purdue) meeting	0.30
12/04/19	RDS	Meeting with D. McGuire, J. Carlisle (both Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re. staffing for various, production volume scenarios	1.80
12/04/19	RDS	Call with D. Fogel (Purdue/Rhodes) to discuss IAC royalties and production volumes / functions in the US organization - both Purdue and Rhodes	0.50
12/04/19	RDS	Call with C. Chomiak (Purdue/Avrio) re scheduling and business planning timelines	0.30
12/04/19	RDS	Prepare email for follow ups to J. Freidrichson (Purdue/Rhodes)	0.50

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2120733-2

Re: **Business Analysis & Operations** 

Date	Consultant	Description of Services	Hours
12/04/19	RDS	Meeting with B. Addicks (Purdue), R. Sublett, and K. McCafferty (both AlixPartners) re supply chain and packaging development functions	1.10
12/04/19	RDS	Conversation with J. Northington (Purdue), R. Sublett, and K. McCafferty (both AlixPartners) re quality headcount scenarios for Avrio, development pipeline and various reporting structures	0.60
12/04/19	RDS	Allocation of historical failure to supply events for Rhodes Generic supplier-level variable contribution analysis	1.10
12/04/19	NAS	Discussion with G. Koch and N. Simon (both AlixPartners) regarding workstream priorities and deliverables for 12/5 meeting.	0.70
12/04/19	NAS	Provide overview to H. Ku (AlixPartners) of OpEx savings included in November 2019 Mundipharma budget materials in order to quantify overall opportunity.	0.60
12/04/19	NAS	Update IAC diligence tracker to reflect latest questions submitted to and documents received from Norton Rose, interviews held with Mundipharma employees, and key takeaways.	1.90
12/04/19	NAS	Discussion with G. Koch, N. Simon (both AlixPartners), R. Schnitzler, T. Melvin, and J. Turner (all PJT Partners) regarding assumptions used in prior Evercore analysis of Mundipharma valuation.	0.30
12/04/19	NAS	Internal discussion with G. Koch and N. Simon (both AlixPartners) regarding proper discount rate and terminal growth rate assumptions to be included in DCF analysis of Mundipharma.	0.50
12/04/19	NAS	IAC diligence team alignment meeting with G. Koch, M. Hartley, N. Simon and H. Ku (all AlixPartners) to review workplan, report outline, and key deliverables in advance of 12/5 update with B. Folse (AlixPartners).	0.90

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2120733-2

Re: **Business Analysis & Operations** 

Date	Consultant	Description of Services	Hours
12/04/19	NAS	Equity cost of capital analysis for Mundipharma through trading comparables	1.10
12/04/19	NAS	Work session with G. Koch, N. Simon, and H. Ku (all AlixPartners) to review revisions to diligence tracker, draft of proposed diligence report outline, and summary of OpEx reduction projections presented by Mundipharma management to Board of Directors in November 2019.	1.50
12/04/19	NAS	Draft legal and functional Mundipharma organization notes for update materials in advance of 12/5 meeting with B. Folse (AlixPartners).	1.00
12/04/19	NAS	Review all diligence overview materials for accuracy and completeness in advance of 12/5 update meeting with B. Folse (AlixPartners).	0.80
12/04/19	NAS	Revise Mundipharma DCF analysis to incorporate revisions to assumed discount rates.	0.40
12/04/19	GJK	Internal discussion with G. Koch and N. Simon (both AlixPartners) regarding proper discount rate and terminal growth rate assumptions to be included in DCF analysis of Mundipharma.	0.50
12/04/19	GJK	Discussion with G. Koch and N. Simon (both AlixPartners) regarding workstream priorities and deliverables for 12/5 meeting.	0.70
12/04/19	GJK	Discussion with G. Koch, N. Simon (both AlixPartners), R. Schnitzler, T. Melvin, and J. Turner (all PJT Partners) regarding assumptions used in prior Evercore analysis of Mundipharma valuation.	0.30
12/04/19	GJK	IAC diligence team alignment meeting with G. Koch, M. Hartley, N. Simon, and H. Ku (all AlixPartners) to review workplan, report outline, and key deliverables in advance of 12/5 update with B. Folse (AlixPartners).	0.90

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel Rhodes Technologies Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2120733-2

Re: Business Analysis & Operations

Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
12/04/19	НК	Work session with G. Koch, H. Ku, and N. Simon (all AlixPartners) to review revisions to diligence tracker, draft of proposed diligence report outline, and summary of OpEx reduction projections presented by Mundipharma management to Board of Directors in November 2019.	1.50
12/04/19	HK	Meeting with H. Ku and N. Simon (all AlixPartners) on OpEx savings included in November 2019 Mundipharma budget materials in order to quantify overall opportunity	0.60
12/04/19	HK	Meeting with E. Ruiz (Purdue), various company vendor specialists, H. Ku, and M. Hartley (both AlixPartners) on vendor trade agreement statuses.	1.00
12/04/19	НК	IAC diligence team alignment meeting with G. Koch, M. Hartley, H. Ku, and N. Simon (all AlixPartners) to review workplan, report outline, and key deliverables in advance of 12/5 update with B. Folse (AlixPartners).	0.90
12/04/19	HK	Review operating expense summaries in IAC due diligence materials.	1.60
12/04/19	IA	Correspondence with Davis Polk on customer agreements.	0.40
12/04/19	LJD	Preread for board meeting on 12/5	0.60
12/04/19	МН	IAC diligence team alignment meeting with G. Koch, N. Simon, M. Hartley, and H. Ku (all AlixPartners) to review workplan, report outline, and key deliverables in advance of 12/5 update with B. Folse (AlixPartners).	0.90
12/04/19	MH	Meeting with E. Ruiz (Purdue), various company vendor specialists, H. Ku, and M. Hartley (both AlixPartners) on vendor trade agreement statuses.	1.00
12/04/19	МН	Call with North Carolina vendor contact to review petition status of new invoice from contract manufacturer.	0.50
12/04/19	MH	Prepare accounts payable release list.	0.40
12/04/19	MH	Research CMO vendor invoice not releasing for payment.	0.40

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2120733-2

Re: **Business Analysis & Operations** 

Date	Consultant	Description of Services	Hours
12/04/19	MH	Complete the project outline for analysis of IAC value.	2.60
12/04/19	MH	Create analysis of new pre-petition invoices to prediction of remaining invoices that may be produced.	1.40
12/04/19	MH	Research split invoice incorrectly marked as pre-petition.	0.40
12/04/19	ADD	Request permission to upload files to the data room.	1.30
12/04/19	ADD	Upload files submitted in response to diligence requests to data room.	1.10
12/04/19	ADD	Compile and format files supplied in response to diligence requests.	2.90
12/04/19	ADD	Review and update data room permissions.	0.40
12/04/19	ADD	Review diligence request and requested outstanding items.	2.20
12/05/19	ADD	Request approval to upload diligence requests.	0.60
12/05/19	ADD	Review diligence request and requested outstanding items.	2.20
12/05/19	MH	Research and correct legal related vendors not being released from accounts payable.	0.70
12/05/19	MH	Discussion with H. Ku and M. Hartley (both AlixPartners) on changes to the critical vendor tracking process.	0.40
12/05/19	MH	Prepare accounts payable release list.	0.40
12/05/19	MH	Prepare additional accounts payable release list and reconcile all changes.	0.60
12/05/19	MH	Research new pre-petition invoice from food services provider that carries an old date.	0.30
12/05/19	LJD	Prepare for and attend board meeting	5.50
12/05/19	BF	Conference call with B. Folse, G. Koch, M. Hartley, N. Simon, and H. Ku (all AlixPartners) to review IAC diligence status, proposed report outline, management	1.80

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2120733-2

Re: **Business Analysis & Operations** 

Date	Consultant	Description of Services	Hours
		interviews to-date, preliminary assessments of value/risk, organizational structure, and go-forward priorities.	
12/05/19	МН	Conference call with B. Folse, G. Koch, N. Simon, M. Hartley, and H. Ku (all AlixPartners) to review IAC diligence status, proposed report outline, management interviews to-date, preliminary assessments of value/risk, organizational structure, and go-forward priorities.	1.80
12/05/19	НК	Update risk analysis for budget materials in due diligence database.	1.90
12/05/19	НК	Review operating expense summaries in IAC due diligence materials.	1.00
12/05/19	HK	Pre-update call walk-through of IAC diligence materials with G. Koch, H. Ku, and N. Simon (all AlixPartners) to ensure accuracy and comprehensiveness.	0.90
12/05/19	НК	Discussion with M. Hartley and H. Ku (both AlixPartners) on changes to the critical vendor tracking process.	0.40
12/05/19	НК	Conference call with B. Folse, G. Koch, M. Hartley, H. Ku and N. Simon (all AlixPartners) to review IAC diligence status, proposed report outline, management interviews to-date, preliminary assessments of value/risk, organizational structure, and go-forward priorities.	1.80
12/05/19	NAS	Conference call with B. Folse, G. Koch, M. Hartley, N. Simon and H. Ku (all AlixPartners) to review IAC diligence status, proposed report outline, management interviews to-date, preliminary assessments of value/risk, organizational structure, and go-forward priorities.	1.80
12/05/19	NAS	Update IAC diligence tracker to reflect most recent documents provided by Mundipharma/Norton Rose and set up organization process for internal AlixPartners analyses.	1.40

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2120733-2

Re: **Business Analysis & Operations** 

Date	Consultant	Description of Services	Hours
12/05/19	NAS	Final review of IAC diligence update materials prior to meeting with B. Folse (AlixPartners).	0.40
12/05/19	NAS	Pre-update call walk-through of IAC diligence materials with G. Koch, N. Simon and H. Ku (all AlixPartners) to ensure accuracy and comprehensiveness.	0.90
12/05/19	NAS	Coordinate all IAC diligence management meetings for 12/6 and week of 12/9, as well as corresponding updates to diligence tracker.	0.70
12/05/19	RDS	Call with D. Lundie (Rhodes) K. McCafferty, and R. Sublett (both AlixPartners) re: Rhodes operations opportunities and forward-looking scenarios	1.20
12/05/19	ADD	Assist data room user with technical support issue.	0.70
12/05/19	ADD	Review and update data room permissions.	0.40
12/05/19	ADD	Call with Rhodes general counsel regarding diligence request.	0.30
12/05/19	ADD	Compile and format files supplied in response to diligence requests.	3.10
12/05/19	RDS	Review IQVIA / IMS API market data	0.70
12/05/19	RDS	Prepare thoughts on API market response strategy	0.70
12/05/19	RDS	Prepare presentation materials for Rhodes generic opioids by customer	0.20
12/05/19	RDS	Rhodes pipeline NPV analysis - R&D group headcount allocation	0.70
12/05/19	RDS	Preparation of time / expense allocation document and correspondence with W. Addicks (Purdue) re the same	0.40
12/05/19	RDS	Call with J. DelConte and R. sublett (both AlixPartners) re API go forward path and board meeting download	0.50
12/05/19	RDS	Review WIIson, NC plant operating metrics - tablet production, quality, exceptions, investigations, etc.	0.60

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2120733-2

Re: **Business Analysis & Operations** 

Date	Consultant	Description of Services	Hours
12/05/19	KM	Call with D. Lundie (Rhodes) K. McCafferty, and R. Sublett (both AlixPartners) re: Rhodes operations opportunities and forward-looking scenarios	1.20
12/05/19	KM	Prepare overview for discussion with D. Lundie (Rhodes) re. Rhodes operations opportunities and forward-looking scenarios	0.30
12/05/19	DS	Provide analysis and commentary to FTI re: customer rebates timing and drivers	1.10
12/05/19	DS	Call with Controller (Rhodes) re: final review of Customer Programs report	0.40
12/05/19	DS	Correspondence with C. Robertson (Davis Polk) re: approval for October Customer Programs report	0.30
12/05/19	GJK	Pre-update call walk-through of IAC diligence materials with G. Koch, N. Simon, and H. Ku (all AlixPartners) to ensure accuracy and comprehensiveness.	0.90
12/05/19	GJK	Mundi strawman updates	1.20
12/05/19	GJK	Conference call with B. Folse, G. Koch, M. Hartley, N. Simon, and H. Ku (all AlixPartners) to review IAC diligence status, proposed report outline, management interviews to-date, preliminary assessments of value/risk, organizational structure, and go-forward priorities.	1.80
12/05/19	GJK	Follow up on Europe budget development	1.00
12/05/19	JD	Review final board materials prior to board meeting	0.50
12/05/19	JD	Participate in PPI board meeting	5.80
12/05/19	JD	Catch up with R. Sublett and J. DelConte (both AlixPartners) re: business plan work stream and potential partnership opportunities	0.50
12/05/19	JD	Review analysis re: CEO compensation	0.70

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2120733-2

Re: **Business Analysis & Operations** 

Date	Consultant	Description of Services	Hours
12/06/19	GJK	Call with I. McClatchy (Norton Rose) to discuss diligence, including meeting with European management	0.90
12/06/19	GJK	Call with J. Theurillat (MN Consulting), G. Koch, N. Simon, M. Hartley (all AlixPartners), and advisors to UCC and Ad- Hoc Committee to discuss evolution of his role at Mundipharma and key business trends.	1.60
12/06/19	GJK	Prepare update on discussions with I. McClatchy (Norton Rose) and J. Theurillat (MN Consulting)	0.40
12/06/19	GJK	Follow up discussions with N. Simon and G. Koch (both AlixPartners) on J Theurillat (MN Consulting) call and LAM	0.90
12/06/19	GJK	Review of European budget changes over time, key drugs	2.40
12/06/19	GJK	Project coordination activities and planning	2.00
12/06/19	DS	Follow up with general counsel re: approval of October Customer Programs report	0.30
12/06/19	RDS	API Market construction	0.70
12/06/19	RDS	Call with J. Friederichsen (Purdue/Rhodes) re API volumes and general market landscape	0.90
12/06/19	RDS	Prepare for IT staffing call (NC/RT/RP)	0.40
12/06/19	RDS	Call with H. Ghnaimeh (Purdue) re IT headcount and transformation plans	1.00
12/06/19	RDS	Purdue and RALP IT infrastructure org structure construction	0.60
12/06/19	RDS	Review working plan by A. Soma (Purdue) for staffing / crewing levels	1.30
12/06/19	NAS	Update diligence tracking document to reflect latest interviews held, requests made, and documents received.	0.80
12/06/19	NAS	Call with J. Theurillat (MN Consulting), G. Koch, N. Simon, M. Hartley (all AlixPartners), and advisors to UCC and Ad-	1.60

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2120733-2

Re: **Business Analysis & Operations** 

Date	Consultant	Description of Services	Hours
		Hoc Committee to discuss evolution of his role at Mundipharma and key business trends.	
12/06/19	NAS	Conference call for UCC Stipulation Presentation regarding Sackler family finances (partial).	0.80
12/06/19	NAS	Consolidate IAC diligence notes and create list of follow- up questions after conference call with J. Theurillat (MN Consulting).	0.40
12/06/19	NAS	Follow up discussions with N. Simon and G. Koch (both AlixPartners) on J Theurillat (MN Consulting) call and LAM	0.90
12/06/19	NAS	Analysis of Mundipharma LAM budget materials from 2017 to present to assess performance trends and changes in projections.	1.50
12/06/19	HK	Meeting with J. Lowne, E. Ruiz (both Purdue), and various company specialists, on vendor trade agreement status updates.	0.30
12/06/19	НК	Attend call for advisors to interview J. Theurillat (MN Consulting).	1.00
12/06/19	НК	Update critical vendor payment summaries for internal discussion with company.	2.70
12/06/19	НК	Review due diligence documents on budget details for European independent affiliated companies.	1.80
12/06/19	IA	Review CEO compensation details received from company for 2018-2019 YTD period,	3.40
12/06/19	LJD	Update call with J. Dubel (Board Member).	0.50
12/06/19	MH	Attend part of call with client management on status of critical vendor payments.	0.20
12/06/19	MH	Analyze additional invoices for treatment as 503(b)(9).	0.40
12/06/19	МН	Review the latest critical vendor status report to assess the final payment capacity.	0.90

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2120733-2

Re: **Business Analysis & Operations** 

Date	Consultant	Description of Services	Hours
12/06/19	MH	Attend call with supply chain manager to discuss deposit payments to a vendor.	0.30
12/06/19	ADD	Call with Purdue CFO, Purdue Associate General Counsel, Purdue Controller, and Skadden to discuss DOJ financial requests.	0.40
12/06/19	ADD	Compile and format files supplied in response to diligence requests.	2.80
12/06/19	ADD	Research diligence request at direction of counsel.	1.50
12/07/19	NAS	Analysis of Mundipharma LAM budget materials from 2017 to present to assess performance trends and changes in projections.	1.70
12/07/19	JD	Review of intercompany receivables/payables	0.50
12/08/19	RDS	Review updated budget projections and provide commentary	0.80
12/08/19	НК	Review IAC diligence materials for OPEX reduction initiatives	2.40
12/08/19	HK	Review IAC diligence materials for COGS reduction initiatives	1.40
12/08/19	ADD	Respond to inquiry from Davis Polk regarding available documentation.	0.30
12/09/19	ADD	Request permission to upload files to the data room.	0.80
12/09/19	ADD	Draft responses to diligence inquiry for Davis Polk.	1.80
12/09/19	ADD	Review November month-end open pre-petition accounts payable.	1.20
12/09/19	ADD	Review diligence request and requested outstanding items.	2.20
12/09/19	ADD	Compile and format files supplied in response to diligence requests.	2.90

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2120733-2

Re: **Business Analysis & Operations** 

Date	Consultant	Description of Services	Hours
12/09/19	НК	Review IAC diligence materials for COGS reduction initiatives	1.50
12/09/19	HK	Review IAC diligence materials for Europe region requests	1.40
12/09/19	IA	Review of retention payment calculations and correspondence with management on calculated payments to specific employees.	0.30
12/09/19	IA	Follow up on OCPs and process for payment.	0.60
12/09/19	IA	Drafting of summary of private travel and other benefits as requested by Davis Polk.	1.80
12/09/19	IA	Review of summary of CEO compensation timeline and details prepared by Davis Polk.	0.70
12/09/19	IA	Follow up with company on open items in CEO timeline summary, put together for diligence purposes.	1.40
12/09/19	IA	Review of private jet travel payment history and timing of payments.	0.60
12/09/19	IA	Correspondence and meeting with management to discuss CEO taxable benefit payments and timeline of agreements.	0.70
12/09/19	IA	Review of updated rebates forecast received from TXP and incorporation into forecast model for inclusion in cash forecast for Purdue.	2.80
12/09/19	IA	Review of information received on payment to CEO for personal travel.	1.10
12/09/19	MH	Prepare accounts payable release list.	0.40
12/09/19	HK	Attend advisor call with Neil Trueman (Mundipharma Chief International Intellectual Property Counsel).	1.10
12/09/19	HK	Review IAC diligence materials for Global IT OPEX reduction initiatives	1.60

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2120733-2

Re: **Business Analysis & Operations** 

Date	Consultant	Description of Services	Hours
12/09/19	НК	Review IAC diligence materials for Global TechOps OPEX reduction initiatives	1.50
12/09/19	НК	Review historical royalties data to support draft Business Plan	0.80
12/09/19	НК	Calls with H. Ku and G. Koch (both AlixPartners) to discuss Mundi cost reduction initiatives	0.80
12/09/19	RDS	Review Avrio marketing and product launch documents	1.10
12/09/19	RDS	Correspondence with B. Evans, D. Fogel (both Purdue) re scheduling calls for the week	0.20
12/09/19	RDS	Make wages motion impacts to compensation analysis	0.80
12/09/19	RDS	Review quality spans of control (NC & RALP)	0.40
12/09/19	RDS	Review NC production spans of control	0.80
12/09/19	RDS	Meeting with K. Darragh (Purdue) re royalty structure allocation from Mundi IACs and PAD group headcount detail	0.60
12/09/19	RDS	Review RT Materials Management headcount	0.60
12/09/19	RDS	Rhodes Technology headcount allocation and classification methodologies	0.30
12/09/19	RDS	Call with B. Evans (Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re headcount in distribution and supply chain (NC)	0.50
12/09/19	RDS	Wilson red/yellow/pink scenario model alterations	0.80
12/09/19	RDS	Call with J. Stymiest (Purdue/Rhodes) re RT R&D manhour allocation exercise	0.20
12/09/19	RDS	Review A. Soma (Purdue / Rhodes) provided shift schedules	0.70
12/09/19	RDS	Rhodes product pipeline analysis with failure to supply one-time charges	1.30

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2120733-2

Re: **Business Analysis & Operations** 

Date	Consultant	Description of Services	Hours
12/09/19	RDS	RP R&D Allocation per K. Kolar (Purdue) notes.	2.30
12/09/19	RDS	Meeting with management, K. McCafferty, J. DelConte, and R. Sublett (all AlixPartners) re: business plan process	0.60
12/09/19	ADD	Review and update data room permissions.	0.50
12/09/19	DS	Compile support files from October's data request for Customer Programs report for Rhodes and send along with request list to controller (Rhodes)	0.50
12/09/19	DS	Compile support files from October's data request for Customer Programs report for PPLP and send along with request list to financial analyst (PPLP)	0.70
12/09/19	DS	Outline key items of Customer Programs report to AlixPartners team for purposes of executing report in coming weeks	0.90
12/09/19	DS	Review of draft weekly sales reports prepared by management in response to Province's data requests	0.40
12/09/19	KM	Analysis preparation re. Rhodes Tech staffing operations models to support various production levels	1.90
12/09/19	KM	Analysis preparation re. Rhodes resource allocations by project	1.30
12/09/19	KM	Analysis preparation re. Rhodes indirect labor spans and layers	0.90
12/09/19	KM	Report preparation re. strategic alliances and API industry activity	1.60
12/09/19	KM	Analysis update re. Wilson manufacturing quality roles and responsibilities	2.30
12/09/19	KM	Meeting with management, K. McCafferty, J. DelConte, and R. Sublett (all AlixPartners) re: business plan process	0.60
12/09/19	KM	Analysis preparation re. Rhodes Tech staffing operations models to support various production levels	1.90

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2120733-2

Re: **Business Analysis & Operations** 

Date	Consultant	Description of Services	Hours
12/09/19	KM	Prepare for and attend call with B. Evans (Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re headcount in distribution and supply chain (NC)	1.00
12/09/19	JD	Catch up conversation with management re: business planning work stream	0.60
12/09/19	JD	Review correspondence re: business plan diligence requests.	0.60
12/09/19	JD	Meeting with management, K. McCafferty, J. DelConte, and R. Sublett (all AlixPartners) re: business plan process	0.60
12/09/19	JD	Review materials re: cognition patent transaction. Review future business plan.	1.10
12/09/19	JD	Correspondence with Province re: open diligence requests. Discussions with management re: open data requests and review latest materials provided.	1.20
12/09/19	GJK	Call with N. Trueman (Mundi IP) and Advisors for overview of Mundipharma IP program	2.00
12/09/19	GJK	Calls with H. Ku and G. Koch (both AlixPartners) to discuss Mundi cost reduction initiatives	0.80
12/09/19	GJK	Review of LAM 2020 OB	2.50
12/09/19	GJK	Project coordination activities including weekly activities list, priorities for Mundi diligence for week	2.00
12/10/19	GJK	Introductory conference call with investment banker for Mundipharma entities (Deutsche Bank), N. Simon and G. Koch (both AlixPartners), and advisors to UCC and Ad-Hoc Committee to discuss timetable and initial views on business	0.60
12/10/19	GJK	Meeting with IAC diligence team including B. Folse, G. Koch, M. Hartley, N. Simon, and H. Ku (all AlixPartners) to align on current priorities.	0.30

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2120733-2

Re: **Business Analysis & Operations** 

Date	Consultant	Description of Services	Hours
12/10/19	GJK	Call with B. Folse and G. Koch (both AlixPartners) to discuss staffing needs and Mundi diligence	0.20
12/10/19	GJK	Updates to Mundi weekly analysis	2.80
12/10/19	GJK	Review and revise LAM 2018-2020 budget review	1.50
12/10/19	GJK	Review and revise Europe 2018-2020 budget review	1.00
12/10/19	JD	Run analysis re: potential severance obligations	0.70
12/10/19	JD	Correspondence with management and Davis Polk re: new retention program and discussion with Province re: same. Review materials on IT separation and retention program.	1.20
12/10/19	JD	Review materials re: OSR lease and Purdue Canada manufacturing agreement.	0.50
12/10/19	JD	Participate in Special Committee Board meeting	0.80
12/10/19	JD	Review update materials re: IAC diligence progress	0.90
12/10/19	JD	Review summary presentation to be presented to management re: status update on business plan process.	0.80
12/10/19	KM	Report preparation re. Rhodes indirect labor potential savings	1.30
12/10/19	KM	Report preparation re. Rhodes Tech indirect labor potential savings	0.80
12/10/19	KM	Report preparation re. Wilson manufacturing quality organizations spans and support structure	1.00
12/10/19	KM	Report preparation re. Rhodes R&D pipeline NPV and project timing	1.00
12/10/19	KM	Report preparation re. product and customer profitability	1.50
12/10/19	KM	Report preparation re. general document structure	2.10
12/10/19	KM	Report preparation re. partnership opportunities for RALP	0.70

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2120733-2

Re: **Business Analysis & Operations** 

Date	Consultant	Description of Services	Hours
12/10/19	KM	Report preparation re. Rhodes Tech direct labor staffing structure options	1.10
12/10/19	KM	Report preparation re. Wilson operations direct labor staffing structure options	2.20
12/10/19	KM	Report preparation re. Wilson indirect labor potential savings	1.90
12/10/19	KM	Prepare Rhodes and North Carolina personnel baseline presentation slides re: project update	1.50
12/10/19	ADD	Review and update data room permissions.	0.80
12/10/19	KM	Advisor call with PJT re: case update	0.50
12/10/19	RDS	Presentation of Rhode variable contribution per dose, prepare slides	1.50
12/10/19	RDS	Assemble slide deck shell for update meeting	1.00
12/10/19	RDS	Slide preparation - Rhodes commercial product average sale price and value mapping analysis	1.80
12/10/19	RDS	Slide preparation - Rhodes tech r&d cost allocation and rationalization	1.10
12/10/19	RDS	Slide preparation - Rhodes tech direct / indirect labor span of control and ratio analysis	1.60
12/10/19	RDS	Slide preparation - Rhodes pipeline NPV analysis	0.90
12/10/19	RDS	Slide preparation - Rhodes & Wilson pharm tech allocation	1.40
12/10/19	RDS	Slide preparation - North Carolina product development allocation	1.20
12/10/19	RDS	Slide preparation - North Carolina quality organization span of control analysis	1.00
12/10/19	RDS	North Carolina - base budget vs low base cost allocation	0.70
12/10/19	RDS	Slide preparation - Rhodes commercial product overview	0.80

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2120733-2

Re: **Business Analysis & Operations** 

Date	Consultant	Description of Services	Hours
12/10/19	RDS	Revise presentation flow - update total Rhodes graphs to reflect products outside of the vertical generic opioids	0.60
12/10/19	HK	Review historical royalties data to support draft Business Plan	1.30
12/10/19	HK	Meeting with IAC diligence team including B. Folse, G. Koch, M. Hartley, N. Simon, and H. Ku (all AlixPartners) to align on current priorities.	0.30
12/10/19	HK	Review IAC diligence materials for Europe region requests	2.80
12/10/19	НК	Meeting with M. Hartley and H. Ku (both AlixPartners) to finalize transition of Critical Vendor management.	0.40
12/10/19	НК	Biz Ops - Review IAC diligence materials for LAM region requests	0.60
12/10/19	НК	Review IAC diligence materials for Intellectual Property Department requests	1.30
12/10/19	НК	Review IAC diligence materials for Global TechOps OPEX reduction initiatives	1.50
12/10/19	MH	Update trade agreement tracking for new activity.	1.10
12/10/19	MH	Meeting with supply chain manager to discuss deposit agreement with vendor.	0.40
12/10/19	MH	Perform initial review of available financial data to study IAC cash flows.	2.60
12/10/19	MH	Research Trade Agreement settlements for three different agreements with a large vendor.	1.30
12/10/19	MH	Meeting with H. Ku and M. Hartley (both AlixPartners) to finalize transition of Critical Vendor management.	0.40
12/10/19	MH	Meeting with IAC diligence team including B. Folse, G. Koch, M. Hartley, N. Simon, and H. Ku (all AlixPartners) to align on current priorities.	0.30
12/10/19	MH	Build new critical vendor reporting tools.	1.20

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2120733-2

Re: **Business Analysis & Operations** 

Date	Consultant	Description of Services	Hours
12/10/19	MH	Attend Debtor's advisors call.	0.90
12/10/19	MH	Prepare accounts payable release list.	0.40
12/10/19	LJD	Work on staffing for IAC support	0.30
12/10/19	BF	Call with B. Folse and G. Koch (both AlixPartners) to discuss staffing needs and Mundi diligence	0.20
12/10/19	BF	Meeting with IAC diligence team including B. Folse, G. Koch, M. Hartley, N. Simon, and H. Ku (all AlixPartners) to align on current priorities.	0.30
12/10/19	NAS	Finish reviewing 2019 Mundipharma LAM budget materials and provide key takeaways to IAC diligence team.	1.90
12/10/19	NAS	Meeting with IAC diligence team including B. Folse, G. Koch, M. Hartley, N. Simon, and H. Ku (all AlixPartners) to align on current priorities.	0.30
12/10/19	NAS	Introductory conference call with investment banker for Mundipharma entities (Deutsche Bank), G. Koch, N. Simon (both AlixPartners), and advisors to UCC and Ad-Hoc Committee to discuss timetable and initial views on business.	0.60
12/10/19	NAS	Provide overview to AlixPartners IAC diligence team regarding content and data room location of relevant Mundipharma Board presentations.	0.30
12/10/19	NAS	Meeting with G. Koch and N. Simon (both AlixPartners) to discuss approach towards building global Mundipharma business plan and align on current responsibilities.	1.10
12/10/19	NAS	Incorporate Europe sales and margin build into preliminary draft of Mundipharma due diligence model.	2.50
12/10/19	GJK	Meeting with G. Koch and N. Simon (both AlixPartners) to discuss approach towards building global Mundipharma business plan and align on current responsibilities.	1.10

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2120733-2

Re: **Business Analysis & Operations** 

Date	Consultant	Description of Services	Hours
12/10/19	GJK	Updates and revisions to Canada 2018-2020 budget review	1.50
12/10/19	GJK	Mundi financial model	0.50
12/10/19	GJK	Finalize Mundi weekly update	0.50
12/10/19	ADD	Compile and format files supplied in response to diligence requests.	2.30
12/10/19	ADD	Prepare November month-end open pre-petition accounts payable update.	3.10
12/11/19	ADD	Review and update data room permissions.	1.00
12/11/19	ADD	Request permission to upload files to the data room.	1.50
12/11/19	ADD	Compile and format files supplied in response to diligence requests.	3.00
12/11/19	GJK	Visit to Norton Rose to review EY Vendor Due Diligence draft; follow up email/calls	1.50
12/11/19	GJK	Project management of Mundi cash flow work stream and overall project; follow up on diligence management	1.50
12/11/19	NAS	Incorporate Mundipharma LAM sales and gross margin data derived from various Board/budget presentations into Mundipharma business plan model.	1.80
12/11/19	NAS	Weekly internal IAC diligence team update call to discuss new findings and process status with B. Folse, G. Koch, M. Hartley, J. DelConte, N. Simon, and H. Ku (all AlixPartners).	0.80
12/11/19	NAS	Draft key takeaways and project status points in advance of broader AlixPartners engagement team call scheduled for 12/13.	1.50
12/11/19	NAS	Incorporate Mundipharma Canada sales and gross margin data derived from multiple Board/budget presentations into Mundipharma business plan model.	0.90

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2120733-2

Re: **Business Analysis & Operations** 

Date	Consultant	Description of Services	Hours
12/11/19	NAS	Update Mundipharma diligence tracker to reflect latest meetings held (including key takeaways) and documents received.	0.70
12/11/19	NAS	Discussion with G. Koch and N. Simon (both AlixPartners) following initial viewing of Mundipharma vendor due diligence report authored by EY.	0.30
12/11/19	NAS	Review new Mundipharma diligence files uploaded to data room, including 2019 midyear review presentation made by Mundipharma CFO (A. Breabout).	0.80
12/11/19	IA	Correspondence with management and counsel for review and approval of IT transition diligence request responses and detailed files.	0.80
12/11/19	IA	Draft email to finance management team for overview of updated cash forecast and assumptions.	0.70
12/11/19	IA	Review of filed fee applications, detailed fees and expense amounts, to update retained professionals payment forecast.	1.80
12/11/19	IA	Update of retained professionals payment forecast to reflect filed fee applications.	1.20
12/11/19	IA	Update of restructuring advisors fees forecast based on filed fee applications.	1.90
12/11/19	IA	Update Purdue cash flow forecast model to incorporate edits to professional fees forecast.	2.30
12/11/19	IA	Correspondence with management regarding submitted diligence requests on additional retention program and review of submitted support data.	1.80
12/11/19	IA	Review of available information on IT employees and requested details from HR management team.	0.70
12/11/19	IA	Draft summary of requested wages and benefit payment details for 9 employees involved in IT transition project.	0.40

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2120733-2

Re: **Business Analysis & Operations** 

Date	Consultant	Description of Services	Hours
12/11/19	BF	Weekly internal IAC diligence team update call to discuss new findings and process status with B. Folse, G. Koch, M. Hartley, J. DelConte, N. Simon, and H. Ku (all AlixPartners).	0.80
12/11/19	BF	Call with L. Donahue, B. Folse, K. McCafferty, J. DelConte and R. Sublett (all AlixPartners) re: business plan analysis progress.	1.00
12/11/19	LJD	Prepare for and attend call with L. Donahue, B. Folse, K. McCafferty, J. DelConte and R. Sublett (all AlixPartners) re: business plan analysis progress.	1.20
12/11/19	MH	Review historical financial data for Canadian IAC.	2.30
12/11/19	МН	Weekly internal IAC diligence team update call to discuss new findings and process status with B. Folse, G. Koch, J. Delconte, M. Hartley, N. Simon, and H. Ku (all AlixPartners).	0.80
12/11/19	MH	Weekly internal IAC diligence team update Reconcile all trade agreement activity with notification tracker.	1.90
12/11/19	MH	Reconcile all trade agreement activity with Intralinks activity tracker.	2.10
12/11/19	MH	Build new critical vendor reporting tools.	0.90
12/11/19	MH	Prepare accounts payable release list.	0.40
12/11/19	MH	Reconcile changes to vendor balance at the request of the UCC.	0.40
12/11/19	НК	Review IAC diligence materials for Global IT OPEX reduction initiatives	0.70
12/11/19	НК	Weekly internal IAC diligence team update call to discuss new findings and process status with B. Folse, G. Koch, M. Hartley, J. Delconte, H. Ku, and N. Simon (all AlixPartners).	0.80

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2120733-2

Re: **Business Analysis & Operations** 

Date	Consultant	Description of Services	Hours
12/11/19	HK	Draft Rhodes' Opioid Market Dynamics slides to support Business Plan meetings	1.60
12/11/19	HK	Meeting with K. McCafferty, J. DelConte, H. Ku, R. Sublett (all AlixPartners), J. Lowne, D. Lundie, and D. Fogel (Purdue) re presentation on RALP cost structure modeling	1.50
12/11/19	HK	Review IAC diligence materials for Global TechOps OPEX reduction initiatives	1.40
12/11/19	RDS	Rhodes NPV alterations based upon R&D department headcount expenses	0.70
12/11/19	RDS	Opioid API market update commentary and slide creation	2.10
12/11/19	RDS	Report review with D. Lundie (Rhodes), M. McCafferty and R. Sublett (both AlixPartners) re. RALP Business Planning and Cost Assessment	1.50
12/11/19	RDS	Meeting with K. McCafferty, J. DelConte, H. Ku, R. Sublett (all AlixPartners), J. Lowne, D. Lundie, and D. Fogel (Purdue) re presentation on RALP cost structure modeling	1.50
12/11/19	RDS	Slide construction - Wilson cost structure under various cost structures, circular nature of generic opioid price considerations	1.10
12/11/19	RDS	Slide construction - API manufacturing landscape and partnership opportunities	0.80
12/11/19	RDS	Slide construction - Rhodes Technology R&D headcount allocation under PHI scenario	0.90
12/11/19	RDS	Slide construction - API partnership opportunities SWAT analysis	0.40
12/11/19	RDS	Slide creation - Rhodes Technology crewing model in direct labor	1.10
12/11/19	RDS	Slide construction - Rhodes Technology indirect : direct labor ratio analysis and sensitivity analysis	0.80

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2120733-2

Re: **Business Analysis & Operations** 

Date	Consultant	Description of Services	Hours
12/11/19	RDS	Call with L. Donahue, B. Folse, K. McCafferty, J. DelConte and R. Sublett (all AlixPartners) re: business plan analysis progress.	1.00
12/11/19	KM	Report preparation re. R&D cost reduction opportunity summary	1.40
12/11/19	KM	Analysis re. Rhodes Tech indirect labor sensitivity analysis	2.10
12/11/19	KM	Report preparation re. Rhodes Tech R&D portfolio NPV and project timing analyses	1.20
12/11/19	KM	Call with L. Donahue, B. Folse, K. McCafferty, J. DelConte and R. Sublett (all AlixPartners) re: business plan analysis progress.	1.00
12/11/19	KM	Report revisions re. RALP Business Planning and Cost Assessment	1.20
12/11/19	KM	Report review with D. Lundie (Rhodes), M. McCafferty and R. Sublett (both AlixPartners) re. RALP Business Planning and Cost Assessment	1.50
12/11/19	KM	Report revisions re. RALP Business Planning and Cost Assessment	0.20
12/11/19	KM	Meeting with K. McCafferty, J. DelConte, H. Ku, R. Sublett (all AlixPartners), J. Lowne, D. Lundie, and D. Fogel (Purdue) re presentation on RALP cost structure modeling	1.50
12/11/19	JD	Call with L. Donahue, B. Folse, K. McCafferty, J. DelConte and R. Sublett (all AlixPartners) re: business plan analysis progress.	1.00
12/11/19	JD	Review and comment on final business plan presentation prior to meeting with management.	1.70
12/11/19	JD	Meeting with K. McCafferty, J. DelConte, H. Ku, R. Sublett (all AlixPartners), J. Lowne, D. Lundie, and D. Fogel (Purdue) re presentation on RALP cost structure modeling	1.50

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2120733-2

Re: **Business Analysis & Operations** 

Date	Consultant	Description of Services	Hours
12/11/19	JD	Review materials re: IT IAC transition work stream	0.60
12/11/19	JD	Weekly internal IAC diligence team update call to discuss new findings and process status with B. Folse, G. Koch, M. Hartley, J. DelConte, N. Simon, and H. Ku (all AlixPartners).	0.80
12/11/19	GJK	Discussion with N. Simon and G. Koch (both AlixPartners) following initial viewing of Mundipharma vendor due diligence report authored by EY	0.30
12/11/19	GJK	Weekly internal IAC diligence team update call to discuss new findings and process status with B. Folse, G. Koch, M. Hartley, J. DelConte, N. Simon, and H. Ku (all AlixPartners).	0.80
12/12/19	JD	Review final package of retention plan diligence answers prior to providing for the UCC advisors.	0.70
12/12/19	JD	Review latest update on critical vendor status and vendor payment positions.	0.60
12/12/19	JD	Pull together additional information re: wage diligence questions.	0.80
12/12/19	JD	Review business plan presentation to determine potential high-level summary details to share with management.	1.30
12/12/19	KM	Meeting with H. Ghnaimeh (Purdue) re: RELP IT organization structure and costs	1.30
12/12/19	KM	Prepare analysis in support of Business Planning and Cost Reduction Assessment presentation to Purdue Management team	1.20
12/12/19	KM	Prepare and document RALP operations scenario summary for discussion with D. Lundie (Rhodes)	1.40
12/12/19	KM	Review feedback from J. Lowne (Purdue) re. RALP business planning and cost reduction assessment	0.20

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2120733-2

Re: **Business Analysis & Operations** 

Date	Consultant	Description of Services	Hours
12/12/19	KM	Prepare analysis for J. Northington (Purdue) re: RT/RP quality organization options	1.10
12/12/19	KM	Meeting with J. Northington (Purdue) re: RT/RP quality organization options	1.60
12/12/19	KM	Prepare analysis for H. Ghnaimeh (Purdue) re: RELP IT organization structure and costs	0.60
12/12/19	RDS	Preparation of API landscape slides	0.80
12/12/19	RDS	Slide construction - Rhodes Technology R&D headcount allocation under PHI scenario	0.90
12/12/19	RDS	Slide construction - Rhodes cost structure under various volume scenarios, quality spans of control and value mapping	1.80
12/12/19	НК	Review IAC diligence materials for OPEX reduction initiatives	1.30
12/12/19	HK	Review IAC diligence materials for Europe region requests	1.70
12/12/19	НК	Review IAC diligence materials for COGS reduction initiatives	2.60
12/12/19	MH	Reconcile all trade agreement activity with email responses from vendor management team.	2.40
12/12/19	MH	Add additional functionality to critical vendor reporting process.	2.60
12/12/19	MH	Attend Debtor professionals call with client management.	0.70
12/12/19	MH	Attend meeting with accounts payable team to coordinate year end payment cutoff activity.	0.90
12/12/19	MH	Prepare accounts payable release list.	0.40
12/12/19	LJD	Participate in a call with management, Davis Polk, PJT and AlixPartners re: status update and ongoing work streams.	0.50

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2120733-2

Re: **Business Analysis & Operations** 

Date	Consultant	Description of Services	Hours
12/12/19	LJD	Review and discuss october bill and fee app	0.30
12/12/19	IA	Follow up on payment of Canadian counsel fees as approved by the court.	0.60
12/12/19	IA	Review of existing materials on IT Capabilities split project.	1.30
12/12/19	IA	Drafting of summary of IT capabilities project to be shared with the UCC as part of retention program diligence.	1.80
12/12/19	IA	Correspondence with management regarding professional fees forecast included in cash forecast.	1.20
12/12/19	IA	Edits to Purdue and Rhodes 13 week cash forecast to incorporate management's comments.	2.60
12/12/19	IA	Review of comments received from management on cash forecast and follow up of open items on rebates and IAC transactions.	1.60
12/12/19	IA	Follow up on questions received on CEO compensation as part of committee diligence requests.	0.30
12/12/19	IA	Follow up on IT transition diligence question items received.	1.70
12/12/19	NAS	Update IAC diligence tracker to reflect latest documents received, interviews conducted, and key conclusions drawn.	0.70
12/12/19	NAS	Incorporate Mundipharma LAM regional operating expense figures in overall Mundipharma business plan model.	1.30
12/12/19	NAS	Incorporate Mundipharma Europe regional operating expense figures in overall Mundipharma business plan model.	0.70

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2120733-2

Re: **Business Analysis & Operations** 

Date	Consultant	Description of Services	Hours
12/12/19	NAS	Incorporate Mundipharma Canada regional operating expense figures in overall Mundipharma business plan model.	0.60
12/12/19	GJK	Update Mundi update document and provide to PJT	0.80
12/12/19	ADD	Review new and outstanding diligence request.	1.90
12/12/19	ADD	Call with Davis Polk to discuss redacting board materials for upload to data room.	0.30
12/12/19	ADD	Call with Davis Polk to discus response to diligence request.	0.30
12/12/19	ADD	Compile and format files supplied in response to diligence requests.	3.30
12/13/19	ADD	Compile documentation diligence items requested by the UCC/AHC.	2.70
12/13/19	ADD	Upload documentation for diligence requests to the data room.	1.70
12/13/19	ADD	Submit requests for outstanding diligence items.	1.60
12/13/19	ADD	Call with Skadden and Purdue GC to discuss real estate documentation request.	0.20
12/13/19	NAS	Update IAC diligence tracker to reflect latest documents received, interviews conducted, and key conclusions drawn.	0.40
12/13/19	IA	Review benefit amounts per employee as approved by the court in preparation for next week's payments to hourly employees.	2.10
12/13/19	IA	Follow up on approvals for IT transition overview presentation, to be shared with the UCC.	0.40
12/13/19	IA	Edit and format Purdue weekly sales by product report, and request of approvals for posting to data room.	1.10

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2120733-2

Re: **Business Analysis & Operations** 

Date	Consultant	Description of Services	Hours
12/13/19	IA	Follow up on questions from management on OCP payment forecast.	1.30
12/13/19	MH	Review Sackler related family due diligence information.	1.80
12/13/19	MH	Prepare for team update call.	0.30
12/13/19	MH	Update trade agreement tracker with new activity.	0.40
12/13/19	ADD	Prepare for status update meeting.	0.70
12/13/19	KM	Discussion with D. Lundie (Rhodes) re. RALP Business Planning and Cost Reduction project next steps	1.20
12/13/19	KM	Prepare program approach slides for presentation to C. Landau (Purdue) re. RALP Business Planning and Cost Reduction project next steps	2.20
12/13/19	KM	Analysis re. RALP partnership opportunities	0.70
12/13/19	KM	Discussion with J. DelConte and M. McCafferty (both AlixPartners) re. RALP Business Strategy and Cost Reduction project	0.20
12/13/19	JD	Review latest weekly sales analysis and provide comments. Compare to latest budget and forecast files.	0.60
12/13/19	JD	Conversation with management re: conversations with operational leadership and scenario analysis.	0.50
12/13/19	JD	Discussion with J. DelConte and M. McCafferty (both AlixPartners) re. RALP Business Strategy and Cost Reduction project	0.20
12/15/19	JD	Review draft slides for management presentation.	0.20
12/15/19	LJD	Review and comment on business plan deck	1.50
12/16/19	LJD	Review info regarding Purdue disclosures and discuss internally and with risk team	0.90
12/16/19	MH	Research vendor payments in response to questions from vendor contacts.	1.10

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2120733-2

Re: **Business Analysis & Operations** 

Date	Consultant	Description of Services	Hours
12/16/19	МН	Update professional firm hold list to release invoices.	0.50
12/16/19	MH	Prepare accounts payable release list.	0.60
12/16/19	MH	Advise client on proper treatment of a pre-petition credit.	0.30
12/16/19	MH	Review new list of pre-petition items to support month end accounting for liabilities subject to compromise.	0.40
12/16/19	HK	Update Due Diligence / information request tracker with uploads to data site.	1.30
12/16/19	HK	Review IAC diligence materials for Europe region requests	2.40
12/16/19	HK	Call with H. Ku and G. Koch (both AlixPartners) to review diligence information management	0.30
12/16/19	IA	Follow up on review and approvals for weekly sales by product reports.	0.60
12/16/19	NAS	Call with G. Koch and N. Simon (both AlixPartners) to review current status of Mundipharma business plan model.	0.30
12/16/19	NAS	Incorporate business development-related operating expense projections into Mundipharma business plan model.	0.80
12/16/19	NAS	Incorporate research and development-related operating expense projections into Mundipharma business plan model.	1.40
12/16/19	NAS	Review and summarize key takeaways from new Associated Press article on Mundipharma and Nyxoid for purposes of IAC diligence.	0.60
12/16/19	NAS	Review Mundipharma business plan model in advance of meeting with G. Koch (AlixPartners).	0.40
12/16/19	GJK	Call with N. Simon and G. Koch (both AlixPartners) to review current status of Mundipharma business plan model.	0.30

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2120733-2

Re: **Business Analysis & Operations** 

Date	Consultant	Description of Services	Hours
12/16/19	GJK	Call with H. Ku and G. Koch (both AlixPartners) to review diligence information management	0.30
12/16/19	JD	Review OSR lease materials prior to call.	0.40
12/16/19	JD	Call with Davis Polk and management re: go forward leasing options.	0.50
12/16/19	JD	Meeting with management and K. McCafferty (AlixPartners) re: business plan scenario analysis and next steps.	1.50
12/16/19	JD	Review business plan presentation and business plan scenario analyses.	1.10
12/16/19	JD	Research public benefit corporations and potential compensation structures.	0.70
12/16/19	JD	Review weekly sales by product against business plan prior to posting.	0.50
12/16/19	KM	Report modifications re:financial impact summary for RALP Business Planning and Cost Assessment	0.70
12/16/19	KM	Meeting with management and K. McCafferty (AlixPartners) re: business plan scenario analysis and next steps.	1.50
12/16/19	KM	Analysis re: Rhodes R&D project valuation for RALP business plan	1.20
12/16/19	KM	Analysis revision re: Non-site supply chain organization structure options	0.70
12/16/19	KM	Report preparation re: agenda and plan for RALP leadership workshop on Jan. 7-8	0.90
12/16/19	KM	Report modifications re: decision framework RALP Business Planning and Cost Assessment	1.10
12/16/19	KM	Report modifications re: end-to-end variable contribution for RALP Business Planning and Cost Assessment	1.30

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2120733-2

Re: **Business Analysis & Operations** 

Date	Consultant	Description of Services	Hours
12/16/19	ADD	Request assistance with error received when updated file.	0.30
12/16/19	ADD	Update and distribute vendor master.	0.40
12/16/19	ADD	Compile data to generate monthly outstanding accounts payable not covered by motion report.	2.60
12/16/19	ADD	Upload documentation submitted in response to diligence requests to the data room.	1.70
12/16/19	ADD	Compile and review files submitted in response to UCC/AHC diligence request.	2.80
12/16/19	ADD	Request approval to upload documents to the data room.	0.60
12/17/19	ADD	Update monthly account payable report per comments from Purdue Controller.	1.70
12/17/19	ADD	Create monthly outstanding accounts payable not covered by motion report.	2.30
12/17/19	ADD	Review monthly accounts payable report with Purdue Controller.	0.40
12/17/19	ADD	Request and compile documentation from Purdue and Rhodes to respond to UCC diligence request.	2.20
12/17/19	ADD	Format and prepare files submitted in response to diligence request for upload to the data room.	1.50
12/17/19	KM	Discussion with D. Lundie (Rhodes) re: RELP leadership workshop agenda and participants	0.30
12/17/19	KM	Discussion with D. Fogel (Rhodes) re: cost allocation approach for RP product portfolio	0.70
12/17/19	KM	Analysis re: allocation of non-labor resources to RP product pipeline	1.60
12/17/19	KM	Preliminary analysis re: cost allocation approach for regulatory affairs resources to RP pipeline product portfolio	1.70

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2120733-2

Re: **Business Analysis & Operations** 

Date	Consultant	Description of Services	Hours
12/17/19	KM	Preliminary analysis re: cost allocation approach for quality resources to RP pipeline product portfolio	1.70
12/17/19	KM	Preliminary analysis re: cost allocation approach for tech ops resources to RP pipeline product portfolio	1.10
12/17/19	KM	Document preparation re: Approach for RALP leadership workshop Jan7-8 2020	2.10
12/17/19	JD	Meeting with management re: public benefit corporation organizational objectives and go forward process for setting corporate scorecard.	0.50
12/17/19	JD	Participate in conference call with PJT Partners and management re: asset monetization materials.	0.70
12/17/19	JD	Review materials re: Novo Nordisk as a public benefit corp.	0.50
12/17/19	JD	Additional research into public benefit corporations and compensation structures.	1.00
12/17/19	JD	Correspondence with management re: accounts receivable write off	0.60
12/17/19	JD	Review latest materials re: Rhodes BD opportunity	0.60
12/17/19	GJK	Meeting with G. Koch, M. Hartley, N. Simon, and H. Ku (all AlixPartners) to discuss IAC diligence request status.	0.40
12/17/19	NAS	Incorporate Technical Operations (supply chain)-related operating and capital expense projections into Mundipharma business plan model.	1.40
12/17/19	NAS	Meeting with G. Koch, M. Hartley, N. Simon, and H. Ku (all AlixPartners) to discuss IAC diligence request status.	0.40
12/17/19	NAS	Incorporate information technology-related operating and capital expense projections into Mundipharma business plan model.	1.60
12/17/19	HK	Review IAC diligence materials for Europe region requests	2.30

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2120733-2

Re: **Business Analysis & Operations** 

Date	Consultant	Description of Services	Hours
12/17/19	HK	Meeting with M. Hartley and H. Ku (both AlixPartners) to discuss Company follow-ups from vendor management status update.	0.10
12/17/19	НК	Meeting with G. Koch, M. Hartley, H. Ku, and N. Simon (all AlixPartners) to discuss IAC diligence request status.	0.40
12/17/19	НК	Update Due Diligence / information request tracker with uploads to data site.	2.40
12/17/19	MH	Attend debtor advisor call.	0.60
12/17/19	MH	Meeting with G. Koch, M. Hartley, N. Simon, and H. Ku (all AlixPartners) to discuss IAC diligence request status.	0.40
12/17/19	MH	Meeting with H. Ku and M. Hartley (both AlixPartners) to discuss Company follow-ups from vendor management status update.	0.10
12/17/19	МН	Meeting with J. Lowne, E. Ruiz, S. Daniel, J. Carlisle, L. Harding (all Purdue), D. Fogel (Rhodes), M. Hartley, and H. Ku (both AlixPartners) on critical vendor management issues.	0.40
12/17/19	MH	Update critical vendor status report with new activity.	0.60
12/17/19	MH	Meeting with plant manager to discuss possible resolution path for polynox supplier.	0.70
12/17/19	LJD	Call with A. Preiss of Akin regarding disclosures	0.40
12/17/19	LJD	Call with PJT regarding disclosures and general update	0.30
12/17/19	MH	Meeting with supply chain manager to review vendor payment issues.	0.50
12/17/19	MH	Prepare accounts payable release list.	0.40
12/18/19	MH	Research vendor payments in response to questions from vendor contacts.	1.30
12/18/19	МН	Develop procedures for processing partial payments to support negotiated trade agreement amounts.	0.90

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2120733-2

Re: **Business Analysis & Operations** 

Date	Consultant	Description of Services	Hours
12/18/19	MH	Update critical vendor status report with new activity.	0.50
12/18/19	MH	Prepare accounts payable release list.	0.40
12/18/19	НК	Update Due Diligence / information request tracker with uploads to data site.	2.50
12/18/19	HK	Review IAC diligence materials for Europe region requests	2.40
12/18/19	NAS	Revise net revenue and gross margin calculations in Mundipharma business plan model to align with reporting format used by company.	0.90
12/18/19	NAS	Finalize addition of Technical Operations (supply chain)- related operating and capital expense projections into Mundipharma business plan model.	1.30
12/18/19	NAS	Revise consolidation piece of Mundipharma business plan model to tie to individual region budgets and add ability to include 2017 historical financials when provided.	1.60
12/18/19	NAS	Review of initial draft of Mundipharma business plan model to identify key takeaways and any variances relative to prior analyses.	0.80
12/18/19	IA	Review and reconciliation of updated retention payment tracker by employee to approved amounts.	1.80
12/18/19	IA	Correspondence and follow up with client on approvals of sales by product reports to be posted to the data room.	0.60
12/18/19	IA	Prepare for IT Transition overview call with Province and management and review of shared materials and submitted questions.	1.20
12/18/19	IA	Review of submitted Purdue and Rhodes customer programs data for monthly customer report.	2.80
12/18/19	JD	Conversations with management re: retention issues and go forward staffing plans.	0.60

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2120733-2

Re: **Business Analysis & Operations** 

Date	Consultant	Description of Services	Hours
12/18/19	JD	Review existing operational update presentations from management. Correspondence with management re: updated slides and potential other operational trackers.	1.20
12/18/19	JD	Review materials to be responsive to outstanding DOJ diligence requests.	0.70
12/18/19	JD	Review correspondence with management re: Rhodes BD deal approval process. Review internal materials re: same.	0.80
12/18/19	JD	Review historic business plan board presentations in response to outstanding diligence requests.	1.00
12/18/19	JD	Review IT integration materials prior to call.	0.70
12/18/19	JD	Call with management and Davis Polk re: future lease options.	0.50
12/18/19	JD	Correspondence with management and Davis Polk re: PRALP and PPI partnership agreements. Review existing organizational documents.	0.90
12/18/19	KM	Document preparation re: Purpose and Goals for RALP leadership workshop Jan7-8 2020	2.10
12/18/19	KM	Preliminary analysis re: cost allocation approach for tech ops resources to RP pipeline product portfolio	0.90
12/18/19	KM	Preliminary analysis re: cost allocation approach for quality resources to RP pipeline product portfolio	1.60
12/18/19	KM	Preliminary analysis re: cost allocation approach for regulatory affairs resources to RP pipeline product portfolio	1.30
12/18/19	KM	Analysis re: allocation of non-labor resources to RP product pipeline	1.50
12/18/19	KM	Call with M.Sisodia (Rhodes) re. NPV calculation approach for RP pipeline	0.90

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2120733-2

Re: **Business Analysis & Operations** 

Date	Consultant	Description of Services	Hours
12/18/19	ADD	Request approval to upload documents to the data room.	0.90
12/18/19	ADD	Research document production history at request of DPW.	0.40
12/18/19	ADD	Request and compile documentation from Purdue and Rhodes to respond to UCC diligence request.	2.20
12/19/19	ADD	Compile and format files submitted in response to UCC/AHC diligence request.	3.00
12/19/19	ADD	Request approval to upload documents to the data room.	0.70
12/19/19	ADD	Upload documentation submitted in response to diligence requests to the data room.	1.40
12/19/19	ADD	Call with Davis Polk, Skadden, J. DelConte and A. DePalma (both AlixPartners) re: DOJ requests.	0.60
12/19/19	ADD	Compile documentation submitted to the UCC outside of the data room for review by Davis Polk.	1.30
12/19/19	KM	Call with M.Sisodia, D. Fogel (both Rhodes) and J. Carlisle (Purdue) re. NPV calculation approach for RP pipeline	0.70
12/19/19	KM	Call with K. Kolar (Rhodes) re. allocation of regulatory affairs, quality, and tech ops resources to the RP pipeline products	0.90
12/19/19	KM	Call with D. Fogel (Rhodes) re. RP pipeline products	0.40
12/19/19	KM	Analysis re: cost of quality labor to the RP product pipeline	1.50
12/19/19	KM	Analysis re: cost of tech ops labor to the RP product pipeline	1.30
12/19/19	KM	Analysis re: cost of regulatory affairs labor to the RP product pipeline	1.50
12/19/19	KM	Document preparation re: cost of RP product pipeline	1.50
12/19/19	JD	Review draft lease proposal to share with OSR.	0.40

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2120733-2

Re: **Business Analysis & Operations** 

Date	Consultant	Description of Services	Hours
12/19/19	JD	Participate in discussion with Davis Polk and PJT Partners re: approval process for Rhodes BD deals.	0.50
12/19/19	JD	Call with Davis Polk, Skadden, J. DelConte and A. DePalma (both AlixPartners) re: DOJ requests.	0.60
12/19/19	JD	Review materials collected to be responsive to various business plan diligence requests from committee advisors.	1.20
12/19/19	JD	Participate in discussion with PJT Partners and management re: Cognition deal.	0.80
12/19/19	IA	Review of actual rebates and comparison to customer rebates information received from Purdue and Rhodes.	1.80
12/19/19	IA	Review of updated monthly November flash report to be posted to the data room.	1.30
12/19/19	NAS	Resolve question regarding beneficiaries of indemnification payments and incorporate answer in November 2019 Monthly Operating Report.	1.90
12/19/19	NAS	Review initial draft of Mundipharma Vendor Due Diligence report authored by EY.	0.30
12/19/19	NAS	Review latest draft of November 2019 Monthly Operating Report for accuracy.	0.80
12/19/19	HK	Review IAC diligence materials for Europe region requests	2.50
12/19/19	НК	Update analysis of historical royalties data to support draft Business Plan	1.80
12/19/19	НК	Update Due Diligence / information request tracker with uploads to data site.	0.60
12/19/19	MH	Update critical vendor status report with new activity.	0.50
12/19/19	MH	Prepare accounts payable release list.	0.40
12/20/19	МН	Prepare second accounts payable release list to resolve issues from AP manager.	0.50

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2120733-2

Re: **Business Analysis & Operations** 

Date	Consultant	Description of Services	Hours
12/20/19	MH	Mundipharma diligence initial impressions and workstream update with B. Folse, G. Koch, M. Hartley, N. Simon, and H. Ku (all AlixPartners).	0.60
12/20/19	МН	Call with B. Sheehan, J. Leighton-Scott (both Mundipharma), G. Koch, N. Simon, M. Hartley, H. Ku (all AlixPartners), and advisors to UCC and Ad-Hoc Committee to discuss Mundipharma Research & Development and Medical Affairs/regulatory operations.	1.80
12/20/19	MH	Update critical vendor status report with new activity.	0.50
12/20/19	MH	Prepare accounts payable release list.	0.40
12/20/19	MH	Call with company and vendor counsel to review trade agreement options with polynox supplier.	0.60
12/20/19	BF	Mundipharma diligence initial impressions and workstream update with B. Folse, G. Koch, M. Hartley, N. Simon, and H. Ku (all AlixPartners).	0.60
12/20/19	HK	Update Due Diligence / information request tracker with uploads to data site.	1.60
12/20/19	HK	Mundipharma diligence initial impressions and workstream update with B. Folse, G. Koch, M. Hartley, H. Ku, and N. Simon (all AlixPartners).	0.60
12/20/19	НК	Call with B. Sheehan, J. Leighton-Scott (both Mundipharma), G. Koch, M. Hartley, H. Ku, N. Simon (all AlixPartners), and advisors to UCC and Ad-Hoc Committee to discuss Mundipharma Research & Development and Medical Affairs/regulatory operations.	1.80
12/20/19	НК	Review draft advisor business overview of Mundipharma proposed transaction.	2.80
12/20/19	NAS	Call with B. Sheeha, J. Leighton-Scott (both Mundipharma), G. Koch, M. Hartley, H. Ku, N. Simon (all AlixPartners), and advisors to UCC and Ad-Hoc	1.80

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2120733-2

Re: **Business Analysis & Operations** 

Date	Consultant	Description of Services	Hours
		Committee to discuss Mundipharma Research & Development and Medical Affairs/regulatory operations.	
12/20/19	NAS	Review Volume 1 of Project Malta Vendor Due Diligence Report prepared by EY.	1.90
12/20/19	NAS	Mundipharma diligence initial impressions and workstream update with B. Folse, G. Koch, M. Hartley, N. Simon, and H. Ku (all AlixPartners).	0.60
12/20/19	GJK	Call with B. Sheehan, J. Leighton-Scott (both Mundipharma), G. Koch, M. Hartley, N. Simon, H. Ku (all AlixPartners), and advisors to UCC and Ad-Hoc Committee to discuss Mundipharma Research & Development and Medical Affairs/regulatory operations.	1.80
12/20/19	JD	Prepare updated analysis of Dr. Landau's compensation over 2018 and 2019 time periods. Prepare correspondence to send to Davis Polk re: same.	1.50
12/20/19	JD	Review draft E&Y R&D report re: IACs.	0.60
12/20/19	JD	Review monthly and weekly NPA data for diligence requests.	0.40
12/20/19	JD	Review potential Rhodes BD deal re: HSR approvals.	0.70
12/20/19	JD	Correspondence with management and PJT Partners re: IMS data requests from FTI	0.30
12/20/19	JD	Review previous deal approval memo re: HSR value thresholds.	0.40
12/20/19	GJK	Mundipharma diligence initial impressions and workstream update with B. Folse, G. Koch, M. Hartley, N. Simon, and H. Ku (all AlixPartners).	0.60
12/20/19	KM	Document preparation re: cost of RP product pipeline	1.10
12/20/19	KM	Document preparation re: RALP leadership workshop	2.30

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2120733-2

Re: **Business Analysis & Operations** 

Date	Consultant	Description of Services	Hours
12/20/19	ADD	Redact documents in preparation for distribution to the UCC/AHC.	2.30
12/20/19	ADD	Prepare for weekly update call.	0.30
12/20/19	ADD	Request approval to upload documents to the data room.	0.70
12/20/19	ADD	Upload documentation submitted in response to diligence requests to the data room.	1.40
12/22/19	JD	Update Dr. Landau compensation analysis. Correspondence with Davis Polk and Willis Towers Watson re: same.	0.70
12/22/19	JD	Review draft Purdue branded business plan materials prior to meeting with management tomorrow.	1.00
12/23/19	JD	Review materials re: open Province diligence questions, review cash flow forecast professional fee summary and correspondence with management re: same, and review various business plan diligence items.	0.80
12/23/19	JD	Update analysis re: Dr. Landau compensation for 2018 and 2019.	1.70
12/23/19	JD	Prepare correspondence for Davis Polk to send to the non-consenting states re: Dr. Landau compensation.	1.00
12/23/19	JD	Meeting with management, PJT Partners, J. DelConte and K. McCafferty (both AlixPartners) re: Purdue branded long-term business plan.	1.20
12/23/19	JD	Review draft Purdue branded business plan materials prior to meeting.	0.50
12/23/19	JD	Meeting with management re: lease counterproposal from OSR and potential counter. Discussion with Davis Polk and CBRE re: same.	1.10
12/23/19	ADD	Upload documentation submitted in response to diligence request to data room	0.60

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2120733-2

Re: **Business Analysis & Operations** 

Date	Consultant	Description of Services	Hours
12/23/19	ADD	Work with Intralinks (data room) technical support to resolve access issue.	0.30
12/23/19	ADD	Request approval to upload files to data room to satisfy diligence requests.	0.70
12/23/19	ADD	Review and format documentation submitted in response to diligence requests for upload to data room.	2.60
12/23/19	KM	Meeting with management, PJT Partners, J. DelConte and K. McCafferty (both AlixPartners) re: Purdue branded long-term business plan.	1.20
12/23/19	KM	Document creation re: RALP leadership workshop Jan 7-8 (agenda, objective and goals)	1.90
12/23/19	GJK	Call with G. Koch and N. Simon (both AlixPartners) to align on priorities for week of 12/23 and discuss key takeaways from 12/19 meeting with tax advisors.	0.50
12/23/19	GJK	Review and notes on VDD Phase 1 workbook	2.50
12/23/19	NAS	Review Europe Quality of Earnings section of Volume 2 of EY Mundipharma Vendor Due Diligence Report.	0.70
12/23/19	NAS	Review Business and Transaction Overview section of Volume 1 of EY Mundipharma Vendor Due Diligence Report.	2.10
12/23/19	NAS	Review Key Transaction Considerations section of Volume 1 of EY Mundipharma Vendor Due Diligence Report.	2.70
12/23/19	NAS	Review appendices related to EBITDA adjustments and net debt calculations included in Volume 1 of EY Mundipharma Vendor Due Diligence Report.	1.10
12/23/19	NAS	Call with G. Koch and N. Simon (both AlixPartners) to align on priorities for week of 12/23 and discuss key takeaways from 12/19 meeting with tax advisors.	0.50

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2120733-2

Re: **Business Analysis & Operations** 

Date	Consultant	Description of Services	Hours
12/23/19	HK	Review IAC diligence materials for Global TechOps OPEX reduction initiatives	1.80
12/23/19	HK	Review draft advisor business overview of Mundipharma proposed transaction.	1.30
12/23/19	MH	Research vendor payment questions referred by client staff.	0.80
12/23/19	MH	Resolve discrepancies between legal invoices referred by legal operations for payment against the release list.	1.10
12/24/19	MH	Create release file for accounts payable, including final resolution of legal discrepancies.	1.20
12/24/19	HK	Review draft advisor business overview of Mundipharma proposed transaction.	2.10
12/24/19	NAS	Review Europe Quality of Earnings section of Volume 2 of EY Mundipharma Vendor Due Diligence Report.	1.60
12/24/19	NAS	Provide summary of Mundipharma Australia settlement article to IAC diligence team.	0.20
12/24/19	NAS	Review LAM Quality of Earnings section of Volume 2 of EY Mundipharma Vendor Due Diligence Report.	1.10
12/25/19	NAS	Review LAM Quality of Earnings section of Volume 2 of EY Mundipharma Vendor Due Diligence Report.	0.30
12/25/19	NAS	Review Canada Quality of Earnings section of Volume 2 of EY Mundipharma Vendor Due Diligence Report.	1.20
12/25/19	GJK	Review and notes on E&Y Vendor Due Diligence Phase 1 report (~30 pages)	3.20
12/26/19	NAS	Review Canada BerHol Quality of Earnings section of Volume 2 of EY Mundipharma Vendor Due Diligence Report.	1.40

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2120733-2

Re: **Business Analysis & Operations** 

Date	Consultant	Description of Services	Hours
12/26/19	NAS	Review Switzerland and Mundipharma IT Services Quality of Earnings sections of Volume 2 of EY Mundipharma Vendor Due Diligence Report.	1.10
12/26/19	NAS	Review Technical Operations Quality of Earnings section of Volume 2 of EY Mundipharma Vendor Due Diligence Report.	2.60
12/26/19	NAS	Review Research and Development Quality of Earnings section of Volume 2 of EY Mundipharma Vendor Due Diligence Report.	1.00
12/26/19	NAS	Review Quality of Net Assets section of Volume 2 of EY Mundipharma Vendor Due Diligence Report.	1.10
12/26/19	НК	Review draft advisor business overview of Mundipharma proposed transaction.	2.10
12/26/19	MH	Create release file for accounts payable.	0.80
12/26/19	KM	Document creation re: RALP leadership workshop Jan 7-8 (agenda, objective and goals)	1.50
12/26/19	KM	Document creation re: RALP leadership workshop Jan 7-8 (case for evaluation)	1.70
12/27/19	JD	Review materials re: Rhodes BD deal and insourcing opportunity. Correspondence with management and PJT Partners re: same.	0.80
12/27/19	JD	Review IT separation agreement materials. Correspondence with management re: same.	0.60
12/27/19	НК	Review draft advisor business overview of Mundipharma proposed transaction.	2.70
12/27/19	НК	Review IAC diligence materials for Global IT OPEX reduction initiatives	1.70
12/27/19	NAS	Review Quality of Net Assets section of Volume 2 of EY Mundipharma Vendor Due Diligence Report.	1.50

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2120733-2

Re: **Business Analysis & Operations** 

Date	Consultant	Description of Services	Hours
12/27/19	NAS	Review Quality of Cash Flow section of Volume 2 of EY Mundipharma Vendor Due Diligence Report.	1.10
12/27/19	NAS	Review Quality of Financial Information section of Volume 2 of EY Mundipharma Vendor Due Diligence Report.	2.30
12/27/19	NAS	Broad overview of Volume 3 of EY Mundipharma Vendor Due Diligence report.	0.70
12/27/19	GJK	Review and notes on VDD Overview section	2.50
12/27/19	GJK	Workbook 1 Review and Notes: Adjusted EBITDA	3.00
12/27/19	GJK	Finalize VDD Workbook 1 Review and Notes	3.00
12/28/19	GJK	VDD Workbook 2 and 3 review - begin review/notes	1.50
12/28/19	JD	Correspondence with Davis Polk and PJT Partners re: transaction overviews.	0.30
12/29/19	JD	Review transaction overview presentations to send to committee advisors. Correspondence with committee advisors re: setting up a call to provide	1.10
12/29/19	JD	Finalize IT separation docs to post to the data room for committee advisors.	0.30
12/29/19	GJK	VDD Volume 2 Review and Notes	2.30
12/29/19	NAS	Review Europe IACs section of Volume 3 of EY Mundipharma Vendor Due Diligence Report.	1.50
12/29/19	NAS	Review LAM IACs section of Volume 3 of EY Mundipharma Vendor Due Diligence Report.	0.50
12/30/19	NAS	Review LAM IACs section of Volume 3 of EY Mundipharma Vendor Due Diligence Report.	1.50
12/30/19	GJK	Review and notes of Vol 2 of VDD	2.00
12/30/19	GJK	Review and notes of Volume 2 of VDD	3.00
12/30/19	HK	Review draft advisor business overview of Mundipharma proposed transaction.	2.40

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2120733-2

Re: **Business Analysis & Operations** 

Date	Consultant	Description of Services	Hours
12/30/19	MH	Update vendor tracking files for trade agreement activity during holiday week.	1.70
12/30/19	JD	Correspondence with Davis Polk re: business development partner and committee communications	0.70
12/30/19	JD	Correspondence with Davis Polk and management re: ownership agreements	0.40
12/30/19	JD	Review ownership documents to be responsive to UCC requests.	0.50
12/30/19	ADD	Compile and review documentation to complete UCC diligence requests.	2.60
12/30/19	ADD	Update designation review tracker.	0.80
12/30/19	ADD	Review of files in data room for potential redactions as part of the designation process.	3.20
12/31/19	ADD	Review of files in data room for potential redactions as part of the designation process.	2.80
12/31/19	ADD	Compile and upload documentation to data room	0.90
12/31/19	ADD	Update designation review tracker.	0.60
12/31/19	RDS	Analysis of margin profile for third-party RP products	0.80
12/31/19	RDS	Prepare slide for budget scenarios of third-party RP volumes	0.40
12/31/19	HK	Review draft advisor business overview of Mundipharma proposed transaction.	2.30
12/31/19	GJK	Review and notes of Vol 2 of VDD	3.00
12/31/19	GJK	VDD Volume 3 Review and Notes	3.00
		Total	845.30

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice #

2120733-2

Re:

**Business Analysis & Operations** 

Client/Matter #

012589.00106

#### Fee Recap:

Consultant	Hours	Rate	Amount
Hart Ku	102.20	440.00	44,968.00
Andrew D DePalma	110.40	480.00	52,992.00
Nate A Simon	100.80	480.00	48,384.00
David Samikkannu	23.80	615.00	14,637.00
Isabel Arana de Uriarte	53.10	615.00	32,656.50
Ryan D Sublett	70.00	725.00	50,750.00
Gabe J Koch	104.50	830.00	86,735.00
Michael Hartley	75.70	830.00	62,831.00
Kevin M McCafferty	110.60	895.00	98,987.00
Jesse DelConte	76.10	945.00	71,914.50
Barry Folse	4.70	1,080.00	5,076.00
Lisa Donahue	13.40	1,165.00	15,611.00
Total Hours & Fees	845.30	_	585,542.00

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2120733-2

Re: **POR Development** Client/Matter # 012589.00107

Date	Consultant	Description of Services	Hours
12/06/19	МН	Attend portion of disclosure call with equity counsel to present arguments in the litigation.	3.10
		Total	3.10

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2120733-2

Re: **POR Development** Client/Matter # 012589.00107

Fee Recap:

Consultant	Hours	Rate	Amount
Michael Hartley	3.10	830.00	2,573.00
Total Hours & Fees	3.10		2,573.00

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2120733-2

Re: **Executory Contracts** Client/Matter # 012589.00108

Date	Consultant	Description of Services	Hours
12/06/19	DS	Obtain and send PRA and TXP subleases to A. DePalma (AlixPartners)	0.40
12/07/19	JD	Correspondence with management re: contract rejection	0.30
12/15/19	JD	Correspondence with management and Davis Polk re: lease rejection and extension issues	0.20
12/26/19	JD	Correspondence with Davis Polk re: lease rejection / assumption process	0.50
12/27/19	JD	Correspondence with management and Davis Polk re: lease rejection / assumption	0.20
12/27/19	JD	Correspondence with management re: professional fee payments	0.20
12/31/19	JD	Correspondence with management re: OSR lease go forward process	0.50
		Total =	2.30

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice #

2120733-2

Re:

**Executory Contracts** 

Client/Matter #

012589.00108

#### Fee Recap:

Consultant	Hours	Rate	Amount
David Samikkannu	0.40	615.00	246.00
Jesse DelConte	1.90	945.00	1,795.50
Total Hours & Fees	2.30		2,041.50

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2120733-2

Re: Retention and Engagement Administration

Date	Consultant	Description of Services	Hours
12/02/19	LCV	Work on Supplemental Declaration.	0.50
12/03/19	LCV	Draft supplemental declaration of L. Donahue.	0.70
12/09/19	LCV	Prepare supplemental declaration re: rate increase notice.	0.40
12/17/19	LCV	Draft communication re: rate increases.	0.40
12/17/19	LCV	Draft supplemental declaration of J. DelConte (AlixPartners) re: information barrier program.	1.10
12/17/19	LCV	Emails with E. Kardos, L. Verry, and N. Andrews (all AlixPartners) re: supplemental declaration.	0.20
12/18/19	LCV	Revise supplemental affidavit.	0.30
12/19/19	LCV	Finalize supplemental declaration of L. Donahue re: rate changes and send for filing.	0.40
		Total	4.00

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2120733-2

Re: Retention and Engagement Administration

Client/Matter # 012589.00112

Fee Recap:

Consultant	Hours	Rate	Amount
Laurie C Verry	4.00	490.00	1,960.00
Total Hours & Fees	4.00		1,960.00

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2120733-2

Re: Fee Statements and Fee Applications

Client/Matter # 012589.00113

Date	Consultant	Description of Services	Hours
12/02/19	ТВ	Prepare fee application for September 2019.	0.80
12/02/19	KAS	Respond to J. DelConte (AlixPartners) regarding offset of retainer.	0.30
12/02/19	JD	Review and finalize September fee statement.	0.60
12/06/19	TB	Review court docket.	0.20
12/06/19	ТВ	Review interim compensation order for pertinent dates and deadlines.	0.30
12/09/19	KMD	Preparation of professional fees for November 2019	3.90
12/10/19	KMD	Preparation of professional fees for November 2019	3.30
12/11/19	KMD	Preparation of professional fees for November 2019	5.00
12/12/19	ТВ	Preparation of October monthly fee statement and supporting exhibits.	2.50
12/12/19	JD	Review and comment on draft October fee application.	0.70
12/17/19	TB	Review court docket.	0.20
12/17/19	KMD	Preparation of professional fees for November 2019	1.90
12/20/19	TB	Review court docket.	0.20
		Total	19.90

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2120733-2

Re: Fee Statements and Fee Applications

Client/Matter # 012589.00113

### Fee Recap:

Consultant	Hours	Rate	Amount
Kiera M Davids	14.10	400.00	5,640.00
Tammy Brewer	4.20	430.00	1,806.00
Kaitlyn A Sundt	0.30	490.00	147.00
Jesse DelConte	1.30	945.00	1,228.50
Total Hours & Fees	19.90	_	8,821.50

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2120733-2

Re: Court Hearings Client/Matter # 012589.00114

Date	Consultant	Description of Services	Hours
12/04/19	JD	Preparation for court hearing on the wage motion.	0.80
12/04/19	JD	Attend court hearing.	3.60
12/04/19	RDS	Dial into court hearings	1.10
12/05/19	RDS	Update analysis of Rhodes generic opioid SKU-level customer analysis	1.70
12/19/19	JD	Participate in court hearing.	1.60
12/19/19	RC	Dial into portion of court hearing related to Ernst & Young's retention and discussions around the AlixPartners cash transfers of value report.	1.30
		Total	10.10

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice #

2120733-2

Re:

Court Hearings 012589.00114

Client/Matter #

### Fee Recap:

Consultant	Hours	Rate	Amount
Ryan D Sublett	2.80	725.00	2,030.00
Jesse DelConte	6.00	945.00	5,670.00
Richard Collura	1.30	1,080.00	1,404.00
Total Hours & Fees	10.10	_	9,104.00

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2120733-2

Date	Consultant	Description of Services	Hours
12/02/19	JDH	Research donations made by family members to various institutions.	2.80
12/02/19	JDH	Analysis of entities owned/controlled by family members.	3.70
12/02/19	RC	Review and update list of investigation team's weekly activities and related progress.	0.50
12/02/19	RC	Review articles and other public information related to Sackler family related charities.	1.00
12/02/19	RC	Review and analysis of Purdue transfers of value analysis.	2.30
12/02/19	RC	Update and provide comments related to Purdue analysis and communicate with K. Darruagh (Purdue) regarding follow-up requests for information.	1.60
12/02/19	RC	Review historical changes to Purdue's corporate organizational charts.	0.70
12/02/19	RC	Prepare status of additional work streams for internal discussion.	0.50
12/02/19	RC	Review SAP system documentation related to transfers of value analysis.	1.20
12/02/19	SJC	Analysis of Mortimer family trusts/entities.	3.00
12/02/19	SJC	Documentation of Mortimer family trusts/entities.	3.00
12/02/19	SJC	Review of Mortimer family trusts/entities.	2.10
12/02/19	FOS	Edit and update draft report re: intercompany and non-cash transfers.	6.90
12/02/19	ADD	Review and update distributions presentation.	2.10
12/03/19	ADD	Call with R. Collura, and A. DePalma (both AlixPartners) re: PPI distribution activity and presentation update	0.90
12/03/19	FOS	Review latest intercompany and non-cash transfers report.	0.20

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2120733-2

Date	Consultant	Description of Services	Hours
12/03/19	FOS	Edit and update draft report re: intercompany and non-cash transfers.	5.30
12/03/19	SJC	Review distributions payments and related SAP entries.	2.90
12/03/19	SJC	Analysis of Mortimer family trusts/entities.	3.00
12/03/19	SJC	Review of Mortimer family trusts/entities.	2.20
12/03/19	RC	Review information related to ownership structure of PPLP and other related entities.	0.70
12/03/19	JDH	Analysis of entities owned/controlled by family members.	4.70
12/03/19	JDH	Research donations made by family members to various institutions.	2.20
12/03/19	RC	Review and analysis of PPLP's audited financial statements.	1.30
12/03/19	RC	Review financial documents produced in connection with the Rhode Island litigation.	1.20
12/03/19	RC	Review discovery requests and related responses related to distributions or entity ownership structures.	1.30
12/03/19	RC	Call with R. Collura, and A. DePalma (both AlixPartners) re: PPI distribution activity and presentation update	0.90
12/03/19	RC	Review Purdue 's internal financial statements.	1.10
12/03/19	RC	Review support documentation related to the cash transfers of value report.	1.00
12/04/19	JDH	Research donations made by family members to various institutions.	1.90
12/04/19	JDH	Analysis of entities owned/controlled by family members.	3.30
12/04/19	RC	Call with R. Collura, A. DePalma, and S. Canniff (all AlixPartners) re: investigation status update	1.00
12/04/19	RC	Review PPI general ledger activity related to cash disbursements.	1.30

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2120733-2

Date	Consultant	Description of Services	Hours
12/04/19	RC	Call with M. Clarens (Davis Polk) to discuss status of various work streams and next steps.	0.80
12/04/19	RC	Review and analysis of financial information for PPLP and PPI.	1.30
12/04/19	RC	Review PPI's intercompany activity and related documentation.	0.60
12/04/19	RC	Prepare list of additional work streams and status of each.	0.40
12/04/19	RC	Review PPI's investment account activity.	1.00
12/04/19	RC	Review information related to ownership changes in organization structure.	0.60
12/04/19	SJC	Review of payments for charitable contributions.	3.00
12/04/19	SJC	Document payments for charitable contributions.	1.70
12/04/19	SJC	Review of distribution supporting documents.	2.00
12/04/19	SJC	Call with R. Collura, A. DePalma, and S. Canniff (all AlixPartners) re: investigation status update	1.00
12/04/19	ADD	Call with R. Collura, A. DePalma, and S. Canniff (all AlixPartners) re: investigation status update	1.00
12/05/19	SJC	Review of documents for charitable contributions.	1.80
12/05/19	SJC	Aggregating and reviewing distributions follow up questions.	3.00
12/05/19	RC	Call with A. DePalma, R. Collura, (both AlixPartners) and K. Darraugh (Purdue) to discuss Purdue's distributions and financial information.	1.20
12/05/19	RC	Review summary of information related to charitable organizations.	1.00
12/05/19	RC	Review summary of information related to Sackler family controlled entities.	1.60

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2120733-2

Date	Consultant	Description of Services	Hours
12/05/19	RC	Review support documentation related to distribution testing.	1.70
12/05/19	RC	Review and analysis of documentation related to PPLP distributions.	1.30
12/05/19	JDH	Analysis of entities owned/controlled by family members.	4.20
12/05/19	ADD	Call with A. DePalma, R. Collura, (both AlixPartners) and K. Darraugh (Purdue) to discuss Purdue 's distributions and financial information.	1.20
12/05/19	ADD	Assist with download and formatting of distribution support documentation.	0.60
12/06/19	JDH	Research additional IACs and other entities controlled by family members.	3.40
12/06/19	RC	Review and analysis of Purdue's financial statements and cash disbursements.	1.80
12/06/19	RC	Review accounting documentation related to Purdue's cash disbursements.	1.30
12/06/19	RC	Review information related to payments to not-for-profit organizations.	1.00
12/06/19	SJC	Draft email for distribution follow up questions, reviewing follow up questions, and reviewing documents for distribution follow up questions.	2.20
12/06/19	FOS	Review documents provided by counsel re: intercompany and non-cash transfers report.	0.60
12/06/19	FOS	Review intercompany and non-cash transfers report.	0.10
12/06/19	FOS	Compose emails to W. DiNicola (Rhodes Tech) re: intercompany settlement files between Rhodes and PPLP.	0.20
12/09/19	FOS	Edit and review draft report re: intercompany and non-cash transfers.	4.00

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2120733-2

Date	Consultant	Description of Services	Hours
12/09/19	FOS	Prepare update on status of intercompany and non-cash transfers report draft.	0.20
12/09/19	SJC	Review information provided by the Sackler Family and create a comprehensive list of all referenced entities for Mortimer side.	3.00
12/09/19	SJC	Review information provided by the Sackler Family and create a comprehensive list of all referenced entities for Raymond side.	1.50
12/09/19	RC	Call with A. DePalma and R. Collura (both AlixPartners) to discuss responses to the DOJ's requests for information related to the cash transfers of value report.	0.40
12/09/19	RC	Prepare email communication to Davis Polk regarding status of work streams.	0.30
12/09/19	RC	Review and analysis of accounting information provided by the debtors regarding Purdue	2.00
12/09/19	RC	Prepare updates to summary of investigation related work streams.	0.10
12/09/19	RC	Review requests from PRA LP and communicate with Davis Polk.	0.20
12/09/19	RC	Review information requests for TXP.	1.20
12/09/19	JDH	Analysis of RS family entities and trusts.	4.60
12/09/19	RC	Prepare email to team regarding accounting information related to Purdue	0.20
12/09/19	RC	Review accounting documentation related to Purdue's cash disbursements.	1.70
12/09/19	RC	Review support documentation complied for cash transfers of value report.	1.90

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2120733-2

Date	Consultant	Description of Services	Hours
12/09/19	ADD	Call with A. DePalma and R. Collura (both AlixPartners) to discuss responses to the DOJ's requests for information related to the cash transfers of value report.	0.40
12/10/19	ADD	Review cash value of transfer presentation and compared data tables to prior versions.	2.40
12/10/19	RC	Prepare for and call with E. Kim and A. Whisenant (both Davis Polk) to discuss the cash transfers of value report.	0.60
12/10/19	RC	Review questions and comments from Davis Polk related to cash transfers of value report.	1.70
12/10/19	RC	Review information in cash report for redactions.	2.00
12/10/19	RC	Prepare open items list related to requests for TXP and PRA LP.	0.80
12/10/19	RC	Review support documentation related to cash transfers of value report.	1.50
12/10/19	RC	Review and analysis of intercompany schedules prepared by the Debtors.	1.40
12/10/19	JDH	Analysis of RS family entities and trusts.	3.90
12/10/19	SJC	Create and analyze trust information in order to create a comprehensive list of all referenced entities for Mortimer side.	3.00
12/10/19	SJC	Review comprehensive list of all referenced entities for Mortimer side created.	2.60
12/10/19	SJC	Review comprehensive list of all referenced entities for Raymond side created (trusts).	2.40
12/10/19	MFR	Revisions to Report 1B (non-cash report).	2.20
12/11/19	MFR	Revisions to Report 1B (non-cash report).	2.10
12/11/19	IF	Call with I. Fisboin and R. Collura (both AlixPartners) to discuss potential redactions to the cash report.	0.40

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2120733-2

Date	Consultant	Description of Services	Hours
12/11/19	SJC	Review of edits to Cash Transfers of Value Report.	1.20
12/11/19	SJC	Review of family trust data - Raymond-side and related edits.	3.00
12/11/19	SJC	Edits to family trust data - Mortimer side.	3.00
12/11/19	SJC	Call with R. Collura, A. DePalma, S.Canniff (all AlixPartners), and DPW litigation team re: cash value transfer deck.	0.80
12/11/19	JDH	Analysis of RS family entities and trusts.	3.10
12/11/19	RC	Call with R. Collura, A. DePalma, S.Canniff (all AlixPartners), and DPW litigation team re: cash value transfer deck.	0.80
12/11/19	RC	Call with I. Fisboin and R. Collura (both AlixPartners) to discuss to potential redactions to the cash report.	0.40
12/11/19	RC	Review information in cash report for potential redactions.	1.70
12/11/19	RC	Review comments from Davis Polk and update cash transfers of value report.	2.50
12/11/19	RC	Review and update schedules and tables in the cash transfer of value report.	2.10
12/11/19	RC	Review supporting documentation related to the cash distributions section of the cash report.	1.50
12/11/19	JDH	Review of MS family entities database.	3.80
12/11/19	ADD	Call with R. Collura, A. DePalma, S.Canniff (all AlixPartners), and DPW litigation team re: cash value transfer deck	0.80
12/12/19	ADD	Review latest versions of cash value transfer draft prior to submission.	2.60
12/12/19	JDH	Review of MS family entities database.	4.20

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2120733-2

Date	Consultant	Description of Services	Hours
12/12/19	RC	Call with M. Clarens, E. Kim and A. Whisenant (all Davis Polk) to discuss cash transfers of value report and potential redactions.	0.40
12/12/19	RC	Call with M. Clarens (Davis Polk) to discuss potential redactions to cash report.	0.10
12/12/19	RC	Review potential redactions to cash report.	0.20
12/12/19	RC	Coordinate with team on reviewing updated information in cash transfers of value report.	0.60
12/12/19	RC	Review and update cash report and provide to Davis Polk.	2.40
12/12/19	RC	Review and update tables and schedules in cash report.	1.80
12/12/19	RC	Review cash report and related support documents for potential redactions.	1.70
12/12/19	RC	Call with E. Kim (Davis Polk) to discuss the cash report.	0.10
12/12/19	RC	Review and prepare responses to questions from Davis Polk regarding the cash transfer of value report.	0.70
12/12/19	RC	Call with M. Clarens (Davis Polk) to discuss cash transfers of value report.	0.20
12/12/19	SJC	Review of edits to Cash Transfers of Value Report.	1.70
12/12/19	SJC	Review of Family Trust data - Raymond Side.	2.70
12/12/19	NAS	Edits to investigation report in preparation for docket release.	0.90
12/12/19	MFR	Revisions to Report 1B (non-cash report).	2.60
12/13/19	MFR	Revisions to Report 1B (non-cash report).	2.30
12/13/19	MH	Call with M. Hartley and R. Collura (both AlixPartners) to discuss Sackler family related due diligence.	0.30
12/13/19	MFR	Call with M. Rule and F. Silva (both AlixPartners) re: draft of intercompany and non-cash transfers report.	0.20

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2120733-2

Date	Consultant	Description of Services	Hours
12/13/19	FOS	Call with M. Rule and F. Silva (both AlixPartners) re: draft of intercompany and non-cash transfers report.	0.20
12/13/19	FOS	Draft intercompany and non-cash transfers report re: intercompany shared services charges.	1.10
12/13/19	RC	Call with M. Hartley and R. Collura (both AlixPartners) to discuss Sackler family related due diligence.	0.30
12/13/19	RC	Review and update questions for TXP Services and related support documentation.	2.30
12/13/19	RC	Review partnership related documents.	1.10
12/13/19	JDH	Review of MS family entities database.	4.30
12/16/19	JDH	Review of family entity database	4.40
12/16/19	RC	Review redacted version of cash transfers of value report.	1.30
12/16/19	RC	Call with M. Clarens (Davis Polk) to discuss case status and recent developments.	0.10
12/16/19	RC	Communicate with team regarding redacted cash transfers of value report.	0.20
12/16/19	RC	Review various articles related to the cash transfers of value report.	0.70
12/16/19	RC	Continue review of redacted cash transfers of value report.	0.80
12/16/19	FOS	Call with M. Rule and F. Silva (both AlixPartners) re: draft of intercompany and non-cash transfers report.	0.20
12/16/19	MFR	Call with M. Rule and F. Silva (both AlixPartners) re: draft of intercompany and non-cash transfers report.	0.20
12/16/19	MFR	Revisions to Report 1B (non-cash report).	3.10
12/16/19	FOS	Compose emails to M. Rule (AlixPartners) re: draft intercompany and non-cash transfers report.	0.10
12/17/19	MFR	Revisions to Report 1B (non-cash report).	3.10

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2120733-2

Date	Consultant	Description of Services	Hours
12/17/19	RC	Communicate with Purdue controller regarding distribution support documentation.	0.20
12/17/19	JDH	Revising family entity database.	4.60
12/18/19	JDH	Family entity data base revisions.	4.10
12/18/19	RC	Review and respond to email communication related to partnership agreements and organizational structure.	0.20
12/18/19	RC	Call with M. Clarens regarding case update and status of work streams.	0.10
12/18/19	RC	Review and comment on distributions analysis support documentation.	1.80
12/18/19	RC	Review and analysis of transactions with US and Ex-Us partners.	1.30
12/18/19	RC	Review status of intercompany and non-cash distributions work streams.	0.50
12/18/19	RC	Review bank statements and SAP detail in response to questions from the UCC's advisors.	2.10
12/18/19	ADD	Compile files requested by the UCC to support Transfer of Value report diligence.	2.30
12/18/19	SJC	Review and edits to Mortimer and Raymond family trust information.	2.70
12/19/19	SJC	Review and edits to Mortimer family trust information.	3.00
12/19/19	SJC	Attend hearing,	1.10
12/19/19	SJC	Review of follow up information received.	1.50
12/19/19	ADD	Research distribution transactions and compile supporting material in response to diligence request.	1.50
12/19/19	RC	Prepare email to Davis Polk regarding additional document requests from the UCC.	0.40
12/19/19	JDH	Review of Family entity database.	4.30

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2120733-2

Date	Consultant	Description of Services	Hours
12/19/19	RC	Review intercompany analysis and non-cash transfers of value.	0.50
12/19/19	RC	Review and research information requests made by the Committee's advisors.	0.70
12/20/19	RC	Call with R. Collura and A. DePalma (both AlixPartners) to discuss documentation related to distribution analysis.	0.80
12/20/19	RC	Call with M. Clarens (Davis Polk) to discuss requests from the Committee's advisors.	0.20
12/20/19	RC	Review documentation related to payments analysis.	2.10
12/20/19	ADD	Call with R. Collura and A. DePalma (both AlixPartners) to discuss documentation related to distribution analysis.	0.80
12/20/19	ADD	Research distribution transactions and compile supporting material in response to diligence request.	2.20
12/20/19	SJC	Review and edits to Mortimer family trust information.	2.60
12/20/19	MFR	Preparation for and conference call with E. Kim (Davis Polk) regarding revisions to Report 1B (non-cash report).	2.40
12/22/19	ADD	Review and analysis of payments made from debtor entities.	2.30
12/22/19	ADD	Review of documentation compiled in response to transfer of value report diligence request.	1.80
12/23/19	ADD	Review of documentation compiled in response to transfer of value report diligence request.	1.30
12/23/19	ADD	Review and analysis of payments made from debtor entities.	2.30
12/23/19	MFR	Revisions to Report 1B (non-cash report).	2.70
12/24/19	MFR	Revisions to Report 1B (non-cash report).	2.40
12/24/19	ADD	Review of documentation compiled in response to transfer of value report diligence request.	1.50

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2120733-2

Date	Consultant	Description of Services	Hours
12/24/19	ADD	Review and analysis of payments made from debtor entities.	3.20
12/26/19	RC	Review support documentation related to payments to IACs and taxing authorities.	2.20
12/26/19	MFR	Revisions to Report 1B (non-cash report).	2.90
12/27/19	MFR	Revisions to Report 1B (non-cash report).	2.10
12/27/19	RC	Review presentation of defenses prepared by counsel to the Raymond Sackler Family.	2.30
12/30/19	ADD	Review of documentation compiled in response to transfer of value report diligence request.	1.60
12/30/19	MFR	Revisions to Report 1B (non-cash report).	2.80
		Total	307.40

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice #

2120733-2

Re:

Client/Matter #

Forensic Analysis 012589.00115

### Fee Recap:

Consultant	Hours	Rate	Amount
Andrew D DePalma	32.80	480.00	15,744.00
Nate A Simon	0.90	480.00	432.00
Fernando O Silva	19.10	615.00	11,746.50
Sam J Canniff	66.70	615.00	41,020.50
Jon D Hecht	67.50	665.00	44,887.50
Isaac Fisboin	0.40	775.00	310.00
Michael Hartley	0.30	830.00	249.00
Mark F Rule	31.10	895.00	27,834.50
Richard Collura	88.60	1,080.00	95,688.00
Total Hours & Fees	307.40	<u> </u>	237,912.00

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice #

2120733-2

Re:

Travel

Client/Matter #

012589.00150

Date	Consultant	Description of Services	Hours
12/01/19	SJC	Travel from ORD to HPN	4.00
12/02/19	NAS	Travel from EWR to HPN	1.50
12/02/19	GJK	Travel from DFW to HPN	4.00
12/02/19	SKL	Travel from DAL to HPN	5.00
12/02/19	DS	Travel to Stamford, CT from New York, NY	1.00
12/02/19	MH	Travel from ATL to HPN	4.00
12/02/19	ADD	Travel from BWI to JFK	3.50
12/02/19	JD	Travel from New York, NY to Stamford, CT	1.00
12/02/19	IA	Travel from New York, NY to Stamford, CT	1.00
12/03/19	HK	Travel from New York, NY to Stamford, CT	1.00
12/03/19	KM	Travel from YYZ to RDU	6.10
12/03/19	RDS	Travel from LGA to RDU	4.10
12/04/19	RDS	Travel from RWI to JFK	3.10
12/04/19	KM	Travel from RDU to YYZ	5.00
12/04/19	JD	Travel from Stamford, CT to White Plains, NY	0.60
12/04/19	JD	Travel from White Plains, NY to New York, NY	1.00
12/04/19	RC	Travel to/from New York, NY and Stamford, CT	1.00
12/05/19	HK	Travel from Stamford, CT to New York, NY	1.00
12/05/19	RDS	Travel from New York, NY to Stamford, CT	1.30
12/05/19	SJC	Travel from Stamford, CT to Boston, MA	3.00
12/05/19	NAS	Travel from Stamford, CT to Jersey City, NJ	1.50
12/05/19	MH	Travel from HPN to ATL	4.00
12/05/19	DS	Travel from Stamford, CT to New York, NY	1.00
12/05/19	SKL	Travel from HPN to DAL	5.00
12/05/19	GJK	Travel from HPN to DFW	4.00

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2120733-2

Re: Travel

Client/Matter # 012589.00150

Date	Consultant	Description of Services	Hours
12/05/19	IA	Travel from Stamford, CT to New York, NY	1.00
12/06/19	RDS	Travel from Stamford, CT to New York, NY	1.10
12/06/19	ADD	Travel from LGA to DCA	3.50
12/08/19	ADD	Travel from DCA to JFK	3.50
12/08/19	KM	Travel from YYZ to HPN	4.50
12/09/19	IA	Travel from New York, NY to Stamford, CT	1.00
12/09/19	GJK	Travel from DFW to HPN	4.00
12/09/19	MH	Travel from ATL to HPN	4.00
12/09/19	HK	Travel from New York, NY to Stamford, CT	1.00
12/09/19	RDS	Travel from New York, NY to Stamford, CT	1.50
12/09/19	JD	Travel from New York, NY to Stamford, CT	1.00
12/09/19	JDH	Travel from New York, NY to Stamford, CT	1.00
12/09/19	SJC	Travel from Boston, MA to Stamford, CT	3.00
12/10/19	JDH	Travel to/from New York, NY and Stamford, CT	2.00
12/10/19	NAS	Travel from Jersey City, NJ to Stamford, CT	1.50
12/10/19	SKL	Travel from DAL to HPN	5.00
12/11/19	GJK	Travel from LGA to DFW	5.00
12/11/19	RDS	Travel from Stamford, CT to New York, NY	1.40
12/11/19	RC	Travel to/from New York, NY and Stamford, CT.	1.00
12/12/19	SJC	Travel from HPN to ORD	4.00
12/12/19	NAS	Travel from Stamford, CT to Jersey City, NJ.	1.50
12/12/19	MH	Travel from HPN to ATL.	4.00
12/12/19	SKL	Travel from HPN to DAL	5.00
12/12/19	HK	Travel from Stamford, CT to New York, NY	1.00
12/12/19	KM	Travel from HPN to YYZ	4.50

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2120733-2

Re: Travel

Client/Matter # 012589.00150

Date	Consultant	Description of Services		Hours
12/12/19	IA	Travel from New York, NY to Stamford, CT		1.00
12/12/19	ADD	Travel from Stamford, CT to New York, NY		1.00
12/12/19	JD	Travel from Stamford, CT to New York, NY		1.00
12/15/19	ADD	Travel from New York, NY to Stamford, CT		1.00
12/16/19	NAS	Travel from Jersey City, NJ to Stamford, CT		1.50
12/16/19	SKL	Travel from DAL to HPN		5.00
12/16/19	GJK	Travel from DFW to HPN		4.00
12/16/19	KM	Travel from YYZ to HPN		4.50
12/16/19	JDH	Travel from New York, NY to Stamford, CT		1.00
12/16/19	JD	Travel from New York, NY to Stamford, CT		1.00
12/16/19	MH	Travel from ATL to HPN		4.00
12/16/19	HK	Travel from New York, NY to Stamford, CT		1.00
12/18/19	ADD	Travel from LGA to MSP		4.50
12/18/19	JDH	Travel from Stamford, CT to New York, NY		1.00
12/18/19	NAS	Travel from Stamford, CT to Jersey City, NJ.		1.50
12/19/19	JDH	Travel to/from New York, NY and Stamford, CT		2.00
12/19/19	KM	Travel from HPN to YYZ		4.50
12/19/19	GJK	Travel from LGA to DFW		4.00
12/19/19	SKL	Travel from HPN to DAL.		5.00
12/19/19	JD	Travel from Stamford, CT to White Plains, NY		0.50
12/19/19	JD	Travel from White Plains, NY to New York, NY		1.00
12/19/19	HK	Travel from Stamford, CT to New York, NY		1.00
12/19/19	MH	Travel from HPN to ATL		4.00
12/23/19	JD	Travel to/from New York, NY and Stamford, CT		2.00
			Total	190.70

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice #

2120733-2

Re:

Travel

Client/Matter #

012589.00150

#### Fee Recap:

Consultant	Hours	Rate	Amount
Sam K Lemack	30.00	440.00	13,200.00
Hart Ku	6.00	440.00	2,640.00
Andrew D DePalma	17.00	480.00	8,160.00
Nate A Simon	9.00	480.00	4,320.00
David Samikkannu	2.00	615.00	1,230.00
Sam J Canniff	14.00	615.00	8,610.00
Isabel Arana de Uriarte	4.00	615.00	2,460.00
Jon D Hecht	7.00	665.00	4,655.00
Ryan D Sublett	12.50	725.00	9,062.50
Gabe J Koch	25.00	830.00	20,750.00
Michael Hartley	24.00	830.00	19,920.00
Kevin M McCafferty	29.10	895.00	26,044.50
Jesse DelConte	9.10	945.00	8,599.50
Richard Collura	2.00	1,080.00	2,160.00
Total Hours & Fees	190.70		131,811.50
Less 50% Travel		_	(65,905.75)
Total Hours		_	65,905.75

### Exhibit B

### **Alix Partners, LLP**

**Summary and Detailed Description of AlixPartners' Expenses** 

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2120733-2

Re: Expense Client/Matter # 012589.00150

### **Disbursement Recap:**

Description		Amount
Airfare		15,931.63
Ground Transportation		10,692.77
Lodging		27,592.25
Meals		5,411.04
Other		207.57
	Total Disbursements	59,835.26

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2120733-2

Date	Disbursement Description	Amount
09/13/19	Lodging Michael Hartley Residence Inns - Stamford 09/16/2019 - 09/18/2019	457.72
10/30/19	Lodging Gabriel Koch Maxwell NYC - New York 10/30/2019 - 11/01/2019	404.32
11/01/19	Meals Gabriel Koch - Dinner	50.00
11/04/19	Meals - Engagement Team Gabriel Koch - Dinner - Gabriel Koch; David Samikkannu	79.00
11/06/19	Meals - Engagement Team Gabriel Koch - Dinner - Gabriel Koch; Isabel Arana De Uriarte; Jesse Delconte; David Samikkannu; Ryan Sublett	250.00
11/07/19	Meals Gabriel Koch - Dinner	50.00
11/08/19	Cab Fare/Ground Transportation Gabriel Koch Hotel to Airport	68.80
11/11/19	Cab Fare/Ground Transportation Gabriel Koch Home to Airport	36.99
11/11/19	Meals Gabriel Koch - Dinner	25.60
11/13/19	Meals Gabriel Koch - Dinner	35.00
11/18/19	Meals Michael Hartley - Dinner	50.00
11/20/19	Meals Gabriel Koch - Dinner	27.79
11/25/19	Conference Calls Vendor: Vodafone Nate Simon	6.04
11/27/19	Conference Calls Vendor: Vodafone Nate Simon	2.37
11/29/19	Airfare Michael Hartley 2019-12-02 BQK - ATL	730.42
11/29/19	Airfare Service Charge Michael Hartley	9.00
11/29/19	Airfare Service Charge Michael Hartley	9.00
11/30/19	Airfare Service Charge Michael Hartley	9.00
11/30/19	Airfare Michael Hartley 2019-12-09 BQK - ATL	578.15
12/01/19	Airfare Service Charge Kevin McCafferty	9.00

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2120733-2

Date	Disbursement Description	Amount
12/01/19	Airfare Change Fees Kevin McCafferty	351.50
12/01/19	Cab Fare/Ground Transportation Samantha Canniff HPN to Hotel - Stamford	43.35
12/01/19	Cab Fare/Ground Transportation Samantha Canniff Home to ORD	75.33
12/01/19	Lodging Samantha Canniff Sheraton Hotel Stamford - Stamford 12/01/2019 - 12/02/2019	213.00
12/01/19	Lodging Jonathan Hecht Residence Inn - Stamford 12/01/2019 - 12/04/2019	767.10
12/01/19	Meals Samantha Canniff - Dinner	12.36
12/01/19	Meals Jonathan Hecht - Dinner	30.54
12/02/19	Airfare Service Charge Samantha Canniff	9.00
12/02/19	Airfare Service Charge Samantha Canniff	9.00
12/02/19	Airfare Service Charge Gabriel Koch	9.00
12/02/19	Airfare Gabriel Koch 2019-12-09 DFW - LGA	535.48
12/02/19	Airfare Service Charge Gabriel Koch	9.00
12/02/19	Airfare Gabriel Koch 2019-12-16 DFW - LGA	425.04
12/02/19	Cab Fare/Ground Transportation Gabriel Koch Home to Airport	31.25
12/02/19	Cab Fare/Ground Transportation Michael Hartley Home to ATL	48.00
12/02/19	Cab Fare/Ground Transportation Michael Hartley Terminal to Client	38.12
12/02/19	Cab Fare/Ground Transportation Isabel Arana De Uriarte Manhattan to Stamford	115.08
12/02/19	Cab Fare/Ground Transportation Andrew Depalma Home to Airport	54.04
01 Cedar Springs Road ite 1100 Ilas, TX 75201	T 214.647.7500 F 214.647.7501 alixpartners.com	

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2120733-2

Date	Disbursement Description	Amount
12/02/19	Cab Fare/Ground Transportation Andrew Depalma Hotel to Client Site	16.50
12/02/19	Cab Fare/Ground Transportation Andrew Depalma LGA to Stamford	150.71
12/02/19	Cab Fare/Ground Transportation Samuel Lemack DAL to DAL	44.39
12/02/19	Cab Fare/Ground Transportation David Samikkannu Stamford to New York	76.63
12/02/19	Cab Fare/Ground Transportation David Samikkannu New York to Stamford	137.52
12/02/19	Cab Fare/Ground Transportation Samantha Canniff Hotel to Purdue	13.30
12/02/19	Mileage Nathaniel Simon 45 Miles	26.10
12/02/19	Parking & Tolls Nathaniel Simon Commute To Purdue Office	14.95
12/02/19	Mileage Hart Ku 40 Miles	23.20
12/02/19	Parking & Tolls Hart Ku	7.78
12/02/19	Train Samantha Canniff - Stamford	97.00
12/02/19	Cab Fare/Ground Transportation Samantha Canniff Purdue to Dinner	13.30
12/02/19	Cab Fare/Ground Transportation Gabriel Koch Airport to Hotel	110.64
12/02/19	Cab Fare/Ground Transportation Jesse Delconte Home to Pp Office	158.09
12/02/19	Parking & Tolls Nathaniel Simon	12.00
12/02/19	Lodging Samantha Canniff Marriott Stamford - Stamford 12/02/2019 - 12/05/2019	876.30
12/02/19	Lodging Jesse Delconte Residence Inn - Stamford 12/02/2019 - 12/04/2019	607.20

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2120733-2

Date	Disbursement Description	Amount
12/02/19	Lodging Gabriel Koch Residence Inn - Stamford 12/02/2019 - 12/05/2019	731.40
12/02/19	Lodging Nathaniel Simon Residence Inns - Stamford 12/02/2019 - 12/05/2019	790.08
12/02/19	Lodging Andrew Depalma Courtyardstamford - Stamford 12/02/2019 - 12/05/2019	799.52
12/02/19	Lodging Samuel Lemack Courtyard - Stamford 12/02/2019 - 12/05/2019	826.08
12/02/19	Lodging Isabel Arana De Uriarte Residence Inn - Stamford 12/02/2019 - 12/05/2019	859.08
12/02/19	Lodging Michael Hartley Courtyard - Stamford 12/02/2019 - 12/05/2019	859.08
12/02/19	Meals Michael Hartley - Breakfast	25.00
12/02/19	Meals Samuel Lemack - Breakfast	17.23
12/02/19	Meals Andrew Depalma - Breakfast	23.67
12/02/19	Meals David Samikkannu - Breakfast	5.97
12/02/19	Meals Michael Hartley - Dinner	50.00
12/02/19	Meals Isabel Arana De Uriarte - Breakfast	3.26
12/02/19	Meals Nathaniel Simon - Dinner	11.33
12/02/19	Meals Gabriel Koch - Breakfast	5.13
12/02/19	Meals - Engagement Team Jesse Delconte - Dinner - Gabriel Koch; Hart Ku; Samuel Lemack; Samantha Canniff; Isabel Arana De Uriarte; Jesse Delconte; Andrew Depalma	350.00
12/02/19	Meals Samantha Canniff - Breakfast	6.70
12/03/19	Cab Fare/Ground Transportation Samantha Canniff Dinner to Hotel	13.30

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2120733-2

Date	Disbursement Description	Amount
12/03/19	Cab Fare/Ground Transportation Samantha Canniff Purdue to Dinner	14.80
12/03/19	Parking & Tolls Nathaniel Simon	12.00
12/03/19	Parking & Tolls Ryan Sublett	24.00
12/03/19	Cab Fare/Ground Transportation Samantha Canniff Dinner to Hotel	13.30
12/03/19	Cab Fare/Ground Transportation David Samikkannu New York to Stamford	159.83
12/03/19	Cab Fare/Ground Transportation Andrew Depalma Client Site to Hotel	8.51
12/03/19	Cab Fare/Ground Transportation Ryan Sublett NYC Home to Newart Airport	94.74
12/03/19	Lodging Hart Ku Sheraton Hotel Stamford - Stamford 12/03/2019 - 12/05/2019	490.36
12/03/19	Lodging Ryan Sublett Renaissance Raleigh North - Raleigh 12/03/2019 - 12/06/2019	379.39
12/03/19	Lodging Kevin McCafferty Renaissance Raleigh North - Raleigh 12/03/2019 - 12/04/2019	379.39
12/03/19	Meals Michael Hartley - Breakfast	25.00
12/03/19	Meals Gabriel Koch - Dinner	31.64
12/03/19	Meals Samuel Lemack - Dinner	34.82
12/03/19	Meals Gabriel Koch - Breakfast	16.18
12/03/19	Meals - Engagement Team Ryan Sublett - Dinner - Kevin McCafferty; Ryan Sublett	100.00
12/03/19	Meals Nathaniel Simon - Dinner	25.10
12/03/19	Meals Nathaniel Simon - Breakfast	16.07
12/03/19	Meals Samantha Canniff - Dinner	50.00
1 Cedar Springs Road e 1100 as, TX 75201	T 214.647.7500 F 214.647.7501 alixpartners.com	

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2120733-2

Date	Disbursement Description	Amount
12/03/19	Meals Samantha Canniff - Breakfast	17.38
12/03/19	Meals Hart Ku - Dinner	22.12
12/03/19	Meals Hart Ku - Breakfast	6.88
12/03/19	Meals Jesse Delconte - Breakfast	3.00
12/03/19	Meals Michael Hartley - Dinner	28.69
12/03/19	Meals - Engagement Team Isabel Arana De Uriarte - Dinner - Isabel Arana De Uriarte; Jesse Delconte	56.60
12/03/19	Meals Andrew Depalma - Breakfast	25.00
12/03/19	Meals Jonathan Hecht - Breakfast	5.49
12/03/19	Meals Samuel Lemack - Breakfast	16.36
12/03/19	Meals Jonathan Hecht - Dinner	50.00
12/03/19	Meals Andrew Depalma - Dinner	50.00
12/03/19	Conference Calls Vendor: Vodafone Andrew DePalma	8.30
12/04/19	Airfare Service Charge Samuel Lemack	566.98
12/04/19	Airfare Service Charge Ryan Sublett	9.00
12/04/19	Airfare Ryan Sublett 2019-12-04 RDU - EWR	243.62
12/04/19	Mileage Richard Collura 38 Miles	22.04
12/04/19	Cab Fare/Ground Transportation Kevin McCafferty Home to YYZ	59.91
12/04/19	Cab Fare/Ground Transportation Kevin McCafferty Airport to Home	40.04
12/04/19	Cab Fare/Ground Transportation Kevin McCafferty LGA to Stamford	95.03
12/04/19	Cab Fare/Ground Transportation Kevin McCafferty Hotel to Purdue HQ	5.11
12/04/19	Parking & Tolls Nathaniel Simon	12.00
2101 Cedar Springs Road Suite 1100 Dallas, TX 75201	T 214.647.7500 F 214.647.7501 alixpartners.com	

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel Rhodes Technologies Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2120733-2

Re: Expense Client/Matter # 012589.00150

Date	Disbursement Description	Amount
12/04/19	Cab Fare/Ground Transportation David Samikkannu New York to Stamford	105.31
12/04/19	Cab Fare/Ground Transportation David Samikkannu Stamford to New York	76.36
12/04/19	Lodging Ryan Sublett Renaissance Tip - 12/04/2019 - 12/05/2019	8.00
12/04/19	Meals Samuel Lemack - Dinner	44.57
12/04/19	Meals Samuel Lemack - Breakfast	15.00
12/04/19	Meals Samantha Canniff - Breakfast	13.79
12/04/19	Meals Hart Ku - Breakfast	11.43
12/04/19	Meals Hart Ku - Dinner	32.37
12/04/19	Meals Gabriel Koch - Breakfast	4.00
12/04/19	Meals Gabriel Koch - Dinner	16.91
12/04/19	Meals Nathaniel Simon - Breakfast	8.58
12/04/19	Meals - Engagement Team Isabel Arana De Uriarte - Dinner - Isabel Arana De Uriarte; Nathaniel Simon; Andrew Depalma	150.00
12/04/19	Meals Andrew Depalma - Breakfast	21.71
12/04/19	Meals Jonathan Hecht - Breakfast	15.50
12/04/19	Meals - Engagement Team Ryan Sublett - Lunch - Kevin McCafferty; Ryan Sublett	25.00
12/04/19	Meals Michael Hartley - Breakfast	12.31
12/04/19	Meals Michael Hartley - Dinner	21.26
12/05/19	Airfare Gabriel Koch 2019-12-05 LGA - DFW	448.32
12/05/19	Airfare Service Charge Samuel Lemack	566.98
12/05/19	Airfare Service Charge Samuel Lemack	566.98
12/05/19	Cab Fare/Ground Transportation Samuel Lemack DAL to DAL	54.34
Cedar Springs Road	T 214.647.7500	

2101 Cedar Springs Road Suite 1100 Dallas, TX 75201

F 214.647.7501 alixpartners.com

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2120733-2

Date	Disbursement Description	Amount
12/05/19	Rental Car Samuel Lemack 3 Days Elmhurst	313.43
12/05/19	Rental Car Kevin McCafferty 1 Day Raleigh	91.56
12/05/19	Cab Fare/Ground Transportation Gabriel Koch Hotel to Airport	68.36
12/05/19	Cab Fare/Ground Transportation Jonathan Hecht CT to NYC	63.33
12/05/19	Cab Fare/Ground Transportation David Samikkannu New York to Stamford	129.40
12/05/19	Parking & Tolls Hart Ku	12.16
12/05/19	Mileage Hart Ku 39 Miles	22.62
12/05/19	Parking & Tolls Nathaniel Simon Commute From Purdue Office To Home	2.75
12/05/19	Mileage Nathaniel Simon 45 Miles	26.10
12/05/19	Cab Fare/Ground Transportation David Samikkannu Stamford to New York	79.38
12/05/19	Cab Fare/Ground Transportation David Samikkannu New York to Stamford	151.94
12/05/19	Cab Fare/Ground Transportation Samantha Canniff Stamford to Boston	246.97
12/05/19	Cab Fare/Ground Transportation Jesse Delconte PP Office to White Plains Courthouse to NYC	852.52
12/05/19	Train Ryan Sublett - Stamford (Round Trip)	30.50
12/05/19	Cab Fare/Ground Transportation Ryan Sublett Stamford to NYC	48.91
12/05/19	Lodging Samantha Canniff Sheraton Commander Hotel - Cambridge 12/05/2019 - 12/08/2019	769.11
12/05/19	Lodging Andrew Depalma Marriott Hotels - 12/05/2019 - 12/06/2019	209.05
12/05/19	Meals Samuel Lemack - Breakfast	3.75
2101 Cedar Springs Road Suite 1100 Dallas, TX 75201	T 214.647.7500 F 214.647.7501 alixpartners.com	

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2120733-2

Date	Disbursement Description	Amount
12/05/19	Meals Samuel Lemack - Dinner	19.08
12/05/19	Meals Michael Hartley - Breakfast	5.18
12/05/19	Meals Michael Hartley - Dinner	49.69
12/05/19	Meals Andrew Depalma - Breakfast	22.53
12/05/19	Meals Kevin McCafferty - Breakfast	7.00
12/05/19	Meals Andrew Depalma - Dinner	50.00
12/05/19	Meals Nathaniel Simon - Breakfast	9.33
12/05/19	Meals David Samikkannu - Breakfast	4.67
12/05/19	Meals Ryan Sublett - Dinner	50.00
12/05/19	Meals Hart Ku - Dinner	40.84
12/05/19	Meals Samantha Canniff - Breakfast	10.63
12/05/19	Meals Samantha Canniff - Dinner	12.25
12/05/19	Meals Hart Ku - Breakfast	7.00
12/05/19	Phone - Internet Access Gabriel Koch	62.83
12/06/19	Airfare Service Charge Andrew Depalma	9.00
12/06/19	Airfare Service Charge Andrew Depalma	9.95
12/06/19	Airfare Service Charge Andrew Depalma	483.73
12/06/19	Cab Fare/Ground Transportation Andrew Depalma Hotel to Airport	130.04
12/06/19	Cab Fare/Ground Transportation Andrew Depalma Airport to Hotel	44.74
12/06/19	Cab Fare/Ground Transportation Michael Hartley Home to ATL	48.00
12/06/19	Cab Fare/Ground Transportation Michael Hartley Client to Airport	32.63

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2120733-2

Re: Expense Client/Matter # 012589.00150

Date	Disbursement Description	Amount
12/06/19	Cab Fare/Ground Transportation Isabel Arana De Uriarte Stamford to Manhattan	71.79
12/06/19	Meals Andrew Depalma - Breakfast	25.00
12/06/19	Meals Andrew Depalma - Dinner	36.71
12/07/19	Airfare Service Charge Nathaniel Simon Wifi To Work On Flight	18.99
12/07/19	Parking & Tolls Ryan Sublett	8.90
12/08/19	Cab Fare/Ground Transportation Samantha Canniff Hotel to Train Station	39.71
12/08/19	Cab Fare/Ground Transportation Andrew Depalma Hotel to Airport	28.51
12/08/19	Cab Fare/Ground Transportation Andrew Depalma JFK to Stamford	150.30
12/08/19	Lodging Samantha Canniff Courtyardstamford - Stamford 12/08/2019 - 12/09/2019	224.26
12/08/19	Lodging Andrew Depalma Courtyardstamford - Stamford 12/08/2019 - 12/12/2019	1,095.46
12/08/19	Meals Andrew Depalma - Dinner	50.00
12/08/19	Meals Andrew Depalma - Breakfast	19.01
12/08/19	Meals Samantha Canniff - Dinner	46.08
12/09/19	Airfare Service Charge Samantha Canniff	9.00
12/09/19	Airfare Samantha Canniff 2019-12-12 HPN - ORD	367.18
12/09/19	Airfare Michael Hartley 2019-12-16 ATL - HPN	785.08
12/09/19	Airfare Service Charge Michael Hartley	9.00
12/09/19	Cab Fare/Ground Transportation Gabriel Koch Home to Airport	31.25

2101 Cedar Springs Road **T** 214.647.7500 Suite 1100 Dallas, TX 75201

**F** 214.647.7501 alixpartners.com

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2120733-2

Date	Disbursement Description	Amount
12/09/19	Cab Fare/Ground Transportation Gabriel Koch Airport to Hotel	117.50
12/09/19	Cab Fare/Ground Transportation Samantha Canniff Hotel to Purdue	10.30
12/09/19	Cab Fare/Ground Transportation Samantha Canniff Purdue to Hotel	11.30
12/09/19	Cab Fare/Ground Transportation Andrew Depalma Hotel to Client Site	9.20
12/09/19	Cab Fare/Ground Transportation Jesse Delconte Home to Pp Office	199.91
12/09/19	Cab Fare/Ground Transportation Jonathan Hecht Stamford to Bronx	110.00
12/09/19	Cab Fare/Ground Transportation Jonathan Hecht Bronx to Stamford	130.31
12/09/19	Cab Fare/Ground Transportation Isabel Arana De Uriarte Manhattan to Stamford	136.51
12/09/19	Cab Fare/Ground Transportation Kevin McCafferty Purdue HQ to Hotel	9.35
12/09/19	Cab Fare/Ground Transportation Michael Hartley Airport to Client	51.38
12/09/19	Cab Fare/Ground Transportation Samantha Canniff Purdue to Hotel	13.08
12/09/19	Mileage Hart Ku 40 Miles	23.20
12/09/19	Parking & Tolls Hart Ku	7.78
12/09/19	Cab Fare/Ground Transportation Ryan Sublett Home NYC to Stamford	194.27
12/09/19	Lodging Kevin McCafferty Residence Inn - Stamford 12/09/2019 - 12/11/2019	466.90

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2120733-2

Date	Disbursement Description	Amount
12/09/19	Lodging Isabel Arana De Uriarte Residence Inn - Stamford 12/09/2019 - 12/12/2019	893.58
12/09/19	Lodging Samantha Canniff Marriott Stamford - Stamford 12/09/2019 - 12/12/2019	876.30
12/09/19	Lodging Hart Ku Sheraton Hotel Stamford - Stamford 12/09/2019 - 12/11/2019	661.66
12/09/19	Lodging Jesse Delconte Residence Inn - Stamford 12/09/2019 - 12/12/2019	962.58
12/09/19	Lodging Ryan Sublett Sheraton Hotel Stamford - Stamford 12/09/2019 - 12/12/2019	789.07
12/09/19	Lodging Michael Hartley Residence Inn - Stamford 12/09/2019 - 12/12/2019	962.58
12/09/19	Lodging Gabriel Koch Residence Inn - Stamford 12/09/2019 - 12/11/2019	595.72
12/09/19	Meals Samuel Lemack - Breakfast	20.25
12/09/19	Meals Michael Hartley - Breakfast	25.00
12/09/19	Meals Gabriel Koch - Dinner	21.47
12/09/19	Meals Gabriel Koch - Breakfast	8.98
12/09/19	Meals Ryan Sublett - Breakfast	19.15
12/09/19	Meals Andrew Depalma - Breakfast	24.88
12/09/19	Meals Hart Ku - Breakfast	5.40
12/09/19	Meals Hart Ku - Dinner	22.12
12/09/19	Meals - Engagement Team Jesse Delconte - Dinner - Isabel Arana De Uriarte; Jesse Delconte; Kevin McCafferty; Andrew Depalma; Ryan Sublett	197.54
12/09/19	Meals Kevin McCafferty - Dinner	10.50
12/09/19	Meals Kevin McCafferty - Breakfast	3.30
Cedar Springs Road e 1100 as, TX 75201	T 214.647.7500 F 214.647.7501 alixpartners.com	

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2120733-2

Date	Disbursement Description	Amount
12/09/19	Meals Michael Hartley - Dinner	50.00
12/09/19	Meals Isabel Arana De Uriarte - Breakfast	6.44
12/10/19	Airfare Service Charge Samuel Lemack	566.98
12/10/19	Cab Fare/Ground Transportation Samuel Lemack DAL to DAL	52.80
12/10/19	Cab Fare/Ground Transportation Jonathan Hecht Bronx to Stamford	100.00
12/10/19	Cab Fare/Ground Transportation Ryan Sublett Dinner to Hotel	6.83
12/10/19	Mileage Nathaniel Simon 45 Miles	26.10
12/10/19	Parking & Tolls Nathaniel Simon Commute To Purdue	12.50
12/10/19	Lodging Ryan Sublett Courtyardstamford - Stamford 12/10/2019 - 12/11/2019	240.36
12/10/19	Lodging Samuel Lemack Courtyardstamford - Stamford 12/10/2019 - 12/12/2019	581.72
12/10/19	Lodging Nathaniel Simon Sheraton Hotel Stamford - Stamford 12/10/2019 - 12/12/2019	480.70
12/10/19	Meals Samuel Lemack - Dinner	34.82
12/10/19	Meals Gabriel Koch - Dinner	29.52
12/10/19	Meals Gabriel Koch - Breakfast	25.00
12/10/19	Meals Samuel Lemack - Breakfast	3.75
12/10/19	Meals Michael Hartley - Breakfast	25.00
12/10/19	Meals Michael Hartley - Dinner	34.02
12/10/19	Meals Hart Ku - Breakfast	13.25
12/10/19	Meals Hart Ku - Dinner	36.07
12/10/19	Meals Ryan Sublett - Breakfast	19.08
12/10/19	Meals Andrew Depalma - Breakfast	24.76

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2120733-2

Date	Disbursement Description	Amount
12/10/19	Meals Jesse Delconte - Breakfast	3.00
12/10/19	Meals Samantha Canniff - Breakfast	6.70
12/10/19	Meals Nathaniel Simon - Dinner	30.65
12/10/19	Meals Nathaniel Simon - Breakfast	9.05
12/11/19	Airfare Change Fees Kevin McCafferty	342.99
12/11/19	Airfare Service Charge Kevin McCafferty	9.00
12/11/19	Cab Fare/Ground Transportation Gabriel Koch Stamford to New York	76.77
12/11/19	Cab Fare/Ground Transportation Gabriel Koch Hotel to Client	10.25
12/11/19	Cab Fare/Ground Transportation Gabriel Koch Client to Hotel	11.19
12/11/19	Cab Fare/Ground Transportation Jonathan Hecht Stamford to Bronx	71.38
12/11/19	Cab Fare/Ground Transportation Jonathan Hecht Bronx to Stamford	115.00
12/11/19	Mileage Richard Collura 38 Miles	22.04
12/11/19	Cab Fare/Ground Transportation Ryan Sublett Stamford to NYC Home	122.18
12/11/19	Parking & Tolls Hart Ku	1.00
12/11/19	Cab Fare/Ground Transportation Andrew Depalma Hotel to Client	13.70
12/11/19	Cab Fare/Ground Transportation Gabriel Koch Hotel to Airport	45.80
12/11/19	Lodging Kevin McCafferty Residence Inn - Stamford 12/11/2019 - 12/13/2019	710.72
12/11/19	Lodging Hart Ku Sheraton Hotel Stamford - Stamford 12/11/2019 - 12/12/2019	298.71
12/11/19	Meals Samuel Lemack - Breakfast	10.00

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2120733-2

Date	Disbursement Description	Amount
12/11/19	Meals Gabriel Koch - Dinner	16.07
12/11/19	Meals Gabriel Koch - Breakfast	14.18
12/11/19	Meals Nathaniel Simon - Breakfast	3.02
12/11/19	Meals Andrew Depalma - Breakfast	22.69
12/11/19	Meals - Engagement Team Andrew Depalma - Dinner - Hart Ku; Samantha Canniff; Nathaniel Simon; Andrew Depalma	177.16
12/11/19	Meals Samantha Canniff - Breakfast	5.95
12/11/19	Meals - Engagement Team Jesse Delconte - Dinner - Samuel Lemack; Isabel Arana De Uriarte; Jesse Delconte; Kevin McCafferty	200.00
12/11/19	Meals Jesse Delconte - Breakfast	3.00
12/11/19	Meals - Engagement Team Ryan Sublett - Dinner - Kevin McCafferty; Ryan Sublett	100.00
12/11/19	Meals Ryan Sublett - Breakfast	23.62
12/11/19	Meals Isabel Arana De Uriarte - Breakfast	5.90
12/11/19	Meals Michael Hartley - Breakfast	10.64
12/12/19	Airfare Change Fees Kevin McCafferty	473.85
12/12/19	Airfare Service Charge Kevin McCafferty	20.00
12/12/19	Airfare Service Charge Kevin McCafferty	9.00
12/12/19	Cab Fare/Ground Transportation Samuel Lemack to	10.00
12/12/19	Cab Fare/Ground Transportation Gabriel Koch Hotel to Client	13.73
12/12/19	Rental Car Samuel Lemack 0 Days Not Provided	(81.52)
12/12/19	Rental Car Samuel Lemack 2 Days Elmhurst	244.57
12/12/19	Cab Fare/Ground Transportation Samantha Canniff Hotel to Work	13.30

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2120733-2

Date	Disbursement Description	Amount
12/12/19	Cab Fare/Ground Transportation Andrew Depalma Stamford to NYC	144.05
12/12/19	Cab Fare/Ground Transportation Samantha Canniff Purdue to HPN	60.33
12/12/19	Cab Fare/Ground Transportation Kevin McCafferty Purdue HQ to LGA	82.77
12/12/19	Cab Fare/Ground Transportation Jonathan Hecht Bronx to Stamford	105.00
12/12/19	Parking & Tolls Nathaniel Simon Commute Home From Purdue Office	5.55
12/12/19	Mileage Nathaniel Simon 45 Miles	26.10
12/12/19	Cab Fare/Ground Transportation Samantha Canniff ORD to Home	61.43
12/12/19	Parking & Tolls Hart Ku	7.78
12/12/19	Mileage Hart Ku 39 Miles	22.62
12/12/19	Lodging Andrew Depalma Marriott Courtyard - 12/12/2019 - 12/13/2019	10.00
12/12/19	Meals Samuel Lemack - Dinner	19.02
12/12/19	Meals Samuel Lemack - Breakfast	10.00
12/12/19	Meals Isabel Arana De Uriarte - Breakfast	5.83
12/12/19	Meals Kevin McCafferty - Dinner	8.92
12/12/19	Meals Kevin McCafferty - Breakfast	5.00
12/12/19	Meals Hart Ku - Dinner	38.82
12/12/19	Meals Samantha Canniff - Breakfast	10.05
12/12/19	Meals Samantha Canniff - Dinner	15.04
12/12/19	Meals Andrew Depalma - Breakfast	23.53

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2120733-2

Date	Disbursement Description	Amount
12/12/19	Meals Nathaniel Simon - Breakfast	8.22
12/12/19	Phone - Internet Access Samantha Canniff	14.00
12/13/19	Cab Fare/Ground Transportation Jonathan Hecht Bronx to Stamford	115.04
12/13/19	Cab Fare/Ground Transportation Jesse Delconte Pp Office to Home	80.58
12/13/19	Cab Fare/Ground Transportation Michael Hartley Client to Airport	40.91
12/13/19	Cab Fare/Ground Transportation Isabel Arana De Uriarte Stamford to Manhattan	67.57
12/13/19	Cab Fare/Ground Transportation Kevin McCafferty YYZ to Home	71.91
12/13/19	Cab Fare/Ground Transportation Michael Hartley ATL to Home	48.00
12/13/19	Cab Fare/Ground Transportation Samuel Lemack DAL to DAL	52.70
12/13/19	Cab Fare/Ground Transportation Gabriel Koch Hotel to Client	16.97
12/13/19	Cab Fare/Ground Transportation Gabriel Koch Client to Hotel	24.10
12/13/19	Meals Nathaniel Simon - Breakfast	5.10
12/13/19	Meals Samantha Canniff - Dinner	45.85
12/14/19	Cab Fare/Ground Transportation Gabriel Koch Hotel to Client	16.34
12/14/19	Cab Fare/Ground Transportation Gabriel Koch Client to Hotel	15.14
12/15/19	Cab Fare/Ground Transportation Andrew Depalma NYC to Stamford	204.85
12/15/19	Cab Fare/Ground Transportation Gabriel Koch Hotel to Client	24.00
12/15/19	Mileage Nathaniel Simon 45 Miles	26.10
12/15/19	Parking & Tolls Nathaniel Simon Commute To Purdue	10.85

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2120733-2

Re: Expense Client/Matter # 012589.00150

Date	Disbursement Description	Amount
12/15/19	Lodging Andrew Depalma Courtyardstamford - Stamford 12/15/2019 - 12/18/2019	732.03
12/15/19	Lodging Jonathan Hecht Residence Inn - Stamford 12/15/2019 - 12/18/2019	790.08
12/15/19	Meals Jonathan Hecht - Dinner	28.44
12/15/19	Meals Andrew Depalma - Dinner	50.00
12/16/19	Mileage Hart Ku 40 Miles	23.20
12/16/19	Parking & Tolls Hart Ku	7.78
12/16/19	Cab Fare/Ground Transportation Gabriel Koch Airport to Hotel	104.10
12/16/19	Cab Fare/Ground Transportation Samuel Lemack DAL to DAL	45.44
12/16/19	Cab Fare/Ground Transportation Gabriel Koch Home to Airport	27.06
12/16/19	Cab Fare/Ground Transportation Michael Hartley Client to Restaurant	34.98
12/16/19	Cab Fare/Ground Transportation Jesse Delconte Home to Pp Office	152.69
12/16/19	Cab Fare/Ground Transportation Isabel Arana De Uriarte Manhattan to Stamford	117.37
12/16/19	Cab Fare/Ground Transportation Kevin McCafferty LGA to Purdue HQ	110.76
12/16/19	Parking & Tolls Nathaniel Simon	12.00
12/16/19	Lodging Nathaniel Simon Residence Inns - Stamford 12/16/2019 - 12/18/2019	526.72
12/16/19	Lodging Isabel Arana De Uriarte Residence Inn - Stamford 12/16/2019 - 12/19/2019	841.80
12/16/19	Lodging Hart Ku Sheraton Hotel Stamford - Stamford 12/16/2019 - 12/19/2019	607.05
edar Springs Road	T 214 647 7500	

2101 Cedar Springs Road **T** 214.647.7500 Suite 1100 Dallas, TX 75201

**F** 214.647.7501 alixpartners.com

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2120733-2

Date	Disbursement Description	Amount
12/16/19	Lodging Samuel Lemack Courtyard - Stamford 12/16/2019 - 12/19/2019	791.49
12/16/19	Lodging Gabriel Koch Residence Inn - Stamford 12/16/2019 - 12/18/2019	477.26
12/16/19	Lodging Kevin McCafferty Residence Inn - Stamford 12/16/2019 - 12/19/2019	759.00
12/16/19	Lodging Jesse Delconte Residence Inn - Stamford 12/16/2019 - 12/19/2019	790.08
12/16/19	Lodging Michael Hartley Residence Inns - Stamford 12/16/2019 - 12/19/2019	790.08
12/16/19	Meals Samuel Lemack - Breakfast	14.61
12/16/19	Meals Jonathan Hecht - Dinner	52.86
12/16/19	Meals Gabriel Koch - Dinner	32.32
12/16/19	Meals Gabriel Koch - Breakfast	18.32
12/16/19	Meals Michael Hartley - Dinner	50.00
12/16/19	Meals Michael Hartley - Breakfast	2.75
12/16/19	Meals Andrew Depalma - Breakfast	24.27
12/16/19	Meals - Engagement Team Isabel Arana De Uriarte - Dinner - Michael Hartley; Samuel Lemack; Isabel Arana De Uriarte; Nathaniel Simon; Richard Collura; Kevin McCafferty; Andrew Depalma; Jesse DelConte	400.00
12/16/19	Meals Hart Ku - Dinner	35.56
12/16/19	Meals Hart Ku - Breakfast	11.48
12/16/19	Meals Nathaniel Simon - Breakfast	3.02
12/17/19	Airfare Service Charge Kevin McCafferty	9.00
12/17/19	Airfare Change Fees Kevin McCafferty	499.96

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2120733-2

Date	Disbursement Description	Amount
12/17/19	Parking & Tolls Nathaniel Simon	12.00
12/17/19	Cab Fare/Ground Transportation Michael Hartley Hotel to Client	30.80
12/17/19	Meals Michael Hartley - Dinner	48.00
12/17/19	Meals Michael Hartley - Breakfast	18.60
12/17/19	Meals Jesse Delconte - Breakfast	3.00
12/17/19	Meals Gabriel Koch - Breakfast	18.93
12/17/19	Meals Gabriel Koch - Dinner	38.02
12/17/19	Meals Samuel Lemack - Breakfast	25.00
12/17/19	Meals Nathaniel Simon - Breakfast	8.58
12/17/19	Meals Hart Ku - Breakfast	17.55
12/17/19	Meals Andrew Depalma - Breakfast	17.80
12/18/19	Airfare Service Charge Andrew Depalma	25.00
12/18/19	Cab Fare/Ground Transportation Isabel Arana De Uriarte Dinner to Residence Inn	8.93
12/18/19	Cab Fare/Ground Transportation Isabel Arana De Uriarte Purdue to Dinner	8.11
12/18/19	Cab Fare/Ground Transportation Gabriel Koch Stamford to New York	82.62
12/18/19	Cab Fare/Ground Transportation Kevin McCafferty Home to YYZ	60.39
12/18/19	Cab Fare/Ground Transportation Andrew Depalma Client Site - Stamford to Airport - LGA	134.61
12/18/19	Cab Fare/Ground Transportation Andrew Depalma Hotel to Client	17.10
12/18/19	Mileage Nathaniel Simon 45 Miles	26.10

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2120733-2

Date	Disbursement Description	Amount
12/18/19	Lodging Andrew Depalma Courtyard Marriott - 12/18/2019 - 12/19/2019	10.00
12/18/19	Lodging Gabriel Koch Maxwell NYC - New York 12/18/2019 - 12/19/2019	200.16
12/18/19	Meals Jonathan Hecht - Dinner	34.38
12/18/19	Meals Gabriel Koch - Breakfast	25.00
12/18/19	Meals Samuel Lemack - Breakfast	16.36
12/18/19	Meals Samuel Lemack - Dinner	35.18
12/18/19	Meals Jesse Delconte - Breakfast	3.00
12/18/19	Meals Michael Hartley - Breakfast	12.15
12/18/19	Meals Michael Hartley - Dinner	45.45
12/18/19	Meals Nathaniel Simon - Breakfast	7.48
12/18/19	Meals Kevin McCafferty - Breakfast	2.89
12/18/19	Meals Andrew Depalma - Dinner	15.50
12/18/19	Meals Andrew Depalma - Breakfast	11.81
12/18/19	Meals Hart Ku - Dinner	23.56
12/19/19	Mileage Hart Ku 39 Miles	22.62
12/19/19	Parking & Tolls Hart Ku	7.78
12/19/19	Cab Fare/Ground Transportation Andrew Depalma Airport to Apartment	33.64
12/19/19	Cab Fare/Ground Transportation Nathaniel Simon 23rd St Path to Debevoise & Plimpton Office	20.30
12/19/19	Cab Fare/Ground Transportation Michael Hartley ATL to Home	81.00
12/19/19	Cab Fare/Ground Transportation Gabriel Koch Hotel to Airport	57.97
12/19/19	Cab Fare/Ground Transportation Samuel Lemack DAL to DAL	62.45
2101 Cedar Springs Road Suite 1100 Dallas, TX 75201	T 214.647.7500 F 214.647.7501 alixpartners.com	

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel Rhodes Technologies Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2120733-2

Re: Expense Client/Matter # 012589.00150

Date	Disbursement Description	Amount
12/19/19	Rental Car Samuel Lemack 3 Days Elmhurst	268.44
12/19/19	Parking & Tolls Samuel Lemack	26.90
12/19/19	Meals Michael Hartley - Dinner	34.79
12/19/19	Meals Michael Hartley - Breakfast	17.95
12/19/19	Meals - Engagement Team Jesse Delconte - Dinner - Isabel Arana De Uriarte; Jesse Delconte; Kevin McCafferty	70.94
12/19/19	Meals Samuel Lemack - Breakfast	15.00
12/19/19	Meals Gabriel Koch - Breakfast	16.04
12/19/19	Meals Samuel Lemack - Dinner	2.17
12/19/19	Meals Isabel Arana De Uriarte - Breakfast	12.30
12/19/19	Meals Hart Ku - Dinner	29.65
12/19/19	Meals Kevin McCafferty - Breakfast	8.00
12/19/19	Meals Kevin McCafferty - Dinner	4.93
12/20/19	Cab Fare/Ground Transportation Isabel Arana De Uriarte Stamford to Manhattan	94.80
12/20/19	Cab Fare/Ground Transportation Kevin McCafferty YYZ to Home	72.02
12/23/19	Cab Fare/Ground Transportation Jesse Delconte Home to Pp Office	130.41
12/23/19	Cab Fare/Ground Transportation Jesse Delconte Pp Office to White Plains Courthouse to NYC	595.01
12/23/19	Train Jesse Delconte - NYC	11.50
12/27/19	Airfare Service Charge Michael Hartley	9.00
12/27/19	Airfare Michael Hartley 2020-01-06 BQK - ATL	630.60
12/28/19	Copy Costs (Outside Source) Gabriel Koch Print Volumes Of Documents	114.03
Cedar Springs Road	T 214.647.7500	

2101 Cedar Springs Road Suite 1100 Dallas, TX 75201

**T** 214.647.7500 **F** 214.647.7501 **alixpartners.com** 

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2120733-2

Date	Disbursement Description	Amount
12/31/19	Airfare Gabriel Koch 2020-01-10 DFW - LHR	6,540.85
12/31/19	Airfare Service Charge Gabriel Koch	9.00
	Total Disbursements	59,835.26